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CHAPTER 1
General introduction, aim and 
outline of the thesis
Adapted from “Interleukin-32 in chronic inflammatory conditions is associated with 
a higher risk of cardiovascular diseases”.
Atherosclerosis. 2017;264:83-91
Michelle S.M.A. Damen
Calin D. Popa
Mihai G. Netea
Charles A. Dinarello
Leo A.B. Joosten
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Nowadays, cardiovascular diseases (CVD) are the leading cause of mortality 
around the globe, leading to about 18 million deaths per year5. In most cases, the 
underlying pathological process of CVD is atherosclerosis and for the most part of 
the last century atherosclerosis was considered to be a cholesterol storage disease. 
However, in the last 30 years a new concept regarding the role of local chronic 
inflammation in the onset and development of atherosclerosis and its complications 
has gained awareness.
Inflammation in cardiovascular diseases
Nowadays, it is known that CVD risk and mortality are increased in patients suffering 
from chronic inflammatory diseases such as rheumatoid arthritis (RA), inflammatory 
bowel disease (IBD) or human immunodeficiency virus (HIV) infection6-8. Traditional 
risk factors such as hypertension, smoking, obesity and inadequate lifestyle, however, 
do not fully account for the increased CVD risk in these patients9, 10. An increased 
burden of atherosclerosis has been indicated to be responsible for the observed 
higher CV risk. Subsequently, common pathophysiological pathways to be shared 
by atherosclerosis and for example RA or HIV have been hypothesized to explain the 
association of these chronic inflammatory disorders with CVD11. Atherosclerosis is 
seen as an active chronic inflammatory disease, in which immune cells and systemic 
markers of inflammation such as pro-inflammatory cytokines, including interleukin 
(IL)-1β, IL-6, TNFα and immune complexes play an important role in blood vessel 
pathology. In addition, the recent CANTOS trial was able to show and validate for the 
first time that reducing inflammation by reducing IL-1β using canakinumab (150mg) 
significantly reduced the risk for cardiovascular events12. Furthermore, many cell 
types that are involved in both early and late-stage atherosclerosis also play a role in 
RA or HIV, including endothelial cells, monocytes and macrophages, B- and T cells.
Endothelial dysfunction occurs at sites where the endothelial cell (EC) layer is 
damaged or activated by smoking, hypertension and dyslipidemia. When damage 
occurs, endothelial cells are activated and start to express adhesion molecules, such 
as intercellular adhesion molecule 1 (ICAM-1), selectins and vascular cell adhesion 
molecule 1 (VCAM-1) on their cell surface. Expression of adhesion molecules is 
induced upon inflammation by pro-inflammatory mediators such as IL-1β, TNFα. 
These factors together with the secretion of chemoattractant mediators including 
IL-8 and chemoattractant protein-1 (MCP-1) determine cell recruitment of 
monocytes and other inflammatory cells into the vascular wall13. Monocytes will 
differentiate into macrophages, which become foam cells by uptake of oxidized LDL 
(oxLDL) Additionally, plaque macrophages release more pro-inflammatory 
mediators (IL-1β, IL-8, TNFα) which attract more immune cells to the plaque 
GENERAL INTRODUCTION
Cardiovascular diseases
Ancient Egyptians already considered the heart as the central organ of the human 
body with hieroglyphic images of the heart showing various vessels attached. It was 
thought that Imhotep, a prominent high priest (ca. 3000-2500 BC) was the first to 
describe that the pulse is associated with the heart1. Later (ca. 1555 BC), cardiac 
rhythm disturbances and heart failure were described. Nevertheless, the first to 
discover the pulmonary circulation with a link between the heart and arteries, was 
doctor Claudius Galenus from Pergamon (130-210 AD)2. Additionally, only in 1628, 
William Harvey (1578-1657) described the closed circulation of blood and the role 
of the heart in pumping blood around which is depicted in Figure 1. Eventually, 
Leonardo da Vinci (1452-1512) was the first to describe arteriosclerosis. He observed 
effects of age on the anatomy of vessels, studied the flow of fluids in an experimental 
setup and described the idea of nutrition and exercise on arterial wall thickening3. 
All of these aspects still represent important topics of research within the field of 
cardiovascular (CV) diseases today.
Figure 1. Cardiovascular models over the course of time4. (A) Erasistratus’ model (B) Galen’s model (C) 
Colombo’s model (D) Harvey’s model the closed circulation.
1312
Chapter 1 – General introduction, aim and outline of the thesis
1
In general, cholesterol is an important lipid in vertebrates, which is crucial in for 
example cellular membranes and for synthesis of steroid hormones, which have 
main physiological functions. Since cholesterol, cholesterol esters and triglycerides 
are only minimally soluble in water they are transported in the bloodstream within 
lipoproteins. Several types of lipoproteins exist with differences in density depending 
on the specific composition with in order of low to high density; chylomicrons, very-
low density lipoprotein (VLDL), intermediate-denisty lipoprotein (IDL; also known 
as VLDL-remnant), , low-denisty lipoprotein (LDL) and high-density lipoprotein 
(HDL). Some particles are known to contribute to atherosclerosis such as LDL, 
VLDL and IDL whereas HDL is thought to have anti-atherogenic properties19. 
Traditionally, the “atherogenic lipid profile” is characterized by increased LDL and 
VLDL, but decreased HDL. Plaque macrophages cannot engulf native, unmodified 
LDL. However, after oxidation of LDL, monocytes/macrophages start to accumulate 
cholesterol20. Oxidation of LDL leads to increased binding affinity to multiple 
receptors on macrophages such as CD36 and Scavenger receptor A (SRA), increasing 
uptake and foam cell formation. LDL particles can substantially vary in size and 
recent studies showed that mostly small dense LDL particles are associated with 
CVD21. In contrast, HDLc plasma concentrations have been negatively correlated 
with CVD making HDLc anti-atherogenic. However, HDL is also heterogeneous and 
current treatment options trying to increase HDLc concentrations did not show any 
beneficial effects on atherosclerosis22. This finding led to an important new idea that 
HDL function might be more relevant than the actual concentration when it comes 
to cholesterol efflux and anti-atherogenic properties.
Besides HDLc, ATP-binding cassette subfamily A/G member 1 (ABCA1, ABCG1) and 
apolipoprotein A-1 (apoA1) are also involved in reverse cholesterol efflux and are 
other anti-atherogenic mediators. ApoA1 is the main particle of HDL and ABCA1 and 
ABCG1 are important transporters in macrophages, facilitating cholesterol efflux. 
Deficient or dysfunctional apoA1, ABCA1 and/or ABCG1 in mice and human studies, 
resulted in increased atherosclerosis23, 24.
These lipid concentrations and functions can however be affected during 
inflammation. There are indications that HDL can be modulated in a way that 
it loses its anti-atherogenic properties and becomes another pro- atherogenic 
lipid25, 26. In low grade chronic inflammatory diseases including RA and HIV, these 
lipid concentrations are known to be affected and can vary enormously depending 
on stage of the disease or type of treatment. Interestingly, it can be concluded 
that both inflammation as well as cholesterol itself can affect the cardiovascular 
disease risk profile. Inflammation can directly affect cholesterol concentrations 
including T-cells (Figure 2). CD4+ T cells lacking CD28 are known to invade unstable 
atherosclerotic plaque regions resulting in weakening of the fibrous cap14. In 
addition, these types of CD4+ T cells can secrete Th1 associated-cytokines and 
possibly contribute to atherosclerotic damage15, 16. Besides, CD4+ T cells can kill 
endothelial cells in vitro, contributing to endothelial cell injury in for example 
coronary plaques17. As mentioned above, IL-1β was shown to be highly important in 
this process of inflammation after showing that inhibition of IL-1β by a human 
monoclonal antibody canakinumab decreased the risk for myocardial infarction18. 
This supports the thought of lowering inflammation by itself next to controlling lipid 
concentrations during the development of CVD.
Figure 2. Schematic illustration of the pathophysiology of atherogenesis.
Lipids and cardiovascular diseases
Next to these above-mentioned mechanisms, other important risk factors such as 
cholesterol and lipid composition have been described as players in atherosclerosis. 
Interestingly, these factors can be modulated by inflammatory molecules, as it 
would happen during prolonged periods of systemic inflammation.
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Figure 3. Schematic illustration of IL-32 signaling.
IL-32 in inflammation
IL-32 has been reported to be involved in a wide range of chronic inflammatory 
diseases such as, RA, IBD, COPD and HIV37-41. Of these diseases, RA is often described 
as the standard prototype autoimmune disease with cytokines such as IL-6 and 
TNFα playing an important role in disease pathogenesis. Therapeutic blockade of 
these cytokines or their receptors showed to improve disease activity, however it 
did not cure the disease. Therefore, new mediators and pathways involved in the 
disease are still under investigation and could lead to new therapeutic targets. 
Interestingly, a few years ago research started to focus on IL-32 in RA pathogenesis. 
A clear correlation between the IL-32 protein expression in synovial tissue biopsies 
of RA patients and the disease activity has been demonstrated42. Besides, both 
synovial tissue macrophages as well as synovial fibroblasts are known to produce 
TNFα, which is a potent inducer of IL-32 and vice versa. Moreover, when RA patients 
were treated with anti-TNF therapy, significant lower levels of IL-32 were detected 
in synovial tissue biopsies, showing a link between TNFα and IL-32 in RA patients43. 
As a proof of concept, recombinant human IL-32 was injected into the joints of mice, 
resulting in joint swelling, cartilage damage and influx of pro-inflammatory cells. In 
case of TNFα deficient mice, these effects were remarkably decreased. Furthermore, 
the pro-inflammatory effects of IL-32 in human samples of synovial tissue biopsies 
and monocytes were observed and mRNA expression of IL-32γ was upregulated in 
specimens from RA patients compared to these from healthy individuals44. This all 
and can modulate cholesterol composition and shift it towards a pro-atherogenic 
profile, showing the importance of trying to interfere with inflammation in chronic 
inflammatory diseases.
The discovery of IL-32
In 1992 Dahl et al. discovered a molecule that was called natural killer cell transcript 
4 (NK4). Gene expression of NK4 was increased when peripheral blood mononuclear 
cells (PBMCs), especially NK or mitogen-stimulated T cells were exposed to a high 
dose of interleukin-2 (IL-2)27, 28. Moreover, it was hypothesized that NK4 could play 
a role in cell adhesion since it contains an Arg-Gly-Asp (RGD) sequence which is 
important for mediating cell adhesion for a variety of proteins29. In 2005 Kim et al. 
showed that recombinant NK4 induced TNFα production in Raw 264.6 macrophages 
showing classical pro-inflammatory properties leading to renaming the molecule to 
interleukin-32 (IL-32)30. The IL32 gene resides on chromosome 16 p13.3 and consists 
of eight small exons. Besides mammals, IL-32 is expressed in several other species 
like bovine and swine, but not in mice. Moreover, alternative splicing of IL-32 mRNA 
results in at least nine different isoforms: IL32γ, IL32β, IL32α, IL-32δ, IL-32ζ, IL-
32ε, IL-32θ, IL-32η and IL-32sm, of which not all functions are known yet31, 32. No 
receptor for IL-32 has been discovered so far, although binding of IL-32 to proteinase 
3 and integrins, αVβ3 and αVβ6 have been described31, 33. Additionally, recombinant 
IL-32γ, in the presence of functional αVβ3, induced in vitro endothelial cell tube 
formation showing a role for IL-32 in angiogenesis34. IL-32 protein can be induced 
by IFN-y. Moreover, IL-32 can stimulate pro-inflammatory mediators by activation 
of signalling pathways nuclear factor –kB (NF-kB) and p38 mitogen-activated 
protein (MAP) kinase30. The intra-cellular nucleotide-binding oligomerization 
domain (NOD)1 and NOD2 ligands can also synergize with IL-32 for IL-6 and IL-1β 
production through a caspase 1-dependent mechanism35. In line with this, silencing 
of endogenous IL-32 induces attenuated IL-1β, IL-6, IL8 and TNFα production in 
endothelial cells and monocytes36 (Figure 3). In general, it can be concluded that IL-
32 acts as a pro-inflammatory cytokine and an endogenous intracellular regulator of 
cytokine production. Although the knowledge on the functions of IL-32 has expanded 
significantly in the last decade, many aspects regarding the exact mechanism of 
action in health and diseases still remain unknown.
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IL-32 expression was detected in arterial vessel walls, endothelial cells and 
macrophages48, 49. Moreover, stimulation of Akt by pro-inflammatory cytokines 
could strongly induce expression of IL-32 in endothelial cells49. Macrophages are 
highly present in atherosclerotic lesions and show a highly increased mRNA and 
protein expression of IL-32 when stimulated with pro- inflammatory mediators 
including, interferon-gamma (IFNγ) and a Toll-like receptor (TLR)3 ligand Poly I:C50, 51. 
Moreover, macrophages are key players in controlling cholesterol levels in blood 
vessel walls. They take up cholesterol, can turn into foam cells, and participate in the 
reverse cholesterol transport (RCT) by expressing functional ATP-binding cassette 
transporter A1 (ABCA1) and ATP-binding cassette transport G1 (ABCG1)52. Since 
macrophages are able to express high levels of IL-32 and in the same time actively 
regulate circulating cholesterol levels, one could hypothesize that IL-32 may be 
somehow related to cholesterol concentrations. Possibly, the intra-cellular capacities 
of IL-32 can interfere with the regulation of cholesterol transporters or foam cell 
formation and therefore influence circulating cholesterol levels. Despite previous 
work describing the IL-32 protein and its various isoforms, knowledge about genetic 
mutations or the function of each isoform is scarce. Recently, it was described that 
a single nucleotide polymorphism (SNP) in the promoter region of IL32 seems to 
affect the expression of the isoforms in PBMCs. Both RA and HIV patients with this 
SNP showed differences in IL-32 isoform expression and in RA patients higher IL-
32 protein concentrations were observed. Intriguingly, it was demonstrated that 
this promoter SNP is associated with higher levels of HDLc53. This mutation in the 
IL32 gene could therefore contribute to a lower risk for CVD in patients with chronic 
inflammatory diseases like RA and HIV in which IL-32 is known to play a role.
AIM AND OUTLINE OF THIS THESIS
IL-32 is a pro-inflammatory cytokine involved in various immunological processes. 
The scope of thesis was to investigate the mechanisms and possible therapeutic 
potential of IL-32 in inflammation and more specifically the role of IL-32 in the 
development of cardiovascular diseases in chronic inflammatory diseases (Fig. 4).
In Chapter 2 of this thesis, we studied whether the IL-32 promoter SNP rs4786370 
has a functional effect in RA patients and individuals at risk for cardiovascular 
diseases. In these subjects, we characterized the lipid profile focusing mostly on 
HDL concentrations and stratified these to the different genotypes.
shows that IL-32 is involved in RA pathogenesis and its chronic inflammatory state. 
Next to this clear role for IL-32 in RA pathogenesis and the link with TNFα, IL-32 
has also been described to be involved in another chronic inflammatory disease, 
HIV. HIV patients showed increased expression levels of IL-32 mRNA and protein 
compared to healthy individuals. In addition, upon silencing of endogenous IL-32, 
HIV replication increased tremendously. This suggests that endogenous IL-32 is 
highly important in suppressing HIV and just like in RA, could be an interesting new 
therapeutic target.
IL-32 in cardiovascular diseases
Since inflammatory pathways have been associated with the pathogenesis of 
chronic inflammatory diseases like RA, IBD, HIV, it is important to study the role of 
these newly described pathways and the corresponding cytokines involved in the 
context of CVD and atherosclerosis.
The pro-inflammatory cytokine TNFα is seen as an important mediator in these latter 
diseases. TNFα by itself is known to be associated with CVD and atherosclerosis45, 46. 
Furthermore, it can promote inflammation via induction of other cytokines such as, 
IL-1β, IL-6 and importantly IL-32. Interestingly, IL-32 is capable of inducing TNFα, 
creating a positive inflammatory loop, which in turn can cause a non-resolving 
inflammatory response contributing to a pro-atherogenic environment. In this way 
IL-32 by itself and via induction of other pro-inflammatory cytokines (IL-1β, IL-6, IL-
8, TNFα) can maintain an inflammatory response.
From IL-1β it is known that it plays a role in atherogenesis by acting on various 
aspects involved in vascular inflammation. The endothelium is the primary target of 
IL-1β triggering systemic inflammation. Additionally, IL-1β sets off the production of 
IL-6, inhibitors of fibrinolysis, prostaglandin E2 (PGE2) and adhesion molecules in the 
endothelium, all of them participating in pathological conditions47. Additionally, IL-
1β is the master cytokine of innate immunity and affecting its expression to control 
atherogenesis has been an important topic of research. Interestingly, the CANTOS 
trial was able to show that controlling IL-1β by canakinumab (150mg) resulted in 
decreased hsCRP and IL-6 levels without affecting lipid concentrations, lowering 
the risk for new myocardial infarctions12, 18. Besides the effects of canakinumab on 
IL-1β as shown by the CANTOS trial, an unexpected role for IL-32 as driver of the 
immune responses via IL-1β was found in another study. When IL-32 levels were 
decreased by siRNA, the pro-coagulant, pro-inflammatory and cytokine effects of IL-
1β, like IL-1β- induced ICAM-1 production, were reduced remarkably36. Therefore, IL-
32 is hypothesized to also be an important player in atherosclerosis. In line with this, 
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differences were observed in cholesterol transporter mRNA expression of ABCA1/
ABCG1 also dependent on the promoter SNP. Finally, we studied the expression of 
calnexin mRNA dependent on the promoter SNP trying to elucidate the mechanism 
behind the IL-32 SNP dependent regulation of cholesterol transporter expression.
In Chapter 7, we integrate the insights we have gained into the role of IL-32 in the 
mechanism behind inflammation-induced cardiovascular disease, and speculate 
on the potential of IL-32 as a new therapeutic agent in this mechanism to try and 
improve treatment of patients suffering from a chronic inflammatory disease with 
an increased risk for CVD. Moreover, we propose a hypothesis of IL-32 being more 
like a novel transcription factor than a cytokine as it is described to this moment.
In Chapter 3, we explored in more detail the role of the IL-32 promoter SNP in RA 
patients and their disease activity. By using disease activity scores (DAS28-CRP) of 
RA patients from the RA BIOTOP cohort we were able to correlate the genotypes 
to 6 months follow-up DAS28-CRP scores to anti-TNF treatment (etanercept or 
adalimumab). We showed a possible predictive role for the IL-32 promoter SNP on 
ex vivo response to anti- TNF treatment in clinical responders to either etanercept 
or adalimumab.
In Chapter 4, an in vivo model of human IL32 transgenic mice were studied to explore 
the role of IL-32 on lipid metabolism and diabetes. Moreover, the effect of IL-32 
presence in mice on their adipose tissue phenotype and possible inflammatory state 
was studied. We exposed IL32 transgenic mice to normal chow diet and characterized 
their IL-32-induced phenotype by measuring ex vivo cytokine production, circulating 
plasma cytokines, adipose tissue cell size and inflammatory markers. Interestingly, 
adipose tissue cell size was significantly increased in IL32 transgenic mice. In line 
with this, circulating concentrations of leptin were increased in transgenic mice 
compared to wild-type mice. Since all mice were only studied under normal chow 
conditions, these findings suggest IL-32 plays an important role in lipid metabolism. 
These observations indicated that it would be of high importance to explore the 
effect of a high fat diet regimen in IL-32tg mice. 
In Chapter 5, we tried to unravel part of the mechanism behind the effect of IL-
32 on lipoprotein metabolism/ regulation of HDLc concentrations. We studied 
the expression of the three main isoforms of IL-32, IL-32α, IL- 32β and IL-32γ and 
cholesterol transporters ABCA1 and ABCG1 in primary liver cells and the HepG2 
liver carcinogenic cell line. Furthermore, overexpression and silencing of IL-32 was 
performed to explore the effects on ABCA1 and ABCG1 expression. In both cell 
types, IL-32γ significantly correlated with ABCA1, ABCG1 and LXRα expression. 
Additionally, intracellular lipid content was decreased in HepG2 cells overexpressing 
IL-32 isoforms.
In Chapter 6, we studied the role of IL-32 and the possibility of IL-32 and the IL-
32 promoter SNP to affect inflammatory responses and lipoprotein metabolism in 
PBMCs from HIV-infected versus healthy individuals. IL-32 isoform mRNA expression 
was different in HIV patients compared to healthy individuals (in)dependent of 
the promoter SNP. HIV-infected showed more IL-32β mRNA expression in PBMCs 
after poly I:C stimulation compared to healthy individuals. Moreover, IL-32γ mRNA 
expression was higher in HIV-infected when bearing the TT genotype whereas 
healthy individuals showed more IL-32γ when bearing the CC genotype. Moreover, 
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INTRODUCTION
In patients with rheumatoid arthritis (RA), cardiovascular disease (CVD) represents 
the leading cause of death1,2. Various studies have demonstrated that besides 
behavioral risk factors and dyslipidemia, inflammation also plays a crucial role in 
the increased risk for CVD3. Additionally, inflammatory pathways in RA but also 
other chronic inflammatory diseases, including psoriasis, have been proposed to 
accelerate atherogenesis contributing to the increased CVD risk 4-6. These patients 
are continuously exposed to varying levels of inflammatory mediators (e.g. 
cytokines) that may alter traditional CVD risk factors, including the lipid pattern, 
both at the concentration and composition level7,8. Normally, a pro-atherogenic 
lipid profile consists of an increased total cholesterol (TC), low-density lipoprotein 
cholesterol (LDLc), triglycerides (TG), and a decreased high-density lipoprotein 
cholesterol (HDLc). However, in RA patients the lipid profile varies throughout 
different stages of the disease9,10. Particularly during active disease, these patients 
have low TC and LDLc levels, while their CVD risk is increased. Hence, due to the 
changeability of inflammatory activity and anti-inflammatory medication, the 
individual lipid profiles may frequently fluctuate during the course of disease 
making it hard to draw conclusions about the impact of these changes on CVD risk11. 
Of all lipids, HDLc is the most susceptible to inflammatory changes in terms of both 
concentration as well as composition12,13 14. In line with this, it was previously shown 
that HDLc becomes less anti-atherogenic or even pro-atherogenic in RA patients 
with an increased inflammatory status11.
Recently, IL-32 has been demonstrated to be an important key modulator of 
inflammation in RA15. In a previous study from our group, IL-32 was found to be highly 
expressed in synovial tissues from patients with moderate and severe rheumatoid 
arthritis and it was strongly correlated with the severity of joint inflammation. IL-32 
can be induced by TNF and can on its own further potentiate TNF expression16,17. Given 
this fact and the well-known roles of TNF in both RA and atherosclerosis, IL-32 was 
recently proposed to contribute to the development of atherosclerotic plaques18-20. 
In 2009 Dinarello et al described IL-32 as a critical regulator of endothelial cell 
function, possibly promoting atherosclerosis by potentiating IL-1β-induced ICAM-1 
and by producing pro-inflammatory cytokines in these cells21. This pro-atherogenic 
role of IL-32 was further supported by a recent report, which showed enhanced IL-32 
expression in atherosclerotic arterial vessel walls22. Additionally, IL-32 was found to 
be expressed by macrophages, with highly increased expression after stimulation 
of these cells with pro-inflammatory components that were previously appointed 
to be involved in atherosclerosis (e.g. toll-like receptor (TLR) 3 agonist Poly I:C 
ABSTRACT
Patients with rheumatoid arthritis (RA) are at higher risk of developing 
cardiovascular diseases (CVD). Interleukin (IL)-32 has previously been shown to 
be involved in the pathogenesis of RA and might be linked to the development of 
atherosclerosis. However, the exact mechanism linking IL-32 to CVD still needs to 
be elucidated. The influence of a functional genetic variant of IL-32 on lipid profiles 
and CVD risk was therefore studied in whole blood from individuals from the NBS 
cohort and RA patients from 2 independent cohorts. Lipid profiles were matched 
to the specific IL-32 genotypes. Allelic distribution was similar in all three groups. 
Interestingly, significantly higher levels of high density lipoprotein cholesterol 
(HDLc) were observed in individuals from the NBS cohort and RA patients from the 
Nijmegen cohort homozygous for the C allele (p=0.0141 and p=0.0314 respectively). 
In contrast, the CC-genotype was associated with elevated low density lipoprotein 
cholesterol (LDLc) and total cholesterol (TC) in individuals at higher risk for CVD 
(plaque positive) (p=0.0396; p=0.0363 respectively). Our study shows a functional 
effect of a promoter single-nucleotide polymorphism (SNP) in IL32 on lipid profiles 
in RA patients and individuals, suggesting a possible protective role of this SNP 
against CVD.
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Male:#114 RA1: Female:#155; Male:#137 and RA2: Female:#232; Male:#121). Only 
within the RA2 cohort there was a larger difference in number of females to males, 
nevertheless in none of the cohorts gender affected the HDLc (data not shown). 
Moreover, individuals carrying one C-allele show a small increase in HDLc levels. 
Concluding, the C-allele for the IL-32 promoter SNP is linked to an increase in HDLc 
levels independent of gender or having RA.
Fig. 1. The IL-32 promoter SNP. A. Location of the IL32 promoter SNP within the IL32 region on 
chromosome 16. B. Genotype frequencies of the IL32 rs4786370 promoter SNP in individuals from 
the NN cohort (NN; CC:19.2%, CT:45.7%, TT:35%), RA patients from the Radboudumc Nijmegen 
(RA1; CC:16.1%, CT:51%, TT:32.9%) and RA patients from the Reade clinic Amsterdam (RA2; CC:23%, 
CT:47.1%, TT:29.9%). Chi-square analysis (IBM SPSS Statistics v.22) showed no significant differences 
in genotype distribution between the cohorts.
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and interferon-gamma (IFNγ))23-25. Moreover, macrophages are known to play an 
important role in controlling cholesterol levels in blood vessel walls as they engulf 
cholesterol, become foam cells, and take part in reverse-cholesterol transport 
(RCT)26,27. Knowing that IL-32 expression can be highly induced in these cells upon 
inflammation, one can argue a role for IL-32 in cholesterol metabolism. Despite 
the suggested role of IL-32 in inflammation, CVD and disease progression in RA, 
studies investigating the IL-32 protein function and IL-32 gene polymorphisms with 
respect to these outcomes in RA are scarce22. However, our group recently showed 
that a single-nucleotide polymorphism (SNP) in the promoter region of the IL-32 
gene seemed to be associated with lower basal expression of IL-32β in peripheral 
blood mononuclear cells (PBMCs) of RA patients28. The same data showed lower 
pro-inflammatory cytokine production in PBMCs after stimulation with various 
compounds in patients bearing the CC genotype28. Additionally, various studies, 
including genome-wide association studies (GWAS) analyses, show effects of gene 
polymorphisms in for example TNF, CD247 and anti-cyclic citrullinated peptide 
(anti-CCP) RA and CVD18,29-31. The present study therefore aims to investigate the 
functional implications of a SNP in the IL-32 gene on the lipid profile and CVD risk in 
RA patients.
RESULTS
Genotype distribution of an IL32 promoter SNP is comparable between 
individuals from the NN cohort and RA patients
The genotype distribution of the IL32 promoter SNP (rs4786370) (Fig. 1A) was 
compared between three different cohorts. One cohort consisted of individuals 
from the NBS NIMA cohort (NN). The other two cohorts consisted of RA patients, 
one group of patients treated at the Radboudumc Nijmegen (RA1) and the other 
at the Reade Clinic in Amsterdam (RA2). No significant differences in genotype 
frequencies were observed between the three cohorts (Figure 1B).
The IL32 promoter SNP affects HDLc levels in both individuals from the 
NN cohort and RA patients
We studied the concentration of HDLc in each cohort because of its importance in 
development of cardiovascular disease. As shown in figure 2, in all three cohorts 
individuals having the CC genotype show higher levels of HDLc compared to either 
individuals with the CT and TT genotype with a significant increase in HDLc within 
the NN and RA1 cohort (p=0.0141 and p=0.0314 respectively). Further analysis was 
performed. focussing on gender differences within each cohort (NN: Female:#120; 
A
B
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Fig. 3 Lipoproteins and presence of plaques. A-D. Lipoproteins stratified for IL-32 promoter SNP 
rs4786370 and the presence or absence of plaques in individuals from the NN cohort. Genotype 
frequency, HDL cholesterol, LDL cholesterol and total cholesterol concentrations were determined 
in these individuals. Number of individuals CC-:25, CC+:20, CT-:61, CT+:46, TT-:37, TT+:45. Chi-square 
analysis (IBM SPSS Statistics v.22) showed no significant differences in genotype distribution between 
the groups. Values are expressed as means ± SEM. p-values are calculated using Mann-Whitney U- 
test, *p < 0.05 Graphpad prism v5.03.
HDLc is linked to the IL32 promoter SNP and the prevalence of CVD 
events in RA patients
CVD is a common problem in RA and the composition of cholesterol levels plays a 
crucial role herein. To determine if the IL-32 promoter SNP was involved in both these 
parameters, genotypes and cholesterol levels were determined in RA patients (RA1 
and RA2 cohort) with versus without a history in CVD (Fig.4A-D). No differences were 
observed in genotype distribution between the two groups (Fig.4A). Even so, HDLc 
levels were lower in individuals with a history of CVD, reaching lowest concentrations 
in individuals with the TT genotype (TT- versus TT+ p=0.0293)(Fig.4B). In contrast, 
patients carrying the CC genotype showed the highest levels of HDLc as was also 
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Fig. 2. HDL cholesterol levels. A HDL cholesterol levels stratified for the IL-32 promoter SNP 
(rs4786370) genotype in individuals from the NN cohort (TT#82, CT:#107, CC:#45, NN cohort) and 
RA patients from two different cohorts (RA1; TT:#96, CT:#149, CC:#47 and RA2; TT:#104, CT:#164, 
CC:#80). A significant induction in HDL cholesterol was observed in both individuals from the NN 
cohort and RA patients of the RA1 cohort carrying the C allele (NN; p=0.0141,RA1; p=0.0314 and RA2; 
p=0.8450). Values are expressed as means ± SEM. p-values are calculated using Mann-Whitney U-test, 
*p < 0.05 Graphpad prism v5.03.
HDLc levels are affected by the IL32 promoter SNP independent of the 
presence of plaques
Within the NN-cohort we were able to stratify the genotype frequency and 
cholesterol levels for the presence or absence of plaques detected by ultrasound 
(Fig. 3A-D). The percentage of individuals with the CC genotype seemed to be 
higher in the plaque negative group compared to the plaque positive group; 20% 
vs. 18% respectively although this did not reach statistical significance (Fig.3A). 
Additionally, individuals carrying the CC or CT genotype showed higher HDLc levels 
than individuals with the TT genotype independent of having plaques. Nevertheless, 
individuals with the CT genotype and having a plaque showed a decrease in HDLc 
(CT- versus CT +: p<0.0004) (Fig.3B).
Both LDLc and TC were not affected by the SNP in IL32 itself. However, higher 
levels of both LDLc and TC were observed in individuals who were found positive for 
plaques (Fig. 3C,D).
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DISCUSSION
The major novel findings of this study are that a promoter SNP in the IL32 gene 
is equally distributed in individuals from the NN cohort as in RA patients, but at 
the same time that this SNP causes an increase in HDLc in both groups. This effect 
doesn’t seem to be influenced by disease activity, the use of medication, the 
presence of plaques or a history of CVD (data not shown). In contrast, other lipid 
concentrations like LDLc and TC are not affected by the SNP but are linked with 
plaques or a history of CVD. This might further expand the knowledge about the 
underlying mechanisms for CVD in RA patients32-34.
Although chronic inflammation is known to affect cholesterol concentration in the 
body resulting in lower HDLc and LDLc levels, some studies have not been able to 
show the benefit of increasing HDLc34-38.
Nevertheless, HDLc does play a role in lowering the risk for CVD, especially in 
individuals with chronic inflammatory diseases like RA39,40. In RA there seems to be a 
tight relationship between the levels of HDLc, LDLc and disease activity, with lower 
levels during periods of active disease41-43. Even though this might speak against an 
increased risk for CVD, it is more the ratio between the levels of these different lipids 
(and probably their composition/function) that matters when assessing CVD risk. 
The fact that HDLc is decreased to a greater extent than the TC in these patients, 
results in a higher atherogenic index (the ratio between TC and HDLc) and therefore 
an increased CVD risk37,44. In addition, HDLc is less capable of exercising its anti- 
atherogenic functions if inflammation levels are still uncontrolled8. Conversely, 
when RA patients receive standard treatment including DMARDs and biological 
agents like anti-TNF therapy, cholesterol levels might increase, which correlates 
with the level of suppression of their disease activity44,45. In our study, no differences 
were observed in disease activity between genotypes concluding that the variation 
in HDLc was not caused by difference in disease activity (Supplementary Fig. 
S1A-B). Nevertheless, CVD is still the number one cause of death in RA, showing the 
importance of exploring how cholesterol metabolism and regulation is affected in 
these patients.
Genetic factors can also play a role in the development of the accelerated 
atherogenesis observed in RA patients as was described previously. Some studies 
describe that several gene polymorphisms for example in TNFα and NFkB1 have 
been found associated with an increased risk of CVD or subclinical atherosclerosis 
in RA18,46,47. Moreover, GWAS studies show many different gene polymorphisms 
observed within the individuals from the NN cohort (Fig 3B). Besides, lower levels 
of LDLc and TC were observed in individuals with a history of CVD (Fig. 4C,D). This 
was completely opposite from what was found in individuals from the NN cohort 
as shown in figure 3C,D. Overall, patients with a history of CVD and carrying the TT 
genotype had lowest HDLc, LDLc and TC (Fig.4B-D).
Fig. 4 Lipoproteins and CVD events. A-D. Lipoproteins stratified for IL-32 promoter SNP rs4786370 
and the presence or absence of an previously described CVD. Allele frequency, HDL Cholesterol, 
LDL Cholesterol and Total Cholesterol concentrations were determined in patients with RA from 
the RA2 cohort (Reade center Amsterdam). Number of individuals: CC-:63(37.5%), CC+: 17(21.1%), 
CT-:145(30.2%), CT+:18(, TT-:90 , TT+: 14. Chi-square analysis (IBM SPSS Statistics v.22) showed no 
significant differences in allelic distribution between the cohorts. Values are expressed as means ± 
SEM. p-values are calculated using Mann-Whitney U-test, *p < 0.05 Graphpad prism v5.03.
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When taken together, we suggest a novel role for a genetic polymorphism in the 
promoter region of IL-32 causes an increase in HDLc levels in individuals from the 
NN cohort and RA patients. This might have functional effects leading to a lower 
prevalence of carotid artery plaques. This has not been investigated in the present 
study, but should be taken into account in future investigations. Our results lead 
to the assumption that IL-32 is a previously unrecognized cytokine involved in 
the process of inflammation and cholesterol metabolism. However, currently we 
are still investigating the exact mechanism behind the role of IL-32 in cholesterol 
metabolism regulation.
METHODS
Patient cohorts
From the total number of participants from the NBS NIMA study, only a subgroup 
of 234 participants, from whom the IL32 promoter SNP was determined, were 
included in this study. The NBS is a population-based survey as described before53. 
Participants aged 50–70 yr were asked to visit the hospital to perform six non- 
invasive measurements of atherosclerosis (NIMA) including pulse wave velocity 
(PWV), augmentation index (Aix), intima-media thickness (IMT), plaque thickness, 
ankle-brachial index (ABI) at rest and after exercise. Additionally, fasting venous 
blood samples were collected. All participants filled out a questionnaire about their 
previous history of vascular disease, medication use, smoking habits, and exercise 
habits. Prevalent CVD was defined as a reported myocardial infarction (MI), transient 
ischemic attack (TIA), stroke (CVA), peripheral arterial disease (PAD), coronary 
artery bypass or angioplasty, or treated angina. The Medical Ethics Committee of 
the Radboud university medical center, Nijmegen (nr.2010-397), The Netherlands 
approved the study protocol, and all participants provided written informed 
consent54. Experiments were conducted according to the principles expressed in the 
Declaration of Helsinki.
Patients with RA who fulfilled the 1987 ACR criteria and/or the 2010 ACR/EULAR 
classification criteria for RA were recruited from the Radboudumc in Nijmegen, The 
Netherlands. These patients underwent a screening program of their CVD risk factors 
between July 2011 and August 2012. Disease-related parameters, lipid profile and 
history of cardiovascular events were registered (Table 1). In addition, the Nijmegen 
inception cohort database was checked for patients who had already been screened 
previously. The Nijmegen inception cohort is a prospective study that started in 
1985 which includes regular visits for disease related parameters and blood samples 
related to RA, also finding new polymorphisms which were not yet described 
in other studies like polymorphisms in IL6ST, IRF5 and PTPN229,48. In at least one 
study which performed GWAS analyses, IL-32 was present in the data which could 
suggest a role for IL-32 in the disease49. In contrast, other studies investigating gene 
polymorphisms in IL-6 for example, were not able to link these to an increased risk of 
subclinical atherosclerosis or CVD in RA when it was hypothesized that these could 
be associated50,51.
IL-32 has previously been described to play a role in the pathogenesis of RA and 
additionally it has been suggested that IL-32 plays a role in atherosclerosis, 
presumably contributing to the increased CVD risk in this population. As mentioned 
earlier, recent data showed that a SNP in the promoter region of the IL-32 gene seemed 
to be associated with lower basal expression of IL-32β and lower pro-inflammatory 
cytokine production in PBMCs of RA patients bearing the CC-genotype28. Therefore, 
we hypothesized that there is also a genetic polymorphism in the promoter region 
of IL-32 that could affect and possibly lower the CVD risk in RA patients. To our 
knowledge, this is the first study demonstrating that a functional SNP in IL-32 is 
linked to an increase in HDLc in RA patients and individuals from the NN cohort, 
suggesting IL-32 by itself can affect cholesterol metabolism. Individuals carrying the 
CT genotype already showed higher HDLc levels compared to individuals bearing 
the TT genotype, while having the CC genotype results in even higher HDLc. This 
suggests that having one C-allele might already affect IL-32 expression in a way that 
results in higher HDL cholesterol. The increased HDLc concentrations in individuals 
bearing the C-allele might be due to lower levels of TNFα, which is known to suppress 
cholesterol synthesis52. Another possible explanation could be that expression of a 
specific IL-32 isoform affects intracellular pathways resulting in for example higher 
cholesterol efflux or increased level of apoA-I (the main protein component of 
HDLc). The SNP however only seems to affect HDLc since no observation was made 
in individuals from the NN cohort or RA patients linking the SNP to lower or higher 
LDLc or TC. In our study, RA patients with a history of CVD had lower LDLc and TC 
compared to patients without a history of CVD and also lower levels than individuals 
from the NN cohort. This might be explained by the fact that these RA patients 
probably received statins after going through an event.
Our study has several limitations. Most of them are related to the difficulties of 
comparing the three heterogeneous cohorts. Various measurements like blood 
pressure or underlying disease (like diabetes) were not notified for all patients or 
individuals within the cohorts making it impossible to correct for all these factors.
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DNA isolation and Taqman genotyping
Blood was obtained from 297 RA patients from the Radboudumc (RA1), 353 RA 
patients of the Jan van Breemen Institute (Reade)(RA2) and 234 individuals from the 
NBS NIMA study (NN). Genomic DNA was extracted from leukocytes in peripheral 
venous blood as previously described55. The samples were quantified and evaluated 
for purity (260/280-nm ratio) with a NanoDrop ND-1000 spectrophotometer (Thermo 
Scientific). The genetic variant in the IL32 promoter (rs4786370) polymorphism was 
determined using the TaqMan SNP assay C_27972515_20, (Thermofisher, Foster 
City, CA, USA). The TaqMan qPCR assays were performed on the AB StepOnePlus 
polymerase chain reaction system (Applied Biosystems). Negative controls were 
included in the assay. No duplicates were used.
IMT measurements
Carotid IMT was determined using an AU5 Ultrasound machine (Esaote Biomedica, 
Genova, Italy) with a MHz linear-array transducer. Longitudinal images of the distal-
most 10 mm of both the far wall and the near wall of both common carotid arteries 
(CCA) were obtained in the optimal projection. Actual measurement of the IMT 
was performed off-line by the sonographer at the time of the examination, using 
semi-automatic edge-detection software (MAth®Std Version 2.0, Metris, Argenteuil, 
France). Reproducibility of our IMT measurements as investigated by the method 
of Bland and Altman had been reported before: the mean (±S.E.M.) difference for 
repeated measurements by the same observer was 0.003 ± 0.007 mm56,57.
Statistical analysis
Normality was tested using the D’Agostino and Pearson omnibus normality test. 
Continuous variables are presented as mean and standard deviation (SD) or as 
median followed by the interquartile range (IQR).
Categorical variables are presented as number followed by percentage. The 
differences between allele frequency and lipid concentrations measured in RA 
patients and individuals from the NN cohort were analyzed using the Mann-Whitney 
test. Chi-square test was used to test for differences between categorical variables. 
A p-value less than 0.05 was considered statistically significant (*p<0.05 and 
**p<0.01). Data was analyzed using GraphPad Prism v5.0.
in patients with RA. Eventually, 297 patients have been identified as participants 
of both the inception cohort and the CVD screening program. These patients were 
included in this study. The stored blood samples of the inception cohort were used 
for the determination of the SNP in the IL-32 gene.
The CARdiovascular research and RhEumatoid arthritis (CARRÉ) study is an ongoing 
prospective cohort investigating cardiovascular (CV) disease and CV risk factors in 353 
patients with RA (CCMO P 01.0408L, METC 0105). In 2000, a random sample was drawn 
of patients registered at the Jan van Breemen Institute (now Reade) in Amsterdam, 
The Netherlands. Patients were eligible if they fulfilled the 1987 American College of 
Rheumatology (ACR) classification criteria, were diagnosed with RA between 1989 
and 2001 and were aged 50 to 75 years. Patient enrollment was between 2001 and 
2002 with follow up visits in 2004-2005 and 2010-2011. CV endpoints were defined as 
a verified medical history of coronary, cerebral or peripheral arterial disease (Table 1). 
Cohort NBS NIMA (NN) Radboudumc (RA1) Reade (RA2)
N 234 297 353
Age, years 61 ± 6 60 ± 12 63 ± 8
Female, no (%) 120 (51.34) 155 (52.2) 232 (65.7)
Disease duration, years n.a. 9 (3-17) 7 (4 – 10)
Rheumatoid factor positive, no (%) n.a. 202 (68.2) 256 (72.5)
Anti-citrullinated protein antibodies positive, no. (%) n.a. 160 (53.9) 187 (54.5)
History of CVD, no (%) 57 (24.4) 63 (22.6) 51 (14.4)
DAS28 n.a. 2.97 (1.18) 3.90 (1.35)
Diabetes, no (%) 14 (6.0) 18 (6.1) 17 (4.8)
Systolic blood pressure, mmHg 130 ± 17 132 ± 17 142 ± 20
Diastolic blood pressure, mmHg 78 ± 10 77 ± 10 81 ± 9
Total cholesterol, mmol/L 5.92 ± 1.11 5.2 ± 1.13 5.77 ± 1.12
HDL cholesterol, mmol/L 1.39 ± 0.40 1.3 ± 0.34 1.46 ± 0.48
LDL cholesterol, mmol/L 3.89 ± 0.98 3.1 ± 1.07 3.69 ± 1.03
Triglycerides, mmol/L 1.29 (0.91-1.81) 1.53 (1.09-2.14) 1.32 ( 3.04 – 4.42)
Table 1. Baseline characteristics of the cohorts. Values are presented as mean ± SD, median (IQR) or 
numbers (percentages).
CVD: cardiovascular disease, DAS28: disease activity score 28, HDL: high density lipoprotein; 
LDL: low-density lipoprotein.
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SUPPLEMENTAL FIGURE
IL-32 promoter SNP rs4786370 predisposes to modified lipoprotein profiles in patients with rheumatoid 
arthritis
Supplementary Fig. S1. DAS28-scores split on the IL-32 promoter SNP genotype within the two 
RA-patients cohorts. A. represents DAS28-scores of RA patients from the RA1 cohort. B. Represents 
DAS28-scores of RA patients in the RA2 cohort.
Supplementary Fig. S1A Supplementary Fig. S1B
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INTRODUCTION
Rheumatoid arthritis (RA) is a common autoimmune and chronic inflammatory 
disease affecting about 1% of the population1, 2. RA is characterized by persistent 
joint inflammation, progressive disability and ongoing systemic inflammation, which 
can lead to joint deformity and low quality of life. Moreover, these characteristics 
are also able to increase the risk for atherosclerosis and cardiovascular disease 
(CVD), which is the main cause of death in these patients3-5. The clinical course of RA 
varies tremendously between patients from spontaneous remission, to mild joint 
symptoms to severe bone destruction. Early and aggressive treatment has been 
shown to improve the outcome. The introduction of biological disease-modifying 
anti- rheumatic drugs (bDMARDs) in combination with “treat-to-target” treatment 
strategy significantly improved the disease outcomes in RA. These bDMARDs 
however still only achieve good response in about 40% of RA patients. The 
variation in clinical response to bDMARDs could be explained by variations in drug 
concentration and pharmacokinetics, which in turn are influenced by age, gender, 
renal or liver function6. Alternatively, the genetic background may also play a role 
and the interplay with the other factors could conduct towards specific profiles 
and increase the chance of achieving a good clinical response, suggesting a niche 
personalized medicine.
The pathogenesis of RA still remains partly unknown but results in a chronic 
inflammatory state. The initial phase involves the activation of T and B cells and the 
induction of pro-inflammatory cytokines such as IL-6, IL- 1β and TNFα7-9. TNFα is 
clearly of high importance in the pathogenesis of RA, which is shown by the fact that 
TNFi’s can effectively reduce the chronic inflammation in RA10,11. Moreover, TNFα 
is also capable of inducing other pro-inflammatory mediators, such as chemokines 
and cytokines IL-6, IL-1β and IL-32, all found to be important in RA11,12. Studies of the 
last decade have shown that the cytokine interleukin-32 (IL-32) by itself is a strong 
inducer of TNFα and the expression levels of IL-32 in synovial biopsies correlated 
with inflammation severity in RA13,14. Moreover, overexpression of IL-32γ in human 
synovial fibroblasts followed by stimulation of TLR2/NOD2, showed a potent 
induction of TNFα mRNA15. In contrast, when IL-32 was suppressed, TNFα production 
was decreased in human monocytes, all showing the important pro-inflammatory 
properties of IL- 32 and its close relation with TNFα15,16. Despite knowing the 
interaction between these two cytokines and the importance in RA, research on 
the specific role of IL-32 in RA remains scarce. Our group recently showed a role 
for a promoter single-nucleotide polymorphism (SNP) in IL-32 that seemed to be 
associated with cytokine production, IL-32 isoform expression and high-density 
ABSTRACT
Objective: Still about 60% of RA patients do not achieve good response with 
biological disease-modifying anti-rheumatic drugs bDMARD treatment (including 
TNF inhibitors, TNFi’s). Previously, a strong link between TNFα and interleukin 
(IL)-32 has been reported in RA. We hypothesize that a promoter single nucleotide 
polymorphism (SNP) rs4786370 in IL-32 can affect clinical responsiveness to TNFi’s 
in RA patients, potentially serving as new biomarker in RA.
Methods: Peripheral mononuclear cells (PBMCs) from RA patients and healthy 
individuals were stimulated with RPMI or recombinant human (rh)TNFα to study 
mRNA and protein expression of pro-inflammatory cytokines. Moreover, “ex vivo 
response” and clinical response to anti-TNFα therapy (etanercept, adalimumab) 
measured by disease activity scores (DAS28), of RA patients were measured and 
were stratified for the IL-32 SNP.
Results: Stimulation of PBMCs from RA patients showed higher IL-32 protein 
production and a tendency towards higher IL-32β/IL-32γ mRNA expression 
compared to healthy individuals. Patients bearing the CC genotype showed higher 
IL-32 protein expression and produced more cytokines. The DAS28 did not depend 
on the presence of the promoter SNP, however, the “ex vivo” cytokine response did 
have a different pattern in clinical responders depending on the genotype.
Conclusion: IL-32 mRNA and protein production was higher in RA patients compared 
to healthy individuals, with a trend towards higher concentrations in patients 
bearing the CC genotype. Furthermore, IL-1 beta production in the CC-genotype 
might predict clinical response to etanercept or adalimumab. These data indicate 
that IL-32 could play a role in predicting the response to treatment in RA.
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The Netherlands) and collecting the buffy-coat enriched layer. Cells were washed 
twice in cold PBS and concentrations were adjusted to 5 × 106 cells/ml in RPMI-1640, 
supplemented 2 mM l- glutamine, 1 mM pyruvate and 50 μg/ml gentamicin (GIBCO 
Invitrogen, Carlsbad, CA). Mononuclear cells (5 × 105) in a 100-μl volume were added 
to round-bottom 96-well plates (Greiner, Nurnberg, Germany) and incubated with 
either 100 μl of culture medium (negative control), Poly I:C (50uL Invivogen), or 
recombinant human TNFα (rhTNFα 10ng R&D Systems). After 24 hour incubation 
at 37°C, the supernatants were stored at - 20°C until further use. Besides these 
experiments, additionally 5 × 105 PBMCs were pre-incubated in round bottom 
96-well plates for one hour at 37 °C with therapeutic in vivo concentrations of 
adalimumab or etanercept. Taking into account the different half-life times, dosing 
and treatment intervals, and therapeutic concentration ranges of the anti-TNFα, 
the same concentration of 5 µg/mL was added for both anti-TNFα bDMARDS (4-6). 
Human IgG was used as negative control. Thereafter, cells were stimulated with 
either Pam3Cys (a TLR2 agonist) or heat killed Candida albicans (ATCC MYA-3573 
(UC 820)). After 24 hours, supernatants were stored at -20 °C until assayed.
Cytokine measurements
Various cytokines were determined in supernatant after stimulation of PBMCs with 
recombinant human TNFα (10 ng/ml) (R&D Systems), recombinant human IL-1β 
(1ng/mL R&D Systems) or Poly I:C (TLR3 agonist)(50 µg/ml) (Invivogen) for 24hours, 
by commercially available ELISA kits according to manufacturer’s instructions. 
Concentrations of human IL-1β, IL-1Ra (R&D Systems, Inc., Minneapolis, MN, 
USA) and IL-6, IL-8, IL-10 (Sanquin Reagents, Amsterdam, The Netherlands) were 
measured. IL-32 production was measured in cell lysates (Triton X 100 0.5%) of 
PBMCs stimulated with various ligands, using the commercially available ELISA kit 
(R&D Systems, Inc, Minneapolis, MN, USA). In brief, Maxisorp plates (Nunc) were 
coated with AF3040 (R&D Systems) diluted in Phosphate Buffered Saline (PBS) 
at a concentration of 0.4 αg/ml and incubated overnight at room temperature. 
Plates were blocked with PBS containing 1 % BSA (Sigma-Aldrich) for 1 hour at 
room temperature. The standard curve was prepared by diluting recombinant IL-32 
ranging from 5000 pg/ml until 39.06 pg/ml in PBS containing 5 % BSA. After a 2hour 
incubation with the cell lysates, detection antibody was added (BAF3040, R&D 
Systems), 0.1 µg/ml in PBS with 5 % BSA for 1hour. Streptavidin (R&D Systems) was 
added for 30 minutes at room temperature after which substrate buffer was used to 
develop a color reaction that was measured by a plate reader.
cholesterol (HDLc) levels in RA patients17,18. The present study therefore aims to 
investigate the possible predictive implications of this SNP in the IL-32 gene on the 
severity of the disease and the clinical response to TNFI’s (including adalimumab or 
etanercept) in RA patients.
MATERIAL AND METHODS
Patient cohort
Blood samples were obtained from patients included in the prospective longitudinal 
prediction cohort study BIO-TOP [Biologic Individual Optimized Treatment Outcome 
Prediction] and isolated immune cells were used for various assays. RA patients >18 
years, treated in the Sint Maartenskliniek (Nijmegen, the Netherlands) who were 
going to start with (or switch to) a biological disease-modifying anti-rheumatic drug 
(bDMARD) were included in this study. The local ethical committee (CMO region 
Arnhem-Nijmegen, NL47946.091.14) was responsible for approval of the BIO-TOP 
study and a detailed description is available in the Dutch trial register (NTR4647 
clinical trial, 17-jun-2014, NTR). Additionally, blood samples of healthy individuals 
were used.
Written informed consent was received from all donors. Experiments with human 
blood were performed in accordance with the Declaration of Helsinki.
DNA isolation and taqman genotyping
Whole blood obtained from 329 RA patients in the BIOTOP study was used to perform 
genomic DNA extraction. Genomic DNA was isolated from whole blood using 
the Qiagen (Valencia, CA, USA) isolation kit and following the standard protocol. 
The samples were quantified and evaluated for purity (260/280-nm ratio) with a 
NanoDrop ND-1000 spectrophotometer (Thermo Scientific). Using the Taqman SNP 
assay C_27972515_20 (Thermofisher, Foster City, CA, USA), each genetic variant in 
the IL32 promoter (rs4786370) polymorphism was determined. The TaqMan qPCR 
assays were performed on the AB StepOnePlus polymerase chain reaction system 
(Applied Biosystems). Negative controls were included in the assay. No duplicates 
were used.
Isolation and ex-vivo stimulation of peripheral blood mononuclear cells 
(PBMCs)
At baseline (before start bDMARD), venous blood was collected into three 10 mL 
EDTA tubes after informed consent. Within 24 hours, PBMCs were isolated by 
density gradient centrifugation using Ficoll-Paque PLUS (GE Healthcare, Zeist, 
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Fig 1. mRNA and expression of IL-32 isoforms IL-32β, IL-32γ, in RA patients and healthy individuals 
in (un)stimulated PBMCs also separated on IL-32 promoter SNP genotypes. A). mRNA expression of 
IL-32β in PBMCs from healthy individuals versus RA patients in unstimulated PBMCs (n=7 healthy 
individuals; n=22 RA patients). B). mRNA expression of IL-32γ in PBMCs from RA patients and healthy 
individuals in unstimulated PBMCs (n=7 healthy individuals; n=22 RA patients). C). mRNA expression 
of IL-32β in unstimulated PBMCs or PBMCs stimulated with rhTNFα from RA patients versus healthy 
individuals with the CC- versus TT-genotype for the IL-32 promoter SNP (n=13 TT; n=9 CC Ra patients). 
D). mRNA expression of IL-32γ in unstimulated PBMCs or PBMCs stimulated with rhTNFα from RA 
patients versus healthy individuals with the CC- versus TT-genotype for the IL-32 promoter SNP (n=13 
TT; n=9 CC RA patients).
IL-32 protein expression is highest in RA patients bearing the CC-
genotype
Even though there were no significant differences observed in IL-32β and IL-
32γ isoforms mRNA expression between RA patients and healthy individuals, 
independent of IL-32 promoter SNP, the endogenous IL-32 protein expression was 
investigated. IL-32 protein concentration was determined in the two groups as a 
whole as well as stratified for IL-32 promoter SNP (Fig.2A-B). Figure 2A shows a 
significantly higher IL-32 protein expression in RA patients compared to healthy 
individuals in unstimulated PBMCs. Of note, the production of IL-32 protein was 
significantly higher especially in the RA patients with the CC-genotype (Fig. 2B), 
whereas in the group bearing the TT-genotype it did not reach statistical significance.
Clinical assessments
Disease activity was measured with the 28-joints disease activity score using 
C-reactive protein (DAS28-CRP) during outpatient clinical visits performed in usual 
care after 3 and 6 months (±1 month). Primary outcome was the DAS28-CRP based 
European League Against Rheumatism (EULAR) response criteria (good versus 
moderate/no response) at month 6.
Statistical analysis
Normality was tested using the D’Agostino normality test. Continuous variables 
are presented as mean and standard deviation (SD). The differences IL-32 mRNA 
expression, IL-32 protein concentrations and cytokine concentrations were analyzed 
using the Mann-Whitney test. A p-value less than 0.05 was considered statistically 
significant (*p<0.05 and **p<0.01). Data was analyzed using GraphPad Prism v5.3.
RESULTS
IL-32 isoform mRNA expression in RA patients versus healthy subjects
PBMCs of RA patients (n=22) and those of healthy individuals (n=7) were isolated 
and IL-32β and IL-32γ mRNA expression were determined. First, IL-32β and IL-32γ 
isoforms expression was determined in unstimulated PBMCs, independent of the 
IL-32 promoter SNP genotype (Fig. 1A-B). Although no significant differences were 
observed, there is a clear trend towards more IL-32β and IL-32γ mRNA expression 
in the RA patients compared to the healthy individuals (Fig. 1A-B). Thereafter we 
examined whether the IL-32 promoter SNP genotype (T/C) would influence this 
latter result (Figure 1C-D). Unstimulated PBMCs of RA patients with the TT-genotype 
showed a tendency towards higher IL-32β mRNA expression compared to healthy 
individuals (Fig.1C). RA patients bearing the CC-genotype did not show differences 
on IL-32β mRNA expression neither in unstimulated nor in the case PBMCs have been 
stimulated with recombinant human TNFα (rhTNFα) (Fig. 1C). Exploring specifically 
IL-32γ, a trend towards higher IL-32γ mRNA expression in unstimulated PBMCs of 
patients bearing the CC genotype could be observed. When stimulated with rhTNFα, 
RA patients bearing the TT-genotype seemed to express more IL-32γ compared to 
the unstimulated condition and the expression of IL-32γ in the group bearing the CC-
genotype. However, none of these observations were statistical significant (Fig. 1D).
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A pro-inflammatory status of RA PBMCs bearing the CC-genotype
After observing differences in IL-32 mRNA isoforms expression and IL-32 protein 
expression between RA patients and healthy individuals, we examined the 
potential role of the CC-genotype in RA patients. We were interested to determine 
whether the genotypes in IL-32 promoter SNP would be associated with a different 
inflammatory response. In order to explore this, we investigated the capacity of ex-
vivo cytokine production by PBMCs after exposure with various proinflammatory 
stimuli. Figures 3A-3C clearly showed that PBMCs isolated from RA patients bearing 
the CC-genotype produce more IL-6 and IL-8, compared to TT genotype.
Depending on the stimuli, the enhanced production of IL-8 reached statistical 
significance after PBMCs have been stimulated with rhIL-1β (Fig. 3B). In line with 
these results, PBMCs bearing the CC genotype produce more IL-1Ra, although this 
was not statistical significant.
DAS28-CRP is not affected by IL-32 promoter SNP genotypes
After observing that RA patients, particularly those bearing the CC-genotype of 
the IL-32 SNP promoter, produce more pro-inflammatory cytokines, we thought 
to investigate whether this could have an impact on disease activity of these RA 
patients. To quantify disease activity, we used well-established DAS28-CRP score. 
As shown in Figure 4A, no differences were observed in DAS28-CRP scores between 
the two genotypes for the IL-32 promoter SNP at baseline. In the subgroups of 
patients who started treatment with respectively adalimumab and etanercept. IL-32 
genotype did not influence the DAS28-CRP at three as well as six months afterwards 
(Fig. 4B-C).
IL-32 genotype could help to predict the response on etanercept and 
adalimumab in RA
In order to provide a possible explanation on the fact that the IL-32 promoter 
SNP did not influence the response of RA patients to therapy with adalimumab 
or etanercept in the first six months, we further thought to assess whether the 
genotype could affect the ex vivo response of PBMCs to various stimuli in the 
presence of etanercept or adalimumab. In addition, we also wanted to address the 
question whether patients who eventually show a good clinical response to these 
bDMARDs have a different inflammatory response at baseline dependent on the 
IL-32 genotype. More specifically, if RA patients with either the CC or TT genotype 
would respond better to the specific bDMARD by showing a different cytokine 
response (Fig. 5A-D and Supplementary Fig S1 and Supplementary tables T1, T2). 
IL-1β production by PBMCs tends to decrease after Candida albicans stimulation in 
Fig 2. Protein expression of total IL-32 in unstimulated PBMCs from healthy individuals and RA 
patients also stratified for IL32 promoter SNP. A) A statistical significant difference was found in IL-32 
protein expression between these groups (p<0,0044) using the Mann-Whitney test in Graphpad Prism 
v5.03 (n=8 TT healthy individuals and n=25 TT RA patients versus n= 8 CC healthy individuals and n=14 
CC RA patients). B) IL-32 protein concentrations were stratified for the IL-32 promoter SNP genotypes 
TT and CC. A significantly higher concentration of IL-32 protein was found in the RA patients carrying 
the CC-genotype compared to healthy individuals with the same genotype (p<0.0105).
Fig 3. Cytokine measurements in PBMCs from RA patients and stratified for the IL-32 promoter SNP 
after stimulation with either Poly I:C and rhIL-1β or rhTNFα. A) IL-6 protein concentration in PBMCs of 
RA patients with the TT- versus CC-genotype for the promoter SNP, at basal level and after stimulation 
B) IL-8 protein concentration in PBMCs of RA patients with the TT- versus the CC-genotype for the 
IL-32 promoter SNP, at basal level and after stimulation C) IL- 1Ra protein concentration in PBMCs of 
RA patients with the TT- versus CC-genotype for the IL-32 promoter SNP at basal level as well as after 
stimulation. Statistical significance was shown by * when p<0.05, GraphpadPrism V5.03. (n=27 TT RA 
patients and n= 15 CC RA patients).
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Fig 5. Percentage of IL-1β production corrected for baseline IL-1β production induced by Candida IgG 
stimulation of PBMCs from RA patients in the presence of anti-TNFα treatment (etanercept). A)IL-1β 
cytokine production after ex vivo stimulation of PBMCs from RA patients with additional etanercept or 
adalimumab for 24h independent of clinical treatment (n=121). B) IL-1β cytokine production after ex 
vivo stimulation of PBMCs from RA patients with additional etanercept, stratified for RA patients that 
clinically responded or not to etanercept (n= 26 non-responders; n=19 responders). C) IL-1β cytokine 
production after ex vivo stimulation of PBMCs from RA patients with additional etanercept, stratified 
for clinical responders to etanercept treatment and IL-32 promoter SNP (n=4 CC; n=15 TT RA patients). 
D) IL-1β cytokine production after ex vivo stimulation of PBMCs from RA patients with additional 
etanercept, stratified for clinical non-responders to etanercept and IL-32 promoter SNP genotype (n=9 
CC and n=17 TT RA patients). Statistical significance was shown by * when p<0.05, GraphpadPrism 
V5.03.
DISCUSSION
In this study, we showed that mRNA expression levels of IL-32 isoforms IL-32β and 
IL-32γ tended to be higher in PBMCs isolated from RA patients as compared to 
healthy individuals. Additionally, intracellular IL-32 protein production was higher 
in RA patients, especially in those bearing the CC-genotype. These patients also 
tended to produce more pro-inflammatory cytokines in-vitro. However, this fact 
did not translate into a higher disease activity, as assessed by DAS28-CRP scores. 
the presence of either adalimumab or etanercept (Fig. 5A). When the IL-1β cytokine 
production was stratified for clinical responders versus non-responders to either 
etanercept or adalimumab (Fig. 5B and Suppl. Fig. S1), higher IL-1 production in 
the clinical responders was noted, though not reaching statistical significance. We 
further divided these groups according to their genotype for the IL-32 promoter 
SNP. Figure 5C/D and supplementary Fig. S1 indicate that for the clinical responders 
to either etanercept or adalimumab, RA patients bearing the CC genotype seem to 
produce more IL-1β after ex vivo stimulation of PBMCs, even reaching a statistical 
significant difference in the case of etanercept treatment. In contrast, no such effect 
was observed for RA patients bearing the TT genotype. To try and explain this effect 
in more detail we calculated the percentage of ex vivo responders to etanercept and 
adalimumab. This data however does not show to be able to predict a possible effect 
of the IL-32 promoter SNP on the clinical responsiveness of RA patients to anti-TNFα 
therapy (Supplementary Tables T1-T2).
Fig 4. Disease activity scores (DAS) 28 in RA patients stratified on IL-32 promoter SNP used therapy 
(etanercept or adalimumab). A) DAS 28CRP separated on IL-32 promoter SNP genotype and 
independent of therapy (n = 37 CC vs 85 TT). B) DAS28CRP separated on IL-32 promoter SNP genotype 
and Etanercept therapy (n =13 CC vs 32 TT). C) DAS28CRP separated on IL-32 promoter SNP genotype 
and Adalimumab therapy (n = 4 CC vs 13 TT).
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term outcomes. Unfortunately, this study showed that the promoter SNP in IL-32 
was not such a marker. Even though it has functional effects on cytokine production 
by PBMCs or on the HDLc concentration, no effect was seen on the level of disease 
activity, as measured by DAS28-CRP. These results are somehow in contrast with 
the study of Gui et al., which observed correlations between the IL-32 levels and 
disease activity23. The number of patients enrolled and the different design might 
explain this discrepancy. Alternatively, IL-32 might differently impact the various 
components of DAS28 score, for instance the number of tender joints or the VAS.
Single nucleotide polymorphisms in other cytokines such as TNFα, IL-1β and IL-6 
have been studied in possible association to response to treatment in RA patients25-28. 
Since IL-32 is strongly linked to TNFα expression and can induce IL-6 and IL-1β, it 
was worth investigating whether this SNP also had an effect on clinical response 
to treatment. No differences were observed when looking at the clinical response 
independent of treatment or anti-TNFα (etanercept or adalimumab) treatment in 
particular, when separated on the promoter SNP for IL-32.
Besides the clinical response, the ex vivo response of PBMCs stimulated with 
additional etanercept or adalimumab and Candida albicans or Pam3Cys was studied 
by looking at IL-1β cytokine production after stimulation. A previous study by Popa 
C et al. could not detect differences in IL-1β cytokine production after anti-TNFα 
treatment29. Interestingly, our data however showed that PBMCs of RA patients 
bearing the CC genotype produced more IL-1β after ex vivo stimulation only within 
the group of RA patients that clinically responded to either etanercept or possibly 
adalimumab treatment. No such differences were observed either for the clinical 
non-responders or patients bearing the TT genotype. This was in line with data from 
another study by Kayakabe K et al. which showed that IL-1β could serve as a possible 
predictive measurement for response to anti-TNFα treatments30.
These results suggest that even though the IL-32 promoter SNP does not have an 
effect on DAS28 scores, there might be a role for the genetic polymorphism in the 
promoter region of IL-32 in the prediction of clinical response to anti-TNFα treatment 
in RA patients also taking into account the observed influence on the production 
of pro-inflammatory cytokines in these patients. Given the previously indicated 
relation between the promoter SNP and HDLc levels in RA patients and the new 
findings of the functional effect of the promoter SNP on cytokine production and 
response to treatment, these data show a possible additional role of IL-32 and its 
promoter SNP in RA. Our results therefore lead to an area of research in which the 
effects of IL- 32 and the promoter SNP in RA have to be studied relevant to response 
Finally, ex-vivo PBMCs stimulations in the presence of the intended medication 
could potentially identify the patients who would become responders according to 
clinical criteria. The determination of IL-32 promoter SNP in this context proved to 
have crucial importance.
IL-32 mRNA isoforms have been studied so far in many different cell types and 
diseases including chronic obstructive pulmonary disease (COPD), various types of 
cancer and RA14,19-21. Nevertheless, the exact expression pattern of the isoforms in 
specific cells or tissues and the function of each isoform still need to be elucidated21. 
It is known that the structure of the two isoforms IL-32β and IL-32γ is quite similar 
and that IL-32γ mRNA can be spliced into IL-32β22. Both isoforms seem to be involved 
in pro-inflammatory processes, including the induction of other pro-inflammatory 
cytokines and chemokines like IL-8, IL-6, IL-1β and TNFα. In our study, we found a 
higher IL-32 protein production from PBMCs of RA patients together with a slightly 
higher IL-32 mRNA expression in the same patients. This is in line with previous data 
pointing to a higher IL-32 mRNA expression in fibroblast-like synoviocytes (FLS) 
of RA patients and also in the PBMCs22,23. Interestingly, here we show that only 
in patients bearing the CC-genotype, the increase in plasma IL-32 concentrations 
reaches statistical significance. This could also be due to the low number of patients 
included for this analysis. Alternatively, this might suggest that the studied SNP in 
IL-32 promoter has functional consequences. Finally, a difference between isoforms 
expression has been observed within the patients, which varied from the expression 
pattern seen in healthy individuals.
In a previous study, we indicated that the promoter SNP is associated with different 
levels of high-density lipoprotein cholesterol (HDLc) concentrations in RA patients, 
namely higher HDLc concentrations17. These results already suggested that this SNP 
might be functional. In the present report, we extended our observations at the level 
of cytokine production and immune responses. PBMCs from RA patients showed a 
difference in cytokine production when the patients were separated according to 
their genotype. Our study is the first to show that and therefore confirms the fact 
that the promoter SNP serves a functional effect.
Given the contribution of IL-32 and TNF to the inflammatory cascade in RA, we further 
investigated whether the SNP in IL-32 promoter region impacts disease activity in 
these patients. Absolute levels of disease activity are set to define the disease state 
of the patients and over time can be used to define improvement or response to 
treatment24. Finding a marker that could predict the latter would therefore be useful, 
although current treat to target treatment strategies already have very good long 
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to treatment and cardiovascular diseases within these patients. In line with this, we 
are currently performing studies to further elucidate the mechanisms behind the 
role of IL-32 in cholesterol metabolism regulation.
Some limitations could be envisaged in our study. One of the most important one 
might be related to the low number of patients per genotype (TT vs CC) for the IL-32 
promoter SNP, especially in the analysis of the data concerning only patients who 
received etanercept or adalimumab. This is caused by the multiple stratifications 
e.g. genotypes, clinical responses; medications/treatments that were performed. 
This could interfere with statistical analysis and power in case a small difference in 
response to treatment would have been observed and sample size is small. Moreover, 
differences in cytokine production of TNFα were not measured directly and because 
of multiple freeze-thaw cycles, this was no longer possible. Therefore, this study 
lacks a very important cytokine measurement within this group of patients.
In conclusion, the present study shows that IL-32 mRNA and protein production was 
higher in RA patients compared to healthy individuals. Moreover, this study is the 
first to show a slightly higher IL-32 expression in patients bearing the CC-genotype 
for the IL-32 promoter SNP (rs4786370). Additionally, the promoter SNP tended 
to be associated with an increased expression of pro-inflammatory cytokines IL-6 
and IL-8 produced by PBMCs of RA patients. These findings add to the previously 
described functional effect of the IL-32 promoter SNP on HDLc concentrations 
within RA patients. Nevertheless, we were unable to show an association between 
the promoter SNP and disease activity and clinical response to adalimumab and 
etanercept.
However, most interestingly, we were able to show a link between the promoter SNP 
and the ex vivo induced cytokine production of IL-1β in RA patients that clinically 
responded to etanercept (or adalimumab).
Therefore, we suggest that the exploration of the role of IL-32 in RA should be continued 
in future research, focussing more specifically on treatment response, inflammation 
induced cardiovascular disease burden and cholesterol metabolism abnormalities.
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Supplementary Table T1
Clinical Responders to Etanercept CC TT
Candida Etan Candida Etan
IL-1β 84,40 84,88
Percentage red (non-responders) 25,00 26,67
Percentage green (responders) 75,00 73,33
Pam3Cys Etan Pam3Cys Etan
IL-1β 163,57 97,26
Percentage red (non-responders) 100 40,00
Percentage green (responders) 0,00 53,33
Table T1. Overview of the percentage of IL-1β production corrected for Candida IgG or Pam3Cys IgG 
(as 100%) ex vivo stimulation in PBMCs of RA patients clinically responding to etanercept treatment 
and stratified for the IL-32 promoter SNP (n=4 CC versus n=15).
Supplementary Table T2
Clinical responders to Adalimumab CC TT
Candida Adal Candida Adal
IL-1β 99,74 95,95
Percentage red (non-responders) 0 62,50
Percentage green (responders) 100 37,50
Pam3Cys Adal Pam3Cys Adal
IL-1β 59,37 91,05
Percentage red (non-responders) 0 25,00
Percentage green (responders) 100 62,50
Table T2. Overview of the percentage of IL-1β production corrected for Candida IgG or Pam3Cys IgG (as 
100%) ex vivo stimulation in PBMCs of RA patients clinically responding to adalimumab treatment and 
stratified for the IL-32 promoter SNP (n=1 CC versus n=8).
Supplementary Figure/tables
Figure S1. Production ofIL-1β induced by Candida IgG stimulation of PBMCs from RA patients in the 
presence of anti- TNFα treatment (adalimumab). A) IL-1β cytokine production after ex vivo stimulation 
of PBMCs from RA patients with additional adalimumab, stratified for RA patients that clinically 
responded or not to adalimumab (n=8 non- responders; n=9 responders). B) IL-1β cytokine production 
after ex vivo stimulation of PBMCs from RA patients with additional adalimumab, stratified for clinical 
responders to adalimumab treatment and IL-32 promoter SNP (n=1 CC; n=8 TT RA patients). C) IL-1β 
cytokine production after ex vivo stimulation of PBMCs from RA patients with additional adalimumab, 
stratified for clinical non-responders to adalimumab and IL-32 promoter SNP genotype (n=3 CC and 
n=5 TT RA patients).
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INTRODUCTION
Over the years obesity has become a major problem worldwide with about 1.9 
billion adults aged 18years or older being overweight and 650 million being obese1. 
Being overweight is a strong indicator for the development of type II diabetes 
(T2D) and other related complications such as coronary artery disease (CAD) and 
atherosclerosis, leading to an increased morbidity and mortality2. A state of chronic 
low-grade inflammation has been documented in obesity. In case of overnutrition, 
lipids will accumulate in adipocytes causing an expansion of the adipose tissue (AT) 
which will activate c-Jun N-terminal kinase (JNK) and nuclear factor-kappa B (NF-
κB) signalling pathways and might alter the production of various adipokines such 
as pro- inflammatory cytokines interleukin-6 (IL-6), tumor necrosis factor alpha 
(TNFα), adiponectin and leptin3-6. Furthermore, chemokines are released, which 
results in macrophage infiltration of AT, maintaining the low- grade inflammatory 
state7. This low-grade inflammation at the AT level may also affect other primary 
metabolic tissues such as the liver and skeletal muscle, known for their important 
role in glucose homeostasis under insulin actions, contributing to a lower insulin 
sensitivity under normal glucose concentrations8,9.
Therefore, the inflammatory state in adipose tissue is suggested to be the most 
important link between increased adipose tissue mass and insulin resistance in obese 
patients. The precise mechanism linking inflammation/cytokines in adipose tissue to 
insulin resistance and the occurrence of T2D are currently still under investigation.
Previous studies indicated that TNFα produced by the adipocytes was able to induce 
insulin resistance in animal models, while blocking TNFα showed improved insulin 
resistance in the same settings2,10.
Nevertheless, similar interventions targeting inflammation in humans either didn’t 
pass clinical trials or showed mixed results, underlying the complexity and importance 
to further evaluate the link between inflammation and diabetes2,11. Interleukin (IL)-
32 is a recently described intracellular cytokine acting as an important regulator of 
TNF production and other inflammatory processes12-15. It plays a pathogenic role 
in various inflammatory diseases including rheumatoid arthritis, which in turn is 
likely to be associated with a higher prevalence of metabolic syndrome16-19. It has 
been recently suggested that IL-32 may play an important role in the pathogenesis 
of obese-associated insulin resistance. IL-32 expression was higher in visceral and 
subcutaneous AT from obese subjects and in monocytes exposed to adipocyte-
conditioned media obtained from obese subjects as compared to lean volunteers20. 
ABSTRACT
Low-grade inflammation has been suggested to be involved in the development of 
insulin resistance in obese subjects. The present study aims to provide additional 
evidence strengthening the role of interleukin (IL)-32 in this key process. Using 
an IL-32 transgenic (IL-32tg) mice model, we observed that IL-32tg fed a normal 
diet had a higher body weight, due to more white adipose tissue (WAT) displaying 
larger adipocytes histologically. These changes have metabolic consequences, with 
significant higher leptin levels and a trend towards hyperinsulinaemia and normal 
glycaemia, suggesting a certain degree of pre-diabetic insulin resistance state. In 
addition, adipocytes of IL-32tg mice were more prone to induce a pro-inflammatory 
inflammatory response locally, which would further contribute to the development 
of insulin resistance and type2 diabetes mellitus (T2D). In conclusion, the results of 
our study provide for the first time evidence of a direct contribution of IL-32 to the 
pathophysiology of insulin resistance and T2D, rendering IL-32 as a novel therapeutic 
target for this 21st century major health problem.
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Blood measurments
Tail vein blood (140-180μL) was collected at the beginning of the study and after 
8weeks, in EDTA-coated tubes for later use. Circulating concentrations of leptin, 
adiponectin, insulin, glucose, cholesterol and free fatty acids (FFA) were measured 
using commercially available ELISA kits.
Histology
Epididymal white adipose tissue (eWAT) were dissected, weighed, and parts were 
fixed in 4% formaldehyde until further processing. Morphometry of fat cells was 
assessed by the use of a digital image analysis method (KS-400 software; Zeiss 
Axiophoto microscope, 40x magnification).
Rna isolation and gene expression
Total RNA was isolated from animal epididymal white adipose tissue (eWAT) 
or cultured cells using TRIzol Reagent (Invitrogen, Carlsbad, CA) following the 
manufacturer’s instructions. RNA was reverse-transcribed (iScript cDNA Synthesis 
Kit; Bio-Rad Laboratories) and real-time PCR was performed using specific primers 
(see table 1) and Power Sybr Green PCR master mix (Applied Biosystems) using a 
the Step-one Real-Time PCR system (Applied Biosystems, Foster City, CA). Melt 
curve analysis was included to assure a single PCR product was formed. Values were 
corrected using the housekeeping gene 36B4.
Statistical analysis
Graphs were created with GraphPad 5.03 Prism software. All mRNA results are 
expressed as relative expression means ± SEM. ELISA data were analyzed by the 
Mann-Whitney U-test, with p<0,05 as the minimum level of significance.
RESULTS
Increased epididymal white adipose tissue weight and cell size in IL32tg mice 
independent of bodyweight Body weight from both IL-32tg and C57BL/6 WT mice 
were measured at the initiation of the study and with a repeated measurement 
every week till the end of the study at 18weeks. Figure 1A shows that the IL-32tg 
mice had a higher bodyweight from the initiation of the experiments, compared to 
the C57BL/6 WT mice. Over time the difference in bodyweight did not change much 
between groups even though IL-32tg mice appear to eat slightly more compared 
to WT mice (Fig. 1B-C). In order to further explain the differences in body weight, 
the weight of various tissues was measured. IL-32tg mice had significantly heavier 
A link with other inflammatory cytokines such as TNF and IL-6 has been suggested 
as responsible for these effects. Nevertheless, overexpression of IL- 32γ, a more 
potent isoforms, in a streptozotocin-induced type 1 diabetic mice model was able to 
contribute to initial islet β-cell injury21.
The aim of the present study is to provide additional evidence strengthening the role 
of IL-32 in the development of obesity and insulin resistance and possible T2D. Using 
a humanized IL-32 transgenic mice model, we searched for direct evidence of IL-32 
implication in obesity-associated insulin resistance and intermediary metabolism 
homeostasis.
MATERIAL AND METHODS ANIMALS
10 (12-16weeks old) Male β-actin IL32tg, obtained from dr. Xiyuan Bai and 10 
(12-16weeks old) male WT mice on a C57BL/6 background obtained from Jackson 
Laboratories were housed with 3-4 mice per cage in filter top cages with water and 
food ad libitum. IL-32tg mice were generated as previously described22. Briefly, the 
open reading frame (ORF) of IL-32γ cDNA was transferred into pCAGGS expression 
vector, which carried β- actin promoter that drives gene expression in all tissues. 
Next, the complete sequence was injected into mouse zygotes of the C57BL/6 strain 
to generate IL-32 transgenic mice. As control mice, wild-type littermates were 
included. They were all fed a regular low fat diet (Research Diet Services, D15030305) 
for 16 weeks. The housing temperature was held at 23°C and a 12:12h light-dark 
cycle was maintained. Bodyweight, blood triglyceride levels, glucose and insulin 
were monitored at the end of the study. Additionally, food intake and bodyweight 
were measured throughout the course of the study. Food intake was monitored on 
a per cage basis. Heart, liver, blood and epididymal white adipose tissue (eWAT) 
were dissected, weighed, and immediately frozen in liquid nitrogen. All animal 
procedures were reviewed and approved by the National Jewish Health Institutional 
Animal Care and Use Committee (IACUC).
Cytokine measurements
Murine Leptin (10x), Adiponectin (2000x), CXCL-1, IL-1β, IL-6, TNFα, IL-10 and IL-
1RA were determined by standard sandwich ELISA. ELISA kits for mice were used 
according to the manufacturer instructions (R&D systems, Minneapolis, MN, USA).
7170
Chapter 4 – IL-32tg mice and obesity-induced metabolic changes
4
eWAT than C57BL/6 WT mice (Fig 1D). No differences were observed between 
C57BL/6 WT mice and IL-32tg mice in the weight of the heart, spleen or liver, 
respectively (Supplemental Fig. 1 A-C). When we further explored the histology of 
AT we discovered that adipocytes in eWAT were significantly enlarged in IL-32tg 
mice compared to C57BL/6 WT mice (Fig, 1E-F).
Fig 1. Various weight measurements in IL-32tg mice versus C57BL/6 WT mice. (A) Body weight per 
group. (B) Difference in weight gain over the course of time. (C) Food intake between groups. (D) 
Tissue weights of eWAT in IL- 32tg mice versus C57BL/6 WT mice. (E) eWAT cell size in C57BL/6 WT 
mice. (F) eWAT cell size in IL-32tg mice. (magnification scale 40x)
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Fig 2. Circulating levels of leptin, adiponectin, insulin, glucose, cholesterol, FFA, IL-32tg versus 
C57BL/6 WT mice. (A)Circulating leptin levels in IL-32tg mice versus C57BL/6 WT mice. (B) Circulating 
adiponectin levels in IL-32tg mice versus C57BL/6 WT mice. (C) Circulating insulin levels in IL-32tg mice 
versus C57BL/6 WT mice. (D) Circulating Glucose levels in IL-32tg mice versus C57BL/6 WT mice. (E) 
Circulating cholesterol levels in IL-32tg mice versus C57BL/6 WT mice. (F) Circulating FFA levels in IL-
32tg mice versus C57BL/6 WT mice.
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levels and a trend towards hyperinsulinaemia with normal glycaemia, suggesting 
a decreased glucose tolerance characteristic to pre-diabetes stages. Finally, we 
observed that eWAT of IL-32tg mice is able to elicit a stronger pro-inflammatory 
response, allegedly contributing to the low-grade inflammation described in AT of 
T2D patients.
Inflammation in AT has been indicated to play a role in obesity-associated metabolic 
changes23. Various inflammatory cytokines have been studied24-26, however the 
role of IL-32 in this field is relatively new. IL- 32 is known for its pro-inflammatory 
capacities in many different diseases27,28. One of the chronic inflammatory diseases 
in which IL-32 is known to play a role is rheumatoid arthritis (RA). Increased IL-32 
concentrations were correlated to disease activity and a promoter SNP in IL-32 was 
found to be associated with high-density lipoprotein cholesterol concentrations 
in RA patients29,30. Furthermore RA is associated with increased prevalence of 
metabolic syndrome which could suggest that IL-32 could play a role herein31,32.
Following up on the findings of Catalán V et al., we were able to show that IL-32tg 
mice were heavier than the WT controls, and this difference remained unchanged 
Mice overexpressing human IL-32 develop functional changes 
resembling metabolic syndrome
After observing that IL-32tg mice are heavier due to more eWAT and larger 
adipocytes.we were interested to explore whether this may have pathophysiological 
consequences. Therefore, we measured circulating levels of various compounds 
mirroring the intermediary metabolism homeostasis. As mentioned before, 
adipokines are key molecules involved in the metabolic processes at AT level. In 
our study, we indicated that the circulating leptin levels were significantly elevated 
within the IL-32tg mice compared to the WT mice (p=0.003)(Fig. 2A). No significant 
differences have been observed in adiponectin, insulin and glucose levels, yet a trend 
towards higher insulin concentrations in the IL-32tg has been depicted, suggesting 
a certain degree of insulin resistance with compensatory hyperinsulinemia in these 
mice (Figure 2 B-D). Finally, circulating cholesterol and FFA have been measured but 
showed no significant difference between the two groups (Fig. 2E-F), with a slight 
trend towards higher cholesterol levels in IL-32tg mice.
Human IL-32 transgenic mice have an altered profile of inflammatory 
mediators in eWAT
Because the histological changes of eWAT in IL-32tg mice turned out to have 
metabolic consequences, we were interested to explore whether these changes are 
favouring the development of a low-grade inflammation at eWAT level, as observed 
in obesity-induced T2D patients. Accordingly, spontaneous cytokine production of 
eWAT has been assessed. There was an increased production of pro-inflammatory 
cytokine IL-6 (p=0.049) and chemokine CXCL-1 in unstimulated eWAT of IL-32tg 
mice compared to WT mice (Fig. 3A-B).
Production of other pro-inflammatory cytokines such as IL-1β and TNFα were 
almost undetectable. Additionally, anti-inflammatory cytokines IL-1Ra and IL-10 
were determined, showing no difference in IL-1RA between the two groups, but 
significantly lower levels of IL-10 in the IL-32tg mice (p=0.013) (Fig 3C-D).
DISCUSSION
In the present study, we show for the first time that eWAT of IL-32tg mice on regular 
chow diet displays morphological and functional changes favouring the development 
of insulin resistance and T2D. The eWAT in IL-32tg is heavier compared to WT mice, 
most probably due to larger adipocytes in IL-32tg mice. This resulted in higher leptin 
?? ???????????????? ???????????????????????? ????? ?? ?????????????????????? ??????? ??????????????????????? ??????? ????????????????? ????????????????????? ????? ?? ???????????????? ?????????????????????????? ?????
Fig 3. Cytokine measurements in eWAT of IL-32tg mice versus C57BL/6 WT mice. (A) IL-6 production in 
eWAT tissue of IL-32tg mice versus C57BL/6 WT mice. (B) CXCL-1 production in eWAT tissue of IL-32tg 
mice versus C57BL/6 WT mice. (C) IL-1Ra production in eWAT tissue of IL-32tg mice versus C57BL/6 
WT mice.
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To conclude, the present study shows for the first time that there is a direct 
association between IL-32 and intermediary metabolism in mice, and that AT might 
play an important role in this processes. Our data corroborated with the recent 
results of Catalan further underline the hypothesis that IL-32 could indeed be an 
essential player in promoting obesity and obesity-induced comorbidities.
throughout the study period despite a slight increase in food intake in the IL-32tg 
mice. This is in line with the observation that IL-32 concentrations were higher in 
obese patients and decreased after weight loss20. Interestingly, Lee et al. showed 
that mice overexpressing IL-32β on a high-fat diet were protected against hepatic 
steatosis and inflammation33. In contrast, overexpression of IL-32γ, a more potent 
isoforms, in a streptozotocin-induced type 1 diabetic mice model contributed to 
initial islet β-cell injury21 Various isoforms of IL-32 seem to play different roles in 
inflammation and changes to metabolic processes.
The increased eWAT mass and adipocytes size were likely to have functional 
consequences in the IL-32tg mice. We found a significant increase in circulating 
leptin concentrations in mice which could be the beginning of a leptin resistant 
state. Previous studies have shown that leptin production regulates energy balance 
by inhibiting hunger and lowering appetite (REF). However, in obesity/metabolic 
syndrome, the increased adipose tissue disturbs adipokine regulation which results 
in a low-grade inflammatory state. Expression of pro-inflammatory mediators 
such as leptin and IL-6 are upregulated whereas anti-inflammatory mediators 
including adiponectin are reduced34. Moreover, increased leptin production in obese 
individuals was linked to leptin resistance due to the inadequate response to lower 
for example food intake. Additionally, it has been suggested that leptin resistance 
is associated with impaired transport of leptin across the blood brain barrier (BBB) 
leading to accumulation of triglycerides in adipose tissue, liver and pancreas which 
results in decreased insulin sensitivity35. Pancreatic β-cell receptors may show a 
decreased responsiveness in the presence of chronically induced leptin levels which 
results in increased insulin secretion. Hyperinsulineamia in turn increases obesity 
leading to a further increased leptin production and creating a positive pro-diabetic 
feedback loop36.
Besides changes in leptin and insulin concentrations, changes in cytokine profile 
and inflammatory state are also linked to obesity and metabolic syndrome even 
though the exact role has not been clearly established23,37. IL-32 is known to be able 
to induce other pro-inflammatory cytokines including IL-6, IL-1β and TNFα. Our 
findings of increased IL-6 and CXCL-1 but decreased anti-inflammatory cytokine IL-
10 are therefore in line with previous data. Furthermore, Catalán V et al. showed that 
pro-inflammatory cytokines including IL-6 and TNFα were decreased when IL-32α 
was silenced, showing a role for IL-32 in the low-grade inflammatory status of obese 
individuals. Since IL-32 was found to be elevated in AT of obese patients, IL-32 seems 
to be part of the positive feedback loop maintaining the inflammatory status in AT 
of these patients.
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SUPPLEMENTARY FIGURES
Supplementary Figure S1. Weight of several organs in wild-type mice versus IL32tg mice. A). Weight 
of the heart in wild-type mice versus IL32tg mice. B) Weight of the spleen in wild-type mice versus 
IL32tg mice. C) Weight of the liver in wild-type mice versus IL32tg mice.
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ABSTRACT
Background and aims: The role of interleukin (IL-)32 in inflammatory conditions is 
well-established, however the mechanism behind its role in atherosclerosis remains 
unexplained. Our group reported a promoter single nucleotide polymorphism in 
IL-32 associated with higher high-density lipoprotein (HDL) concentrations. We 
hypothesize that endogenous IL-32 in liver cells, a human monocytic cell line and 
carotid plaque tissue, can affect atherosclerosis by regulating (HDL) cholesterol 
homeostasis via expression of cholesterol transporters/mediators.
Methods: Human primary liver cells were stimulated with recombinant human (rh)
TNFα and poly I:C to study the expression of IL-32 and mediators in cholesterol 
pathways. Additionally, IL-32 was overexpressed in HepG2 cells and overexpressed 
and silenced in THP-1 cells to study the direct effect of IL-32 on cholesterol 
transporters expression and function.
Results: Stimulation of human primary liver cells resulted in induction IL-32α, 
IL-32β and IL-32γ mRNA expression (p<0.01). A strong correlation between the 
expression of IL-32γ and ABCA1, ABCG1, LXRa and apoA1 was observed (p<0.01) 
and intracellular lipid concentrations were reduced in the presence of endogenous 
IL-32 (p<0.05). Finally, IL32γ and ABCA1 mRNA expression were upregulated in 
carotid plaque tissue and when IL-32 was silenced in THP-1 cells, mRNA expression 
of ABCA1 was strongly reduced.
Conclusion: Regulation of IL-32 in human primary liver cells, HepG2- and THP-1-cells 
strongly influences the mRNA expression of ABCA1, ABCG1, LXRα and apoA1 and 
affects intracellular lipid concentrations in the presence of endogenous IL-32. These 
data, for the first time show an important role for IL32 in cholesterol homeostasis.
INTRODUCTION
Cardiovascular diseases (CVD) are currently the leading cause of death in developed 
countries with atherosclerosis as the most important contributor to the disease 
burden1,2. Atherosclerosis is characterized by inflammation and the accumulation of 
lipids in the vessel wall causing plaque formation3. Additionally, triggers such as, 
smoking, hypertension, dyslipidemia and hyperglycemia are known to contribute to 
plaque formation3-5. Ongoing inflammation in the plaque further activates monocytes 
to differentiate into macrophages, which will take up lipids to generate foam cells. 
Moreover, many studies have indicated that pro-inflammatory cytokines including 
TNFα, IL-1β, IL-6, IFNγ, contribute to the development of atherosclerosis6-8.
Recently, Heinhuis et al. suggested that the intracellular pro-inflammatory cytokine 
interleukin (IL)-32 could play an important role in atherosclerosis9. IL-32 has been 
shown to play a role in inflammatory diseases with an increased risk for CVD, such as 
rheumatoid arthritis (RA) and human immunodeficiency virus (HIV)10-13. IL-32 can be 
spliced into various isoforms with IL-32α, IL-32β and IL-32γ being most intensively 
studied and IL- 32γ being the most active isoform14. In atherosclerotic plaques, IL32 
is expressed, and in macrophages IL32 overexpression increases the expression 
of chemokine (C-C motif) ligand 2 (CCL2), soluble vascular cell adhesion molecule 
(sVCAM-1), matrix metalloproteinase 1 (MMP1), MMP9, and MMP13. IL-32 promotes 
inflammation by induction of pro-inflammatory cytokines like TNFα, IL-6, IL-1β and 
IL-815, 16. Furthermore, IL-32 seems to be a regulator of endothelial cell function were 
it enhances IL-1β-induced intracellular adhesion molecule 1 (ICAM-1)17.
In contrast to these pro-atherogenic actions, IL32 could also have anti-
atherosclerotic effects by increased HDL cholesterol18. Recently, a promoter 
single nucleotide polymorphism (SNP) in IL32 was found to be associated with 
HDL cholesterol (HDLc) concentrations in both RA patients as well as individuals 
with an increased CVD risk, again suggesting a role for IL-32 in CVD18. Individuals 
homozygous for the C- allele showed higher HDLc concentrations compared to 
individuals being heterozygous or homozygous for the T- allele. HDLc is considered 
to be atheroprotective even though Mendelian randomization studies and drug 
trials showed there is no causality dependent on HDL cholesterol levels but rather 
atheroprotective HDL functions are more relevant metrics to analyze19,20. Therefore, 
IL32 could still have an atheroprotective role. The HDL metabolism starts in the 
liver, which is an important organ in HDL biosynthesis and a regulator of plasma 
HDL concentrations. Additionally, the small intestine and especially enterocytes 
are involved in biosynthesis of HDLc. Dietary lipids including, cholesterol esters and 
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triacylglycerols are first hydrolyzed in the interstitial lumen of the intestine after 
which the product are taken up by enterocytes21. These products are re-synthesized 
by the enterocytes and packed into either chylomicrons or HDLc for secretion into 
the circulation. sMoreover, the biosynthesis of HDL involves synthesis and secretion 
of apolipoproteins (apoA-I and apoA-II) followed by acquisition of lipids and 
generation of mature HDL22,23. Lipidation of nascent, discoidal apoA-I containing 
HDL particles must occur to form mature HDL. A critical participant herein is the 
ATP-binding cassette A1 (ABCA1) expressed on liver cells and enterocytes. These 
nascent, discoidal apoA-I containing HDL particles are secreted via hepatic and 
enterocyte ABCA1 and are matured in circulation via the lecithine-cholesterol-
acyltransferase (LCAT) function and formation of spherical HDL particles24. In the 
absence of ABCA1, extremely low levels of HDLc and apoA-I are observed which 
contribute to an increased risk for CVD.
An important mechanism involved in regulation of excessive cholesterol is reverse 
cholesterol transport (RCT). During RCT, excessive cholesterol is transferred from 
peripheral tissues and the arterial wall back to the liver for removal from the 
body25,26. This cholesterol efflux is also mediated via ABCA1 which is induced by 
activation of liver X receptor alpha (LXRα)27-29. Alternatively, ABCG1 transports 
excessive cholesterol outside the cells30,31. Upon return to the liver, HDLc can be 
taken up by scavenger receptor class B, type 1 (SR-B1) for degradation of HDL. 
Another alternative pathway by which HDLc is metabolized and transported to the 
liver is via the cholesteryl ester (CE) transfer protein (CETP). Knowing the effect of 
IL-32 on HDLc concentrations and the importance of the role of the liver in HDLc and 
cholesterol efflux, one can argue a role for IL-32 in HDLc metabolism and synthesis 
in liver cells. However, despite previous studies on the role of IL-32 in cardiovascular 
disease, studies investigating the exact mechanism behind how IL-32 influences 
cholesterol homeostasis remain scarce. The present study aims to investigate the 
precise role of IL-32 on HDLc homeostasis, focussing on cholesterol transporters 
involved in this process in human primary liver cells and the human monocytic cell 
line THP1.
MATERIAL AND METHODS
Culturing primary human liver cells, HepG2 and THP-1 cell lines and 
carotid artery plaque tissue
Patients undergoing liver surgery in our hospital donated human liver tissue. The 
anonymized liver tissue was used to isolate primary human liver cells as previously 
reported32. Human liver cells were seeded in Williams B medium containing 10 % 
human serum and penicillin/streptomycin. This study (2014-1453) was reported and 
approved by our ethical committee of the Radboud University Medical Centre.
The human liver cell line HepG2 was cultured in complete Dulbecco’s Modified 
Eagle’s Medium with glutamax (Gibco) containing 10 % heat-inactivated Fetal Calfs 
Serum (FCS), pyruvate (Gibco) and gentamycin (Gibco). Trypsin was used to detach 
the adherent cells and the cell line was passaged twice a week in a 1:5 ratio.
The human monocytic cell line THP1 was used to study overexpression and silencing 
of IL-32 and its effect on cholesterol transporters. The cell line was cultured in 
Roswell Park Memorial Institute (RPMI) 1640 medium containing heat-inactivated 
10 % FCS, pyruvate and gentamycin. Cells were growing in suspension and passaged 
twice a week in fresh medium.
Fresh carotid artery plaque tissue was kindly provided by the department of surgery 
from the Radboud University Medical Center and upon arrival was separated into 4 
pieces to perform various analyses. Samples were then stored at -80°C for further use.
Quantitative PCR
Human primary liver cells were seeded ~200,000 cells per well in a 24 well plate in 0.5 
ml Williams B medium containing 10 % human serum and penicillin/streptomycin. 
The next day, cells were stimulated with TNF (100 ng/ml) (R&D Systems) or Poly I:C 
(50 µg/ml) (Invivogen) for 24 hours. Subsequently, medium was removed and stored 
and 0.5 ml Tri-reagent (Sigma-Aldrich) was added per well. After lysing the cells 
by incubating the cells with Tri-reagent for 30 minutes at room temperature, the 
solution containing lysed cells were was stored at - 20 °C until further processing. 
HepG2 cells and THP-1 cells were lysed in TriZol reagent and also stored for later use. 
Carotid artery tissue was crushed in TriZol reagent using Magnalyser green beads 
(Roche). RNA was isolated as previously described33. After RNA isolation, mRNA 
was transformed into cDNA by applying an iScript kit (Bio-Rad) to transform mRNA 
into cDNA. IL-32 primers were previously developed and other primers sequences 
were extracted from the Harvard Primerbank database34. Primers were produced 
by Biolegio (Nijmegen, The Netherlands) and a StepOnePlus qPCR system (Applied 
Biosystems) was used to analyze relative mRNA expression. Relative expression was 
calculated by normalizing for GAPDH and 2^-dCt method.
Western blotting
Twenty-four hours after stimulation, primary liver cells were washed with PBS and 
lysed with standard cell lysis buffer on ice for 30 minutes. Subsequently, cells were 
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scraped with a cell scraper and transferred into a safe-lock tube. Proteins were boiled 
in Laemmli buffer under denaturing and reducing conditions. SDS-Page gels (12%) 
were prepared and marker plus proteins were loaded onto the gels. After running 
the gels, proteins were transferred onto nitrocellulose membranes with an iBlot 
apparatus (Invitrogen). After transferring the proteins, blots were blocked with 5 % 
milk proteins in Tris-buffered Saline (TBS) with 0.1 % tween-20 (Invitrogen) for at 
least 1 hour at room temperature. Next, blots were washed in TBS-T (TBS containing 
0.1% tween-20) and incubated overnight on the roller mixer at room temperature 
in TBS-T containing primary antibody against IL-32 (AF3040, R&D Systems), at 
a concentration of 0.2 µg/ml, or against ApoA1 (Acris Antibodies GmbH, Herford, 
Germany), at a concentration of 1.0 µg/ml. The following day, blots were washed with 
TBST and the IL-32 blots were incubated with rabbit-anti-mouse-HRP (Dako P0449, 
1:5000 in TBST) while the ApoA1 blots were incubated with rabbit-anti-mouse-HRP 
(Dako P0260, 1:5000 in TBST) and incubated for 1 hour at room temperature on 
the roller mixer. Next, blots were washed and incubated with ECL (GE Health care 
Life Sciences) before scanning the blots. Finally, actin was detected on the blots by 
using anti-actin antibodies (Santa Cruz Biotechnology) and appropriate secondary 
antibody (Dako) followed by ECL incubation and scanning of the blots.
IL-32 ELISA
Maxisorp plates (Nunc) were coated with AF3040 (R&D Systems) diluted in Phosphate 
Buffered Saline (PBS) at a concentration of 0.4 g/ml and incubated overnight at 
room temperature. Next morning, plates were blocked with PBS containing 1 % 
BSA (Sigma-Aldrich) for 1 hour at room temperature. Standard curve was prepared 
by diluting recombinant IL-32 ranging from 5000 pg/ml until 39.06 pg/ml in PBS 
containing 5 % BSA. Standard curve was added followed by the supernatant samples 
from the primary liver cells. ELISA plates were incubated for 2 hours on a shaker. 
After the incubation, plates were washed and detection antibody was added 
(BAF3040, R&D Systems), 0.1 µg/ml in PBS with 5 % BSA. Plates were incubated for 
1 hour at room temperature on the shaker. Subsequently, plates were washed and 
streptavidin (R&D Systems) was added and the plates were incubated for 30 minutes 
at room temperature on the shaker. After the last incubation, plates were washed 
and substrate buffer was added and the color reaction was closely monitored until 
the reaction was terminated by adding stop solution. Finally, the plates were read by 
a plate-reader and IL-32 concentrations were calculated.
Overexpression of IL-32 in HepG2 cell line
Half million HepG2 cells were seeded per well in a 24-well plate in RPMI-1640 including 
5 % FCS and incubated overnight at 37 °C and 5 % CO2. The following day, medium 
was replaced by the same fresh medium and transfection medium containing IL-
32 plasmids (pCDNA3-IL32, pCDNA3-IL32, pCDNA3-IL32) or a control plasmid 
(pCDNA3-eGFP) was prepared. Transfection medium per transfection was prepared 
as follow; 1) dissolve 0.5 g plasmid DNA in 25 l serum free RPMI-1640, 2) add 1.5 
l Fugene HD (Promega) directly to the DNA mixture, 3) vortex 1-2 seconds and 
incubate for 15 minutes at room temperature, 4) add 25 l dropwise per well while 
gently shaking the plate, 5) incubate for 24 or 48 hours at 37 °C and 5 % CO2. After the 
incubation, RNA and protein samples were isolated for determining gene expression 
and IL-32 protein expression as previously described. BODIPY flowcytometry assay
Transfected HepG2 cells and THP-1 cells were used for the BODIPY FACS analysis. 
In more detail, 1 million (HepG2) or 2,5x10^5 (THP-1) cells per well were used for the 
transfection after which cells were detached, spun down and resuspended in PBS 
containing 4 % Formaldehyde (FA) for 15 minutes on ice. Thereafter, the cells were 
spun down again and resuspended in PBS with 5 % BSA and BODIPY (1:500) for 45 
minutes on ice in the dark, after which the BODIPY signal was measured.
Overexpression and silencing of IL-32 in THP1 cells
THP-1 cells (15 x 106 cells/15mL) were differentiated into macrophages (75 cm2 – 
tissue culture flask; Corner) in RPMI-1640 including 10 % FCS, PMA (Sigma-Aldrich) 
at 10 ng/mL, β-mercaptoethanol (Sigma-Aldrich) at 50 µM and incubated for 48 
hours at 37 °C and 5 % CO . 2.5 x 106 cells/800 µL were electroporated by using Amaxa 
Nucleofactor technology (Lonza, Basel) according with the protocol described by35. 
For IL-32 knockdown, 1 µg of ON-TARGETplus SMARTpool siRNA per transfection 
was used or 1 µg of ON-TARGETplus SMARTpool control siRNA (Dharmacon Inc.), 
sequences were describe by36. For IL-32 overexpression, 0.5 µg of pCDNA3 plasmid 
expressing human IL-32γ of eGFP was used as a control. Transfected cells (3 x 105/100 
µL) were plated on flat-bottom 96-well plates (Costar) and 100 µL of transfection 
medium was added. After 4 and 24 h the cell monolayers were collected by adding 
200 µL of TRIzol and stored at -80°C until mRNA extraction. Comparable studies 
were performed in order to determine transfection (eGFP) efficiency which was 
around 30%.
Foam cell formation of THP-1 cells and human derived percoll 
monocytes
THP-1 cells (15 x 106 cells/15mL) were differentiated into macrophages (75 cm2 – 
tissue culture flask; Corner) in RPMI-1640 including 10 % FCS, PMA (Sigma-Aldrich) 
at 10 ng/mL, β-mercaptoethanol (Sigma-Aldrich) at 50 µM and incubated for 48 
hours at 37 °C and 5 % CO2. 5 x 10^5 cells per well were seeded in 24 wells plate 
and starved for 4h in RPMI-1640 supplemented 2 mM l-glutamine, 1 mM pyruvate 
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and 50 μg/ml gentamicin (GIBCO Invitrogen, Carlsbad, CA) after which oxidized 
LDL was added (25ug/mL) for 24h at 37 °C and 5 % CO2. Human pheripheral blood 
mononuclear cells were isolated using density centrifugation over Ficoll-Paque.
Next, percoll isolation of monocytes was performed as previously described37. In 
brief, 150-200 x 10^6 PBMCs were layered on top of a hyper-osmotic Percoll solution 
and centrifuged for 15 minutes at 580 g. The interphase layer was isolated and cells 
were washed with cold PBS. Cells were resuspended in RPMI+++ An extra purification 
step was added by adhering Percoll isolated monocytes to polystyrene flat bottom 
plates (Corning, NY, USA) for 1h at 37 °C and 5 % CO2; subsequently a washing step 
with warm PBS was performed to yield maximal purity. Once, percoll monocytes 
were obtained they were differentiated to macrophages for 6 days in 10% human 
pool serum. On day 6 medium was removed and cells were starved for 4h similar to 
the THP-1 cells before being fed oxidized LDL for 24h. After 24h supernatants were 
collected and cells were stored in TRIzol reagent for mRNA isolation.
Statistics
Statistical analysis were performed by using the Mann-Whitney U test, Spearman 
correlation test or One-way Anova including Kruskal-Wallis test and Dunn’s Multiple 
comparison test. In each figure the applied statistical test is indicated.
RESULTS
Induction of IL-32 isoforms in human primary liver cells by TNFα or TLR3 
ligand poly I:C
Primary liver cells were stimulated with recombinant human TNFα (rhTNFα) or 
Poly I:C to study whether these cells were capable of expressing IL-32. Stimulation 
of cells with rhTNFα resulted in a slight upregulation of IL-32α mRNA expression 
(Fig. 1A). Moreover, the protein level of IL-32β was determined intracellularly and 
was induced mostly by rhTNFα but also Poly I:C stimulation (Fig. 1D-E). Poly I:C 
stimulation resulted in a slight increase in IL-32γ mRNA expression but almost no to 
minor increase in either IL-32β or IL-32α respectively compared to medium control 
(Fig. 1A-B-C). Furthermore, Poly I:C stimulation resulted in higher extracellular IL-32 
protein levels (Fig. 1F).
Fig. 1 Induction of IL-32 expression in human primary liver cells. (A) Stimulation with TNFα induced 
significantly IL-32α (n=7, Mann-Whitney U test, p=0.0070). (B)Significant differences between TNFα 
and Poly I:C induced IL-32β (n=7, Mann-Whitney U test, p=0.0023). (C) Poly I:C stimulation enhanced 
the expression of IL-32γ both compared with medium control (n=7, Mann-Whitney U test, p=0.0111) 
or TNFα (n=7, Mann-Whitney U test, p=0.0070). (D) Induction of IL-32β protein by TNFα or Poly I:C in 
primary liver cells from 3 donors (actin as loading control). (E) Relative expression of L-32β protein 
expression corrected for Actin expression after stimulation (med, TNFα, Poly I:C). (F) IL-32 protein 
expression after TNFα and Poly I:C stimulation in culture supernatants of human primary liver cells 
(n=5 (with replicates), Mann-Whitney U test, medium vs Poly I:C p=0.0176; TNFα vs Poly I:C p=0.0471).
Induction of IL-32 in human primary liver cells leads to enhanced 
expression of important regulators of cholesterol homeostasis which 
correlate strongly with IL-32γ mRNA expression
Here, we explored whether TNFα- or TLR3-poly I:C-induced IL-32 expression in 
human primary liver cells modulates the expression of cholesterol transporters and 
regulators of cholesterol homeostasis. Furthermore, we studied whether there was 
a correlation between mRNA expression of IL-32 isoforms and the components 
involved in the cholesterol homeostasis. As shown in figure 2A-D, stimulation of 
human primary liver cells with poly I:C resulted in increased expression of ABCA1, 
ABCG1, ApoA1 and LXRα mRNA. Besides mRNA levels, protein levels of ApoA1 were 
also studied and showed to be increased after stimulation with poly I:C, and possibly 
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after rhTNFα stimulation (Fig. 2E-F). As a positive control to study the function of 
the cells, we determined the rhTNFα- and poly I:C-induced IL-8 mRNA expression 
in the liver cells (supplementary Fig 1A). Additionally, a strong positive correlation 
between the IL-32γ isoform and ABCA1, ABCG1, ApoA1 and LXRα expression was 
observed after the cells were stimulated with poly I:C (Fig.2F-I). Cells stimulated with 
rhTNFα also showed positive correlations to the same mediators (supplementary 
Fig 1B-E). These correlations were not observed when looking at IL-32α nor IL-32β 
expression and these mediators (Supplementary Table S1).
Endogenous expression of IL-32γ and ABCA1 mRNA in HepG2 cells
To further study the effect of IL-32 isoforms on the expression of cholesterol 
mediators, a human liver cell line was used (HepG2 cell line) (Fig. 3A-D). At first, 
unstimulated HepG2 cells were studied to look at the basal mRNA expression levels 
of IL-32 and cholesterol mediators. Similar to the observation made in human 
primary liver cells, also HepG2 cells showed expression of the three isoforms of IL-
32 (IL-32α, IL-32β and IL-32γ) and ABCA1 (Fig. 3A-D). Interestingly, IL-32γ expression 
was already upregulated after 4 hours of culture in only DMEM complete medium 
with 10% FCS hi, together with ABCA1 expression, while IL-32α didn’t show any 
expression and IL-32β only minor expression (Fig. 3A-B). As shown in figure 4A and 
4B the relative expression IL-32α and IL-32β increased after 24h but resulted in 
an even more pronounced expression after 48h of culture. Within the same time, 
expression of both IL-32γ and ABCA1 decreased (Fig. 3C-D). Highly interesting, a 
positive correlation between IL-32 isoforms and ABCA1 expression was again mostly 
observed for the IL-32γ isoform (Fig. 3E and Supplementary figure 2).
Fig. 2 Induction of cholesterol transporters ABCA1/ABCG1, HDL particle ApoA1 and transcription factor 
LXRa in human primary liver cells and their correlation with IL-32γ after Poly I:C stimulation of cells for 
24h. (A) Stimulation with Poly I:C significantly induced ABCA1 (n=7, Mann-Whitney U test, medium vs 
Poly I:C p=0.0041; TNFα vs Poly I:C p=0.011). (B) ABCG1 expression was significantly induced by Poly I:C 
(n=7, Mann-Whitney U test, medium vs Poly I:C p=0.0023; TNFα vs Poly I:C p=0.0262). (C) HDL particle 
ApoA1 was significantly induced by Poly I:C (n=7, Mann- Whitney U test, medium vs Poly I:C p=0.0260; 
TNFα vs Poly I:C p=0.0411). (D) Poly I:C stimulation significantly induced transcription factor LXRα 
(n=7, Mann-Whitney U test, medium vs Poly I:C p=0.0023; TNFα vs Poly I:C p=0.0262). (E) Induction of 
ApoA1 protein after Poly I:C stimulation in 2 different donors. (F) Relative expression of ApoA1 protein 
corrected for Actin expression in two donors. (G) Positive correlation between IL-32γ and ABCA1 
(Spearman r=0.4727, p=ns). (H) Positive correlation between IL-32γ and ABCG1(Spearman r=0.9091, 
p=0.0003***). (I) Positive correlation between IL-32γ and LXRα(Spearman r=0.6726, p=0.0277*). 
(J) Positive correlation between IL- 32γ and ApoA1 (Spearman r=0.9455, p<0.0001***). All graphs 
showing relative mRNA expression adjusted for GAPDH expression. (n=5, data includes replicates).
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Fig. 3 Time-dependent induction of IL-32γ and cholesterol transporter ABCA1 in human HepG2 cells. 
A) Expression of IL-32α is significantly induced after 48h compared with 24h, while at 4h the expression 
of IL-32α was not detectable (4replicates, Mann-Whitney U test, p=0.0286). B) Expression of IL-32β 
was already detected at 4h and significantly enhanced after 24h and after 48h (4 replicates, Mann-
Whitney U test, p=0.0286). C) Expression of IL-32γ was already high at 4h and decreased after 24h 
and 48h (4 replicates, Mann-Whitney U test, p=0.0286). D) Expression of the cholesterol transporter 
ABCA1 was high at 4h and significantly decreased after 24h and 48h (4 replicates, Mann- Whitney U 
test, p=0.0286). E) Correlation between IL-32γ and ABCA1 at different time points showed to be highly 
significant p<0.0001 and a Spearman r of 0.9580. All conditions were kept in DMEM complete medium 
with 10% Fetal Calf Serum heat-inactivated. Time course started after plating the cells.
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Overexpression of IL-32α, IL-32β or IL-32γ results in strong induction of 
cholesterol transporters and reduced intracellular lipid concentrations 
in HepG2 cells
Since we noted strong correlations between mRNA expression of IL-32 isoforms and 
cholesterol transporters, we were interested in the function of these cholesterol 
transporters in the presence of IL-32. HepG2 cells were therefore transfected with 
pCDNA3 constructs containing either eGFP (as a negative control), IL-32α, IL-32β or 
IL-32γ. As shown in figure 4A, overexpression of the various isoforms of IL-32 resulted 
in protein expression of that specific isoform after 48h of transfection. Moreover, 
overexpression of the IL-32α isoform resulted in a trend towards an increased 
expression in LXRα and ABCA1 (Fig. 4B-C). Additionally, overexpression of the IL- 
32β and IL-32γ isoforms resulted in an increased expression of LXRα (non-significant 
for IL-32γ), ABCA1 and ABCG1 (Fig. 4B,C,D). However, important mediators such 
as ApoA1(mRNA and protein) and SR-B1 (mRNA) were not affected in HepG2 cells 
overexpressing the isoforms of IL-32 (Supplemental Fig. S3). Finally, we performed 
a boron-dipyrromethene (BODIPY) staining to study the intracellular lipid content 
of the transfected versus untransfected HepG2 cells. BODIPY fluorescence was 
significantly lower in HepG2 cells transfected with the IL-32β isoforms and showed 
a trend towards lower expression in IL-32α and IL-32γ transfected compared to the 
untransfected control or eGFP transfected negative control (Fig.4E). The strongest 
reduction of BODIPY was observed after transfection of HepG2 cells with IL-32β.
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Fig. 4 Modulation of transcription factor LXRα and cholesterol transporters ABCA1/ABCG1 resulted in 
lower intracellular lipid content after IL-32 overexpression in human HepG2 cells. A) Overexpression 
of different IL-32 isoforms in human HepG2 liver cells at 24h and 48h. IL-32α (approx. 19 kDa), IL-32β 
(approx. 26kDa), IL-32γ (approx. 29kDa) B) Transcription factor LXRα was significantly induced after 
overexpression of IL-32β (5 replicates, Mann- Whitney U test, p=0.0317). C) Overexpression of IL-32α 
(p=0.0317), IL-32β (p=0.0159), IL-32γ (p=0.0159) significantly induced ABCA1 expression (5 replicates, 
Mann-Whitney U test). D) Overexpression of IL-32β and IL-32γ enhanced the expression of ABCG1 (5 
replicates, Mann-Whitney U test, p=0.0079). E) Mean fluorescent intensity was significantly reduced 
after overexpression of IL-32β (4 replicates, Mann-Whitney U test, p=0.0286). Replicates are from 2 
independent experiments with technical replicates within each experiment.
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Silencing of IL-32γ strongly reduces ABCA1 mRNA expression
As described above, overexpression of the IL-32γ isoform in HepG2 liver cells 
resulted in an increased expression and possible function of ABCA1. To study the role 
of IL-32γ into more detail, we studied IL-32γ and ABCA1 expression in carotid artery 
plaque tissue and performed knockdown experiments of IL-32γ. Due to the fact that 
HepG2 cells did not survive the procedure to knockdown IL-32γ, we were prompted 
to use another cell line. We performed silencing and overexpression experiments in 
a human monocytic cancer cell line (THP1 cell line). This, because ABCA1 expression 
and function is also very important for monocytes in the circulation, contributing 
to reverse cholesterol transport. Using THP1 cells, IL-32γ overexpression resulted 
in high expression of IL-32γ as well as ABCA1 (Fig. 5A,D). When IL-32γ was silenced, 
IL-32γ and ABCA1 expression were completely diminished (Fig. 5B,E). This effect 
was not caused by the transfection method itself, since THP1 cells transfected with 
eGFP or spC negative controls did not result in these effects on ABCA1 expression 
(Fig. 5A,B,D,E). The spIL-32 construct is also capable of silencing other isoforms of 
IL-32 as is shown by the silencing of IL-32β (Fig. 5. C). Besides, since we observed 
similar expression patterns of induced cholesterol transporters in THP-1 cells, we 
performed overexpressing experiments in THP-1 cells to perform the BODIPY 
staining. Overexpressing IL-32γ in THP-1 cells resulted in a decrease of BODIPY 
fluorescence (Supplementary figure 4). Moreover, after observing the importance 
of IL-32γ on ABCA1 expression in liver cells and THP-1 cells, we were curious if this 
effect is also present in plaque tissue in which ABCA1 expression can affect foamcell 
formation. We were able to show an increased expression of IL-32γ and ABCA1 mRNA 
in carotid artery plaque tissue (Fig. 5F-G). Finally, THP-1 derived macrophages and 
human derived percoll monocytes (differentiated to macrophages) were loaded 
with oxidized LDL (25ug/mL; 50ug/mL respectively) for 24h to study the expression 
of IL-32 isoforms and mediators involved in cholesterol metabolism in foam cells.
Interestingly, IL-32 isoform expression of IL-32α, IL-32β and IL-32γ seemed to be 
decreased or unchanged compared to normal macrophages (Supplementary figure 5). 
Nevertheless, cholesterol mediators ABCA1, ABCG1 and LXRα seemed to be induced, 
albeit not significantly (Supplementary figure 5).
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Fig. 5 IL-32 regulates cholesterol transporter ABCA1 in THP1 cells and is expressed in human carotid 
artery plaque tissue. (A) Human THP1 cells transfected with different plasmids (pCDNA3-eGFP or 
pCDNA3-IL32γ) or no plasmids (wt control) showed significant induction of IL-32γ when the cells 
were transfected with pCDNA3-IL32γ (p<0.05* or p<0.01** (6 replicates, One-Way ANOVA, Kruskal 
test, Dunn’s Multiple Comparison Test)). (B) Silencing of IL-32γ showed significant reduction of IL-32γ 
expression compared to the wt control or smartpool-control (6 replicates, One-Way ANOVA, Kruskal-
Wallis test, Dunn’s Multiple Correction Test). (C) Silencing of IL-32β showed significant reduction of 
IL-32β expression compared to the wt control or smartpool-control (6 replicates, One-Way ANOVA, 
Kruskal-Wallis test, Dunn’s Multiple Correction Test).(D) Overexpression of IL-32γ iduced significant 
expression of ABCA1. (E) Silencing of IL-32γ downregulated ABCA1 significantly in THP1 cells. (F) 
Human carotid artery plaque tissue showed induced expression of IL-32γ mRNA compared to healthy 
tissue (p=0.0017*). (G) Human carotid artery plaque tissue showed induced expression of ABCA1 
mRNA compared to healthy tissue (p=0.0124*).
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DISCUSSION
In the present study, we aimed to investigate the effect of IL32 on proteins involved 
in cholesterol metabolism in liver cells and atherosclerotic plaques. We show for the 
first time that both human primary liver cells and a HepG2 cell line express IL-32 
mRNA and protein and that human carotid artery tissue expresses IL-32γ mRNA. 
Moreover, the three main IL-32 isoforms, IL-32γ, IL-32β and IL-32α can be induced 
either by recombinant human (rh)TNFα or a synthetic analogue of a double-stranded 
RNA virus (Poly I:C) stimulation in these liver cells. mRNA expression of components 
important in cholesterol metabolism such as, ABCA1, ABCG1, LXRα and apoA1 
are correlated to expression levels of the IL-32γ isoforms in unstimulated human 
primary liver cells and HepG2 cells. Additionally, overexpression of IL-32β and IL-
32γ resulted in induction of ABCA1 and ABCG1 in HepG2 cells and overexpression 
of IL-32γ induction of ABCA1 expression in THP-1 cells. By performing the BODIPY 
flowcytometry assay, we could show that in the presence of endogenous IL-32, 
intracellular lipid concentrations were decreased. Moreover, silencing of IL-32 in 
THP-1 cells caused a strong reduction of ABCA1 expression. Lastly, we also observed 
increased mRNA expression of IL-32 and ABCA1 in human carotid artery tissue 
obtained from carotid endarterectomy surgery.
A recent study suggested the existence of an association between IL-32 and HDL 
cholesterol, which can become relevant for patients with an increased risk to develop 
CVD such as RA patients. A single nucleotide polymorphism (SNP) in the promoter 
region of IL32 was described to be correlated with higher HDLc concentrations in RA 
patients, suggesting a possible role for IL-32 in determining CVD risk18. Moreover, 
this SNP possibly results in more IL-32 protein expression38. This suggests, higher IL-
32 protein concentrations are linked with higher HDLc concentrations.
Next to IL-32 mRNA and protein, we also studied the expression of various cholesterol 
transporters/mediators involved in cholesterol metabolism such as, ABCA1, ABCG1, 
ApoA1 and LXRα. Tight regulation of low-density lipoprotein (LDL) and high-density 
lipoprotein (HDL) cholesterol is important to prevent cardiovascular disease, such as 
atherosclerosis. Circulating HDLc concentrations are regulated by biosynthesis and 
degradation processes in which the liver plays an important role22. HDL biosynthesis 
is regulated by the production and secretion of apoA-I by the liver and lipidation of 
these apolipoproteins by ABCA1 transporters expressed on liver cells23. Expression 
of this cholesterol transporter ABCA1 in hepatocytes plays an important role in 
the biosynthesis and regulation of circulating HDL cholesterol26,39,40. Furthermore, 
enterocytes are also involved in the biosynthesis and maintenance of HDL. Via a 
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complex network of cholesterol transporters the small intestine establishes a 
balance between the amount of excreted and absorbed cholesterol and in that 
way influences RCT41,42. Moreover, downregulating absorption of cholesterol in 
the intestine has been shown to improve RCT41. Besides, degradation of HDLc is 
regulated by different pathways. One way, the body can get rid of circulating 
HDLc is by uptake of HDLc via the SR-B1 transporter on liver cells. An alternative 
pathway is the degradation of HDLc by CETP. A third way HDLc can be affected is 
by catabolism in the kidney via cubilin endocytosis and SRB1 in the proximal tubulus 
of the kidney. HDLc will be reabsorbed and degraded mostly via SRB1 whereas 
cubulin and megalin endocytose essentially lipid-free apoA-I43,44. These changes in 
HDL composition occur during the important RCT pathway. Excessive cholesterol is 
transported from the peripheral tissues, such as the vessel wall back to the liver for 
excretion, preventing atherosclerosis. During RCT, accumulated cholesterol from 
macrophages in the vessel wall is removed to HDL or lipid-poor apolipoprotein 
(apo)A1 by different mechanisms, including one which is dependent on the cell 
membrane expression of ABCA1 on macrophages45,46. Up regulation of ABCA1 
would therefore favour an anti-atherogenic environment whereas down regulation 
of ABCA1 could create an atherogenic state by reducing cholesterol efflux and HDLc 
concentrations. Our aim of the study was to understand the mechanism behind 
the regulation of HDLc concentrations by IL-32. Our results show that induction of 
IL-32γ, is correlated with induced ABCA1 mRNA expression in unstimulated human 
primary liver cells and HepG2 cells. IL-32β expression did not show any correlation 
and IL-32α even showed a negative correlation with ABCA1, ABCG1 and LXRα mRNA 
expression. Additionally, overexpression experiments of IL-32 isoforms in HepG2 
cells showed that IL-32β and IL-32γ are associated with upregulation of ABCA1 and 
ABCG1. Due to the fact that HepG2 cells were no longer viable after knocking down 
IL32, overexpressing and silencing experiments of IL-32γ were performed in THP1 
macrophages. In the presence or absence of IL-32γ, ABCA1 expression was strongly 
induced or reduced respectively. This definitely demonstrated that IL-32γ is a key 
player in driving ABCA1 expression. We suggest that this effect is most likely caused 
by the direct regulation of LXRα expression by IL-32. LXRα is known to mediate, at 
least partially, the expression of ABCA147. Furthermore, we show that the most potent 
isoform of IL-32, IL-32γ together with ABCA1, ABCG1 and LXRα are also strongly 
upregulated by Poly I:C stimulation of primary liver cells and HepG2 cells. These data 
are conflicting with previous data by Castrillo A et al., which showed that LXRα and 
therefore ABCA1 are inhibited after activation of Toll-like receptors (TLRs) 3 and 4 
by microbial ligands like viruses or bacteria48. One explanation for this could be the 
fact that two completely different cell types are used in our experiments compared 
to the macrophages used in Castrillo’s experiments. Moreover, it is possible that 
stimulation of hepatocytes with a viral component such as poly I:C could trigger a 
slightly different intracellular pathway or the expression of IL-32 in these cells is of 
more importance and therefore results in different effects in various cell types.
Besides, the changes we found on cholesterol transporters expression seem 
functional, since intracellular lipid concentrations were lower in cells overexpressing 
IL-32 isoforms. These data show a completely new function of endogenous IL-
32 in liver cells and THP-1 derived macrophages even suggesting a possible anti- 
atherosclerotic function for the pro-inflammatory cytokine. However, when 
studying THP-1 macrophage foam cells or foam cells generated from human percoll 
monocytes differentiated to macrophages, isoforms of IL-32 were reduced or 
unchanged and only ABCA1, ABCG1 and LXRα were induced. This might be explained 
by the fact that oxidized LDL is taken up by different receptors such as CD36 and 
scavenger receptor A which could result in a different intracellular signal cascade 
compared to poly I:C stimulation or overexpressing experiments49.
Another explanation for the new link between IL-32 and ABCA1 could be explained 
by the fact that ABCA1 also has other important functions besides regulating HDL 
cholesterol. Previous studies showed that intracellular cholesterol homeostasis was 
required for a housekeeping function of cells. Additionally, recent studies indicated 
that cholesterol regulation, more specifically sterols, are dynamically regulated, 
bioactive and are intrinsic players in the immune response that couples metabolism 
to host defence [50]. The question whether IL-32 is anti- or pro-atherogenic is still 
difficult to answer. For now we can conclude that IL-32 has many pro- inflammatory/
pro-atherogenic capacities but that this study shows that IL-32γ closely associates 
with ABCA1 and other cholesterol mediators and in that way serves as an anti-
atherogenic mediator.
Some limitations could be envisaged in our study. One of these limitations could 
be the fact we did not measure HDL functionality but only HDLc concentrations 
even though previous studies have showed functionality being more important 
than HDL cholesterol concentration in determining cardiovascular disease risk19,51. 
Furthermore, additional experiments could not be performed due to lack of sample 
since all samples were used for the initial experiments.
To conclude, the present study shows for the first time the existence of a direct 
association between IL-32 and cholesterol homeostasis in humans. We provide clear 
and novel evidence that IL-32 is an important regulator of cholesterol transporters 
ABCA1 and ABCG1, possibly explaining the variation of HDLc concentrations 
previously observed in individuals bearing a SNP in IL-32 gene. Whether these 
101100
Chapter 5 – Interleukin-32 upregulates the expression of ABCA1 and ABCG1
5
interactions would further translate into a higher or lower CV risk remains to be 
elucidated in future studies, as well as the gain of more knowledge and understanding 
of the complex interactions between inflammatory effectors, lipids homeostasis 
and atherosclerosis.
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SUPPLEMENTARY FIGURES
Supplemental Fig. 1 mRNA expression in human primary liver cells and correlations of IL-32γ mRNA 
with ABCA1,ABCG1, LXRα, ApoA1 mRNA after TNFα stimulation. (A) IL-8 mRNA expression in human 
primary liver cells afterrhTNFα and poly I:C stimulation. (B) Positive correlation between IL-32γ and 
ABCA1 (Spearman r=0.7964, p=0.0004). (H) Positive correlation between IL-32γ and ABCG1(Spearman 
r=0.9179, p<0.0001***). (I) Positive correlation between IL-32γ and LXRα(Spearman r=0.9134, 
p<0.0001***). (J) Positive correlation between IL-32γ and ApoA1 (Spearmanr=0.9571, p<0.0001***).
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Supplemental Fig. 2 Correlation between basal expression of IL-32α or IL-32β and cholesterol 
transporter ABCA1 in human primary liver cells. (A) Correlation between IL-32α and ABCA1 at different 
time points showed no correlation.
(B) Correlation between IL-32β and ABCA1 at different time points showed a negative correlation 
(p=0.0155, r=- 0.6923).
Correlation
1 10 100
0.1
1
10
100
24 h 
24 h 
24 h 
24 h 
48 h
48 h
48 h
48 h
Spearman r: -0.04762
p = 0.9349 (ns)  
IL-32  
A
B
CA
1
Correlation
1 10 100 1000
0.01
0.1
1
10
100
4 h 
4 h 
4 h 
4 h 
24 h 
24 h 
24 h 
24 h 
48 h
48 h 48 h48 h
Spearman r: -0.6923
p = 0.0155 (*)  
IL-32
A
B
CA
1
Supplementary Figure 2
(A) (B)A B
107106
Chapter 5 – Interleukin-32 upregulates the expression of ABCA1 and ABCG1
5
Supplemental Fig. 3 mRNA and protein expression of various mediators involved in cholesterol 
metabolism in HepG2 cells overexpressing IL-32 isoforms IL-32α, IL-32β and IL-32γ. (A) SR-B1 mRNA 
expression in HepG2 cells overexpressing various isoforms of IL-32. (B) ApoA1 mRNA expression after 
24h in HepG2 cells overexpressing various isoforms of IL-32. (C) ApoA1 mRNA expression after 48hin 
HepG2 cells overexpressing various isoforms of IL-32. (D) Protein expression of ApoA1 after 24h in 
supernatants of HepG2 cells overexpressing various isoforms of IL-32. (E) Protein expression of ApoA1 
after 48h measured in supernatants of HepG2 cells overexpressing various isoforms of IL-32.
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Supplemental Fig. 4. Mean Fluorescence Intensity and % BODIPY positive THP-1 cells overexpressing 
IL-32 isoforms IL-32α, IL-32β and IL-32γ. (A) Mean FLuorescence Intensity (10^3) of THP-1 cells 
overexpressing IL-32 isoforms and fed ox-LDL for 24h prior to BODIPY staining. (B) % BODIPY positive 
TH-1 cells overexpressing various isoforms of IL- 32 and fed ox-LDL for 24h prior to BODIPY staining.
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Supplemental Fig. 5. mRNA expression of THP-1 cells fed ox-LDL for 24h and human isolated percoll 
monocytes fed ox-LDL for 24h. (A) mRNA expression of IL-32α in THP-1 cells generated foam cells. 
(B) mRNA expression of IL-32β in THP-1 cells generated foam cells. (C) mRNA expression of IL-32γ in 
THP-1 cells generated foam cells. (D) mRNA expression of ABCA1 in THP-1 cells generated foam cells. 
(E) mRNA expression of ABCG1 in THP-1 cells generated foam cells. (F) mRNA expression of LXRα in 
THP-1 cells generated foam cells. (G) mRNA expression of ApoA1 in THP- 1 cells generated foam cells. 
(H) mRNA expression of IL-32β in human percoll derived monocytes generated foam cells. (I) mRNA 
expression of IL-32γ in human percoll derived monocytes generated foam cells. (J) mRNA expression 
of ABCA1 in human percoll derived monocytes generated foam cells. (K) mRNA expression of ABCG1 
in human percoll derived monocytes generated foam cells. (L) mRNA expression of LXRα in human 
percoll derived monocytes generated foam cells.
Supplementary Figure 5
(A) (B) (C) (D)
(E) (F) (G)
(H) (I) (J) (K)
(L)
A
J K
N
L
O
 SUPPLEMENTARY TABLE S1
ABCA1 ABCG1 ApoA1 LXRa
IL-32α (poly I:C) r=-0.3000
p=ns
r=-0.08333
p=ns
r=-0.2667
p=ns
r=-0.03833
p=ns
IL-32α (TNFα) r=-0.3319
p=ns
r=-0.3187
p=ns
r=-0.02418
p=ns
r=-0.3187
p=ns
IL-32β (poly I:C) r=-0.4000
p=ns
r=0.3500
p=ns
r=0.1167
p=ns
r=-0.08333
p=ns
IL-32β (TNFα) r=-0.01429
p=ns
r=0.2357
p=ns
r=0.6143
p=0.0148*
r=0.2357
p=ns
Table S1. Correlations between IL-32 isoform expression and cholesterol mediator expression in 
human primary liver cells stimulated with poly I:C and rhTNFα.
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ABSTRACT
Background and aims: Subjects successfully treated for the human immunodeficiency 
virus (HIV-1) are facing persistent immune activation and dyslipidemia which may 
contribute to the increased risk for cardiovascular diseases. IL-32 is known to play 
a role in HIV replication, inflammation and lipid metabolism. The aim of our study 
was to explore the expression pattern of IL-32 (in)dependent of the IL-32 promoter 
SNP and its effects on inflammatory response of PBMCs and cholesterol metabolism 
dysfunction within HIV-infected individuals on stable antiretroviral therapy 
compared to healthy individuals.
Methods: Peripheral mononuclear cells (PBMCs) from ART-treated HIV-infected 
individuals (n=40) and healthy individuals (n=18) were stimulated with various 
ligands to study the mRNA and protein expression of IL-32 and other cytokines. 
mRNA expression of cholesterol transporters (ABCA1 and ABCG1) and chaperone 
protein calnexin were determined. Additionally, data was stratified for the IL-32 
SNP (C/T) and possible correlations between IL32 SNP, IL-32β/γ isoforms expression, 
ABCA1, ABCG1 and calnexin expression were explored.
Results: Stimulation of PBMCs from HIV-infected and healthy individuals resulted 
in similar mRNA expression of IL-32β, IL-32γ, ABCA1, ABCG1 and calnexin. 
Furthermore, inflammatory cytokine concentrations after stimulation were also 
similar. Stratification for the IL-32 promoter SNP showed a tendency toward higher 
IL- 32γ mRNA expression in HIV-infected bearing the TT genotype which was linked 
to the CC genotype in healthy controls. mRNA expression of ABCA1 and ABCG1 was 
significantly different depending the promoter SNP. mRNA expression of chaperone 
protein calnexin showed a similar trend although not significant. Finally, positive 
correlations between IL-32β/γ and ABCA1/ABCG1, IL-32β/γ and calnexin were found.
Conclusion: IL-32 mRNA of isoforms IL-32β and IL-32γ were differentially affected 
by the promoter SNP in HIV-infected individuals compared to healthy controls. 
Additionally, variation was observed for ABCA1, ABCG1 and calnexin mRNA 
expression linked to the SNP and IL-32 isoform expression. These SNP dependent 
differences could provide new insight in the role of IL-32 in the cardiovascular 
risk in HIV-infected individuals and suggest new targets for treatment to improve 
cardiovascular complications.
INTRODUCTION
During chronic HIV-1 infection, natural killer (NK) cells, monocytes, macrophages 
and especially T-cells are affected. These immune cells produce pro-inflammatory 
cytokines and chemokines, such as interleukin (IL)-6, tumour necrosis factor 
(TNF)-α, IL-1β, IL-8, interferon (IFN)-γ, resulting in hyper-immune activation and 
intense depletion of CD4+ T lymphocytes, a decrease in naive CD8+ T lymphocytes 
and increased viral load [1- 4]. Despite clinical benefits of the potent combined 
antiretroviral therapy (cART), HIV infected individuals still suffer from persistent 
immune activation and dyslipidemia contributing to the increased metabolic and 
cardiovascular morbidity and mortality seen in HIV infection [5, 6]. This increased 
cardiovascular disease risk can be linked to various processes such as lipodystrophy, 
endothelial dysfunction, accelerated atherosclerosis and dyslipidemia triggered by 
either the inflammation itself or treatment [7-10]. Conversely, changes in (intra)
cellular cholesterol load of HIV-1 susceptible cells may play an essential role during 
HIV infection, since replication of enveloped viruses at the cell membrane, like HIV, 
critically depend on cholesterol[11, 12].
Recently, various reports have highlighted a role for IL-32 in HIV [13-16]. IL-32 serum 
levels and IL-32 expression in gut and lymphatic tissue were found to be elevated in 
HIV infected patients compared to healthy individuals. Furthermore, it was shown 
that IL-32 in vitro could suppress viral replication [17]. Additionally, IL- 32 expression 
is linked to TNFα and vice versa, which suggests IL-32 as an important cytokine 
involved in the immune response against HIV. Recently, a promoter single nucleotide 
polymorphism (SNP) in IL-32 was shown to be associated with higher concentrations 
of IL-32 protein and increased high-density lipoprotein concentration (HDLc) in RA 
patients [14]. Possibly, by modulating transmembrane cholesterol transporters.
The present study aims to investigate the role of IL-32 and this SNP in HIV-infected 
individuals, focusing on the inflammatory response of peripheral blood mononuclear 
cells (PBMCs) and cholesterol metabolism dysfunction.
METHODS
Patients and controls
The HIV-infected individuals enrolled in our study have been participating in a 
single-center, open-label, randomized, controlled trial (RAPID trial) in adult HIV-
infected study participants with undetectable (<40 copies/mL) viral load who have 
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been receiving a standard backbone of two NRTI’s (either TDF/FTC or ABC/3TC) with 
either a NNRTI (EFV or RPV) or a boosted PI (DRV/r, ATZ/r or LPV/r) as initial regimen. 
Written informed consent was obtained from all participants prior to inclusion. Blood 
was taken at baseline to study laboratory measurements. In addition, N= 18 controls 
have been enrolled. The trail was registered at clinicaltrails.gov (NCT02383355). This 
trial was conducted according the principles of the declaration of Helsinki and was 
approved by the local ethics committee (CMO Arnhem-Nijmegen).
DNA isolation and Taqman genotyping
Blood was obtained from all HIV-infected individuals and healthy controls included in 
the study. Genomic DNA was isolated from whole blood using the Qiagen (Valencia, 
CA, USA) isolation kit and following the standard protocol[18]. The genotype for the 
IL32 promoter (rs4786370) polymorphism was screened by the TaqMan SNP assay 
C_27972515_20, (Applied Biosystems, Foster City, CA, USA). The TaqMan qPCR 
assays were performed on the AB StepOnePlus polymerase chain reaction system 
(Applied Biosystems).
Quantitative PCR
Peripheral blood mononuclear cells (PBMCs) from HIV-infected and healthy 
individuals were stimulated with Poly I:C (50 µg/ml) (Invivogen), recombinant human 
(rh)TNFα (10 ng/ml) (R&D Systems) or E.coli lipopolysaccharide (LPS) (1ng/mL) for 24 
hours. Subsequently, supernatants were collected for cytokine measurements and 
cells were stored in TriZol reagent at -200C until further use. RNA was isolated using 
Trizol reagent (Invitrogen) according to a protocol supplied by the manufacturer. 
After RNA isolation, mRNA was transformed into cDNA by applying an iScript kit 
(Bio-Rad) to transform mRNA into cDNA. IL-32 primers were previously developed 
and other primers sequences were extracted from the Harvard Primerbank database.
Primers were produced by Biolegio (Nijmegen, The Netherlands) and a StepOnePlus 
qPCR system (Applied Biosystems) was used to analyze relative mRNA expression. 
Relative expression was calculated by normalizing for GAPDH and 2^-dCt method.
Determination of cytokine levels
Human TNF-α, IL-6, IL-8, IL-1β, IL-1Ra, IL-10, IFN-γ, IL-17 and IL-22 were determined 
in culture supernatants using commercial Enzyme-Linked Immunosorbent Assay 
(ELISA) kits (Sanquin, and R&D Systems), according to the manufacturer’s protocol. 
Human IL-32 was determined in cell lysates in Triton X 100 0.5%, using a commercial 
ELISA kit (R&D Systems).
Statistical analysis
Normality was tested using the D’Agostino normality test. Continuous variables 
are presented as mean and standard deviation (SD). The differences IL-32 mRNA 
expression, IL-32 protein concentrations and cytokine concentrations were analyzed 
using the Mann-Whitney test. A p-value less than 0.05 was considered statistically 
significant (*p<0.05 and **p<0.01). Data was analyzed using GraphPad Prism v5.3.
RESULTS
Patient characteristics
Forty HIV-infected individuals were included in the study. In addition, 18 healthy 
individuals were included in this study also no differences we observed with respect 
to demographical aspects (Table 1). Differences were observed between groups for 
age, BMI and gender distribution (Table 1).
HIV-infected characteristics total Healthy controls characteristics Difference between groups
Age (years), median
(IQR)
48 (43-58) 27 (23-30) **
Female sex, n (%) 1 (2.5%) 11 (55%) **
Body mass index, mean
(SD) (kg / m2)
25.5 (±3.6) 22.9 (±2.8) **
Current smoker, n (%) 10 (25%) 0 (0%)
Diabetes mellitus, n (%) 2 (5%) 0 (0%)
cART regimens N.A
Backbone (2 NRTIs), n
(%) TDF/FTC ABC/3TC TDF/3TC 
3TC/FTC
30 (75%)
8 (30%)
1(2.5%)
1 (2.5%)
Boosted PI, n (%) 6 (15%)
NNRTI, n (%) 33 (82.5%)
Zidovudine, n (%) 1 (2.5%)
Viral load(<50
copies/mL), n (%)
40 (100%)
Nadir CD4 (106 cells/L),
median (IQR)
280 (230-340)
CD4 count (106 cells/L),
median (IQR)
665 (542-792)
HIV1 diagnosis (years),
median (IQR)
9 ()
cART exposure (years),
median (IQR)
6 ()
Table 1. Characteristics of HIV-infected vs healthy individuals.
117116
Chapter 6 –HIV-infected individuals, IL-32 and cardiovascular risk profile
6
IL-32β and IL-32γ mRNA expression differs between PBMCs from HIV-
infected vs healthy individuals dependent on IL-32 promoter SNP
First, peripheral blood mononuclear cells (PBMCs) of HIV-infected and healthy 
individuals were isolated and mRNA expression of IL-32β and IL-32γ was determined. 
A statistical significant difference for IL-32β after stimulation with synthetic double-
stranded RNA ligand poly I:C was observed (p<0.0001) with HIV-infected individuals 
expression being higher compared to healthy individuals (Fig. 1A-B). Subsequently, 
we determined the mRNA expression of IL-32β and IL-32γ when stratified for the 
IL-32 promoter SNP genotype (TT-, CT- and CC-genotype) in both groups, in (un)
stimulated PBMCs with poly I:C (TLR3 agonist), rhTNFα, LPS 1ng/mL (TLR4 agonist) 
(Fig. 1C-H). We found that HIV-infected individuals with the TT-genotype showed 
significantly higher IL-32β mRNA expression compared to healthy individuals 
(p=0.0041) (Fig. 1C). Moreover, HIV-infected individuals showed a significant increase 
in IL-32γ mRNA expression after rhTNFα (p=0.0153) stimulation, with a similar 
trend in the other conditions (RPMI, poly I:C and LPS)(Fig.1D). Additionally, HIV-
infected subjects bearing the CT genotype showed a significantly increased IL-32β 
mRNA expression after poly I:C stimulation (p=0.0082) (Fig. 1E). In contrast, healthy 
individuals bearing the CC genotype showed significantly different levels of IL-32γ 
mRNA compared to HIV-infected individuals after poly I:C and rhTNFα stimulation of 
PBMCs (p=0.0095 and p=0.0190 respectively)(Fig. 1H). The expression pattern of IL-
32γ mRNA was therefore completely opposite in HIV-infected individuals compared 
to healthy individuals depending on the SNP genotype (TT vs CC respectively).
> Figure 1. mRNA expression of IL32 isoforms IL-32β and IL-32γ in PBMCs from HIV-infected individuals 
versus healthy individuals (in)dependent of the IL-32 promoter SNP. A) IL-32β mRNA expression in 
HIV-infected versus healthy individuals independent of the IL-32 promoter SNP (n=37 HIV patients, 
n=18 HC) (* poly I:C stimulation p<0.0001). B) IL-32γ mRNA expression in HIV-infected versus healthy 
individuals independent of the IL-32 promoter SNP (n=36 HIV, n=18 HC). C) IL-32β mRNA expression 
in HIV-infected vs healthy individuals stratified for the IL-32 promoter SNP TT-genotype (n=14 HIV, 
n=9 HC) (*poly I:C stimulation p=0.0041). D) IL-32γ mRNA expression in HIV-infected versus healthy 
individuals stratified for the IL-32 promoter SNP TT genotype, *rhTNFα stimulation (p=0.0153) (n=14 
HIV, n=9 HC). E) IL-32β mRNA expression in HIV-infected vs healthy individuals stratified for the IL-
32 promoter SNP CT-genotype (n=17 HIV, n=4 HC *poly I:C stimulation p=0.0082). F) IL-32γ mRNA 
expression in HIV-infected vs healthy individuals stratified for the IL-32 promoter SNP CT-genotype 
(n=17 HIV , n=4 HC). G) IL-32β mRNA expression in HIV-infected vs healthy individuals stratified for 
the IL-32 promoter SNP CC-genotype (n=6 HIV, n=4 HC). H) IL-32γ mRNA expression in HIV-infected 
vs healthy individuals stratified for the IL-32 promoter SNP CC- genotype (*poly I:C and *rhTNFα 
stimulation (p=0.0095, p=0.0190) (n=6 HIV, n=4 HC)). Data was shown as mean + SEM and analysis 
was performed by Mann-Whitney U-test.
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IL32 promoter SNP does not affect cytokine production in HIV-infected 
individuals and healthy individuals
After observing differences in IL-32 isoforms expression according to genotype, we 
explored whether these differences also translate into modifications of inflammation 
by changes in cytokine production. PBMCs from HIV-infected individuals as well as 
healthy individuals were stimulated with various ligands to study the capacity of ex-
vivo cytokine production by PBMCs. Figures 2A-2E show that no clear differences 
were observed between PBMCs isolated from HIV -infected or healthy individuals 
independent of the promoter SNP. Additionally, T-cell derived cytokines IFNγ, IL-17 
and IL-22 did not differ between the groups (Suppl. Fig. 2A-I). Yet, after observing 
changes in IL-32 isoform mRNA expression dependent on the promoter SNP, we 
were interested whether the different genotypes would also be associated with 
changes in the production of pro-inflammatory cytokines by PBMCs (Suppl. Fig. 
1A-O). Significant differences were not observed when cytokine production was 
stratified for the promoter SNP.
IL-32 promoter SNP genotype differentially affects mRNA expression 
of cholesterol transporters ABCA1 and ABCG1 in HIV-infected versus 
healthy individuals
It is known that dyslipidemia occurs during HIV-1 infection. Moreover, previous 
observations by our group showed that IL-32 and the IL-32 SNP are associated with 
high-density lipoprotein cholesterol concentrations [14]. In addition, cholesterol 
in general and cholesterol transporter ABCA1 have been described to play a role in 
HIV infection [19, 20].Therefore, we were curious for the effects of the promoter 
SNP on cholesterol mediators in HIV infection. Figure 3A and 3B show that there are 
no differences in mRNA expression between HIV-infected and healthy individuals 
in general. Nevertheless, when mRNA expression data was stratified for the IL-32 
promoter SNP, clear statistical significant changes were observed for ABCA1 mRNA 
expression after poly I:C stimulation in the TT genotype (Fig. 3C) (p=0.0326 poly I:C HIV 
vs HC). A similar trend was observed for the other stimuli and was also visible in ABCG1 
mRNA expression in the groups bearing the TT genotype (Fig. 3D). Furthermore, ABCG1 
mRNA expression was elevated in unstimulated PBMCs from healthy individuals 
bearing the CT genotype (p=0.0353)(Fig. 3F). In addition, ABCG1 mRNA expression 
was significantly higher expressed in PBMCs from healthy individuals stimulated with 
either poly I:C or rhTNFα compared to HIV-infected individuals (p=0.0381, p=0.0381 
respectively)(Fig. 3h). Finally, we studied whether HDLc, LDLc and total cholesterol 
(TC) concentrations in HIV-infected were affected by the promoter SNP, however no 
significant differences were observed (Data not shown).
?????????????????????????????????? ???? ???? ?????????????????????????????????????????????????????????????? ??????????????????????????????????? ???? ???? ???????????????????????????????????????????????????? ??????
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Figure 2. Cytokine expression of PBMCS from HIV-infected individuals versus healthy individuals after 24hour 
stimulations, independent on IL-32 SNP genotype. A) IL-6 cytokine expression in HIV-infected individuals versus 
healthy individuals (n=40 HIV, n=18 HC). B) IL-8 cytokine expression in HIV-infected individuals versus healthy 
individuals (n=40 HIV, n=18 HC). C) IL-1β cytokine expression in HIV-infected individuals versus healthy individuals 
(n=40 HIV, n=18 HC). D) IL-10 cytokine expression in HIV-infected individuals versus healthy individuals (n=40 HIV, 
n=18 HC). E) TNFα cytokine expression in HIV-infected individuals versus healthy individuals (n=40 HIV, n=18 HC). 
Data was shown as mean + SEM and analysis was performed by Mann-Whitney U-test.
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IL-32 promoter SNP does not affect Calnexin mRNA expression in HIV-
infected or healthy individuals
HIV can affect its cellular uptake by targeting chaperone protein Calnexin, which 
under normal circumstances, regulates cholesterol transporter folding of ABCA1 in 
the nucleus affecting the signalling of ABCA1 to the cell membrane [21]. Since HIV 
may affect IL-32 isoform mRNA expression when stratified for the promoter SNP 
and this SNP was shown to influence the expression of ABCA1 and ABCG1, we were 
interested to investigate whether the promoter SNP also affects the expression 
of calnexin in HIV-infected versus healthy individuals. Figure 4A again shows 
that independent of the IL-32 promoter SNP, there are no differences in calnexin 
mRNA expression levels between groups. Contrary to these findings, when calnexin 
mRNA expression was stratified for the promoter SNP, expression levels of calnexin 
showed the same trend linked to the genotype as seen for the mRNA expression of 
ABCA1 and ABCG1 in both groups (Fig. 4B-C). In HIV-infected individuals bearing 
the TT-genotype both calnexin and ABCA1/ABCG1 mRNA expression was highest. 
Conversely, healthy individuals showed the highest calnexin and ABCA1/ABCG1 
mRNA expression to the CC-genotype.
> Figure 3. mRNA expression of cholesterol transporters ABCA1 and ABCG1 in PBMCs from HIV 
infected versus healthy individuals after 24hours stimulation and stratified for the IL-32 promoter 
SNP. A) ABCA1 mRNA expression independent on IL-32 promoter SNP in HIV-infected versus 
healthy individuals (n=37 HIV, n=17 HC). B)ABCG1 mRNA expression independent of IL-32 promoter 
SNP in HIV-infected versus healthy individuals (n=37 HIV, n=17 HC). C) ABCA1 mRNA expression in 
HIV-infected individuals vs healthy individuals stratified for the IL-32 promoter SNP TT genotype. 
Statistical significant differences were observed between HIV-infected and healthy individuals after 
poly I:C stimulation p=0.0326 (n=14 HIV, n=9 HC). D) ABCG1 mRNA expression in HIV-infected vs 
healthy individuals stratified for the IL-32 promoter SNP TT genotype (n=14 HIV, n=9 HC). E) ABCA1 
mRNA expression in HIV-infected vs healthy individuals stratified for the IL-32 promoter SNP CT 
genotype (n=17 HIV, n=4 HC). F) ABCG1 mRNA expression in HIV-infected vs healthy individuals 
stratified for the IL-32 promoter SNP CT genotype. Statistical significant differences were observed 
after RPMI stimulation p=0.0353 (n=17 HIV, n=4 HC). G) ABCA1 mRNA expression in HIV-infected vs 
healthy individuals stratified for the IL-32 promoter SNP CC genotype (n=6 HIV, n=4 HC). H) ABCG1 
mRNA expression in HIV-infected vs healthy individuals stratified for the IL-32 promoter SNP CC 
genotype. Statistical significant differences were observed after poly I:C stimulation p=0.0381 and 
rhTNFα stimulation p=0.0381 (n=6 HIV, n=4 HC). Data was shown as mean + SEM and analysis was 
performed by Mann- Whitney U-test.
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ABCA1/ABCG1 and calnexin are correlated with different inflammatory 
isoforms of IL-32
Observing a similar trend in mRNA expression of the cholesterol transporters 
and calnexin linked to the IL-32 promoter SNP genotypes, we explored whether a 
certain isoform of IL-32 is associated with their expression levels. Both IL-32β and 
IL-32γ are known to be potent (pro-inflammatory) isoforms that can induce varies 
other immune mediators [22-24]. IL-32γ mRNA expression in PBMCs was strongly 
correlated with ABCA1 and ABCG1 mRNA expression (Table 1.) (r=0.828 p=4.52E-10 
for ABCA1 and r=0.843 with p=1.14E-10 for ABCG1) but showed a negative correlation 
with calnexin (Table 1) (r=-0.460 p=6.19E-03). In contrast, IL-32β showed a positive 
correlation with calnexin mRNA expression (Table 2.) (r=0.732 p=1.96E-06) and a 
negative correlation with ABCA1 and ABCG1 (Table 2)( r=-0.726 with p=1.17E-06 for 
ABCA1 and r=-0.587 p=2.59E-4 for ABCG1).
Figure 4. Calnexin expression in PBMCs from HIV-infected individuals stratified for the IL-32 promoter 
SNP versus expression in PBMCs from healthy individuals. A). Calnexin mRNA expression independent 
of IL-32 promoter SNP in HIV-infected versus healthy individuals (n=34 HIV, n=17 HC). B) Calnexin 
mRNA expression in HIV-infected versus healthy individuals bearing the TT-genotype for the IL-
32 promoter SNP (n=14 HIV, n=9 HC). C) Calnexin mRNA expression in HIV-infected versus healthy 
individuals bearing the CT-genotype (n=14 HIV, n=4 HC). D) Calnexin mRNA expression in HIV-infected 
versus healthy individuals bearing the CC-genotype (n=6 HIV, n=4 HC). Data was shown as mean + SEM 
and analysis was performed by Mann-Whitney U-test.
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IL32y mRNA
expression 
baseline
Calnexin mRNA 
expression 
baseline
ABCA1 mRNA
expression 
baseline
ABCG1 mRNA
expression 
baseline
IL32y mRNA
expression baseline
Correlation Coefficient 1,000 -,429* ,808** ,842**
Sig. (2-tailed) 1,1E-02 1,52E-09 6,63E-11
N 37 34 37 37
Calnexin mRNA
expression baseline
Correlation Coefficient -,429* 1,000 -,519** -,465**
Sig. (2-tailed) 6,19E-03 2,00E-03 6,00E-03
N 34 34 34 34
ABCA1 mRNA
expression baseline
Correlation Coefficient ,808** -,519** 1,000 ,943**
Sig. (2-tailed) 1,52E-09 2,00E-03 2,41E-18
N 37 34 37 37
ABCG1 mRNA
expression baseline
Correlation Coefficient ,842** -,465** ,943** 1,000
Sig. (2-tailed) 6,63E-11 6,00E-03 2,41E-18
N 37 34 37 37
Table 1. Spearman correlation of IL-32 isoform IL-32γ with Calnexin, ABCA1, ABCG1 mRNA expression 
in unstimulated PBMCs from HIV-infected individuals.
IL32y mRNA
expression 
baseline
Calnexin mRNA 
expression 
baseline
ABCA1 mRNA
expression 
baseline
ABCG1 mRNA
expression 
baseline
IL32y mRNA
expression baseline
Correlation Coefficient 1,000 -,488* ,803** ,862**
Sig. (2-tailed) 4,70E-02 1,81E-04 1,8E-05
N 19 17 16 16
Calnexin mRNA
expression baseline
Correlation Coefficient -,488* 1,000 -,391 -,556*
Sig. (2-tailed) 4,70E-02 1,34E-01 2,50E-02
N 17 17 16 16
ABCA1 mRNA
expression baseline
Correlation Coefficient ,803** -,391 1,000 ,924**
Sig. (2-tailed) 1,81E-04 1,34E-01 3,34E-07
N 16 16 16 16
ABCG1 mRNA
expression baseline
Correlation Coefficient ,862** -,556* ,924** 1,000
Sig. (2-tailed) 1,8E-05 2,50E-02 3,34E-07
N 16 16 16 16
Table 2. Spearman correlation of IL-32 isoform IL-32γ with Calnexin, ABCA1, ABCG1 mRNA expression 
in unstimulated PBMCs from healthy individuals.
IL32b mRNA
expression 
baseline
Calnexin mRNA 
expression
baseline
ABCA1 mRNA
expression 
baseline
ABCG1 mRNA
expression 
baseline
IL32b
mRNA
expression baseline
Correlation
Coefficient
1,000 ,768** -,687** -,535**
Sig. (2-tailed) 2,95E-07 5,0E-06 1,0E-03
N 35 32 35 35
Calnexin
mRNA
expression baseline
Correlation
Coefficient
,768** 1,000 -,519** -,465**
Sig. (2-tailed) 2,95E-07 2,00E-03 6,00E-03
N 32 34 34 34
ABCA1
mRNA
expression baseline
Correlation
Coefficient
-,687** -,519** 1,000 ,943**
Sig. (2-tailed) 5,0E-06 2,00E-03 2,41E-18
N 35 34 37 37
ABCG1
mRNA
expression baseline
Correlation
Coefficient
-,587** -,465** ,943** 1,000
Sig. (2-tailed) 1,0E-03 6,00E-03 2,41E-18
N 35 34 37 37
Table 3. Spearman correlation of IL-32 isoform IL-32β with Calnexin, ABCA1, ABCG1 mRNA expression 
in unstimulated PBMCs from HIV-infected individuals.
IL32b mRNA
expression 
baseline
Calnexin mRNA
expression 
baseline
ABCA1 mRNA
expression 
baseline
ABCG1 mRNA
expression 
baseline
IL32b mRNA
expression baseline
Correlation Coefficient 1,000 ,765** -,362 -,444
Sig. (2-tailed) 3,50E-04 1,69E-01 8,48E-02
N 19 17 16 16
Calnexin mRNA
expression baseline
Correlation Coefficient ,765** 1,000 -,391 -,556*
Sig. (2-tailed) 3,50E-04 1,34E-01 2,54E-02
N 17 17 16 16
ABCA1 mRNA
expression baseline
Correlation Coefficient -,362 -,391** 1,000 ,924**
Sig. (2-tailed) 1,69E-01 1,34E-01 3,34E-07
N 16 16 16 16
ABCG1 mRNA
expression baseline
Correlation Coefficient -,444 -,556* ,924** 1,000
Sig. (2-tailed) 8,48E-02 2,54E-02 3,34E-07
N 16 16 16 16
Table 4. Spearman correlation of IL-32 isoform IL-32β with Calnexin, ABCA1, ABCG1 mRNA expression 
in unstimulated PBMCs from healthy individuals.
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DISCUSSION
In the present study, we investigated the role of IL-32 and a promoter SNP in IL-32 
in HIV-infected individuals versus healthy individuals, focusing on the inflammatory 
response of PBMCs and the cardiovascular risk profile associated with cholesterol 
metabolism dysfunction. More specifically, we explored whether the promoter SNP 
would be involved in regulation of important mediators responsible for cholesterol 
transport and could be involved in the persistent immune activation due to chronic 
low-grade inflammation. We have shown that differences were observed in mRNA 
expression in the important pro-inflammatory isoform IL-32β, but not in IL-32γ, 
between HIV-infected and healthy individuals. Furthermore, when mRNA expression 
was stratified for the promoter SNP genotypes, there was a statistical significant 
difference in IL-32γ mRNA expression between the two groups depending on the 
TT- or CC-genotype. These observed differences however did not translate into 
differences in cytokine production by PBMCs of IL-6, IL-8, IL-10, IL-1β, TNFα, IFNγ, 
IL-17 and IL-
22. Interestingly, we found a clear effect of the promoter SNP on cholesterol 
transporters ABCA1 and ABCG1 following the same trend as IL-32γ mRNA expression 
between the TT- and CC-genotypes in HIV-infected versus healthy individuals. 
Moreover, a tendency towards IL-32 SNP dependent mRNA expression of chaperone 
protein calnexin was depicted. Finally, strong expression correlations were detected 
between IL- 32γ and cholesterol transporters ABCA1/ABCG1 and between IL-32β 
and calnexin in both HIV-infected and healthy individuals.
Various isoforms of IL-32 have been shown to be involved in cancer, rheumatoid 
arthritis but also HIV [25-28]. The two most potent and pro-inflammatory isoforms 
are IL-32β and IL-32γ due to alternative splicing, IL-32γ can be spliced into IL-32β [29]. 
Unfortunately, the exact mechanism, expression pattern and role of these main two 
isoforms in HIV has not been fully explored and studies trying to determine effects 
of IL-32 in general showed conflicting data regarding the beneficial effect of IL-32 in 
HIV infection [16, 17, 30]. Furthermore, it is known that both IL-32β and IL-32γ are 
involved in the induction of other pro-inflammatory mediators such as, IL-6, IL-1β, 
IL-8, TNFα and IFN-inducible genes. IL-32 isoforms could therefore play an important 
role in the defence against or maintenance of persistent immune activation in HIV. In 
our study, we found differences between mRNA expression of IL-32 isoforms IL-32β/
IL-32γ (in)dependent of promoter SNP genotype in PBMCs from HIV-infected versus 
healthy individuals. Expression of IL-32β mRNA was significantly increased after poly 
I:C stimulation in PBMCs of HIV-infected. This finding is in line with previous reports 
indicating higher IL-32 mRNA and protein levels in HIV-infected individuals versus 
controls [15, 31]. The fact that we only found significant differences in IL-32β could 
be explained by the study design in which we studied the expression of IL-32 mRNA 
in PBMCs from virologically suppressed HIV-infected individuals and not in patients 
during acute HIV infection or treatment naive [15]. Alternatively, discrepancies at 
IL-32 protein level might be related to IL-32alfa, another IL-32 isoform, even if no 
differences are found at mRNA level.
In the present report we extended our previous observations on the influence of IL-32 
SNP (C/T) on the expression IL-32 isoforms and the production of pro-inflammatory 
cytokines by PBMCs. When mRNA expression levels were stratified for the IL-32 
promoter SNP a significant difference was observed for IL-32γ mRNA expression 
between HIV-infected individuals and healthy individuals bearing the TT- or CC-
genotype respectively. This is the first time the IL-32 promoter SNP is shown to be 
important for the specific isoform production of IL-32 in HIV-infected versus healthy 
individuals and could suggest that this SNP could be important to predict disease 
progression due to the highly potent IL-32γ isoform in decreasing HIV-1 viral load or 
could possibly explain the persistent immune activation in these patients [32]. Yet, 
these differences at mRNA expression level did not result in differences in cytokine 
production by PBMCs between HIV-infected individuals and healthy individuals.
Previous literature on the interaction of HIV, inflammation, lipids and cardiovascular 
risk on the one hand, and our recent observations on IL-32 SNP and changes in 
high-density lipoprotein cholesterol (HDLc) concentrations in rheumatoid arthritis 
patients on the other, we explored the latter in the HIV-infected individuals [14]. 
Interestingly, lipid profile and metabolism of chronically HIV-infected individuals is 
altered.
Nevertheless, no differences in HDLc were observed in HIV-infected individuals (in)
dependent of the promoter SNP. Low grade persistent inflammation is associated 
with early onset of atherosclerosis resulting in an increased risk for cardiovascular 
disease [33]. Important changes associated with dyslipidemia may include 
hypertriglyceridemia, increased levels of low-density lipoprotein cholesterol (LDLc) 
and decreased levels of high-density lipoprotein cholesterol (HDLc). Unfortunately, 
the exact mechanism behind the occurrence of these changes remains unclear [34]. 
ABCA1 and ABCG1 are important transmembrane cholesterol transporters playing 
a role in determining HDL circulating levels and have also been described to be 
important for controlling HIV infection [35-37]. ABCA1 and ABCG1 are responsible 
for cholesterol efflux from human macrophages to prevent foamcell formation 
and atherogenesis. However, high intracellular concentrations of cholesterol are 
important for HIV replication, therefore maintaining a high intracellular cholesterol 
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concentration is beneficial for the virus and its replication [38]. Moreover, lipid rafts 
are used by the virus to enter targeted cells and therefore high levels of lipid rafts 
on the cell membrane would favour HIV replication. Interestingly, the virus is able to 
affect intracellular mechanisms increasing cholesterol load on the lipid rafts, using 
a mechanism involving HIV-1 Nef protein and calnexin at the endoplasmic reticulum 
(ER) level, eventually leading to lower ABCA1 function [11, 21]. By suppressing 
ABCA1, cholesterol efflux from cells is decreased resulting in high cellular lipid 
contents and lipid rafts on the plasma membrane [39]. Our results show that the 
promoter SNP in IL-32 strongly affects the mRNA expression of ABCA1 and ABCG1.
Furthermore, we were able to detect a strong positive correlation between ABCA1/
ABCG1 expression and the expression of the IL-32γ isoform. This could suggest 
that HIV-infected individuals bearing the TT-genotype for the IL-32 promoter SNP 
produce more IL-32γ and therefore show an increased ABCA1 expression possibly 
resulting in decreased intracellular cholesterol concentrations. This could lead to an 
environment in which it is more difficult for the virus to infect cells.
Cholesterol is essential for viral replication that it has developed a way to interfere with 
the cholesterol metabolism. HIV infection, by the activity of viral protein Nef, impairs 
cholesterol efflux mediated by ABCA1 [37]. Nef can interact with endoplasmatic reticulum 
chaperone calnexin, which regulates folding and maturation of glycosylated protein 
including, ABCA1 [21]. The interaction between calnexin and ABCA1 is interrupted by 
Nef which resulted in dysfunctional ABCA1 and reduced cholesterol efflux [21, 40]. In our 
study we were able to show a significant association of IL-32β expression and calnexin 
expression, which however was not dependent on the IL-32 SNP could. Most likely, the 
two isoforms of IL-32 serve alternate cellular functions which is in line with previous 
studies [22, 24]. In addition, IL-32γ is known to be spliced to IL-32β and later to IL-32α 
as a less potent inflammatory isoform to reduce inflammation [29]. Therefore, IL-32γ 
and IL- 32β might be related to other immune regulatory functions against HIV infection 
than IL-32α. The question whether IL-32 expression and in more detail the two isoforms 
IL-32β/IL-32γ are important for host defence or cause a detrimental immune response 
favouring the virus and cardiovascular problems, still remains to be answered. At the 
moment, we can conclude that IL-32 and its’ isoforms have many capacities and that 
this study shows two distinct functions involved in HIV infection dependent on which 
isoform is being expressed. In the case of expression of IL-32γ cholesterol transporters 
are upregulated. This could be associated with an increased cholesterol efflux and 
protection against cardiovascular problems. In contrast, when IL-32β is expressed, 
cholesterol transporter is reduced but higher levels of calnexin are being expressed 
which could add to a beneficial environment for the virus and increase the risk for CVD.
Some limitations could be envisaged in our study. One of these might be related 
to the low number of HIV- infected per genotype (n= 16 TT vs n= 7 CC) for the IL-32 
promoter SNP. In addition, there were statistical significant differences between the 
HIV-infected and healthy individuals regarding to age, BMI and gender distribution. 
We know from a previous study that gender does not affect the distribution of the 
IL-32 promoter SNP. Yet, age and BMI could be confounding factors when exploring 
cholesterol metabolism [14]. Moreover, the absence of protein measurements 
related to IL-32, ABCA1 and calnexin leave us with mRNA expression patterns (in)
dependent of the IL-32 promoter SNP. This however does not necessarily translate 
to similar protein expression patterns. Finally, it would be interesting to study 
Nef expression in relation to the promoter SNP and whether the effect of the 
promoter SNP on calnexin expression actually affects ABCA1 functionality therefore 
decreasing cholesterol efflux.
In conclusion, our study shows that IL-32β but not IL-32γ mRNA expression differs 
between HIV-infected and healthy individuals, and shows important differences 
when stratified for the IL-32 SNP, especially for the IL- 32γ isoform. Additionally, 
the promoter SNP (rs4786370) is associated with the expression of cholesterol 
transporters ABCA1 and ABCG1. Our data suggests an important role for IL-32 
isoforms in HIV infection. The exploration of the role of IL-32 and the regulation 
of specific isoforms of IL-32 in HIV should be continued in future research in order 
to provide novel insights in unravelling the underlying mechanism for CVD and 
persistent inflammation.
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Supplementary Figures Suppl. S1 A-O
Supplementary Figure S1. Cytokine expression of PBMCS from HIV-infected individuals versus healthy 
individuals dependent of IL-32 SNP genotype. A) IL-6 production by PBMCs from HIV-infected and 
healthy individuals after stimulation with various ligands for 24h stratified for the TT genotype 
(n=16 HIV, n=10 HC). B) IL-6 production by PBMCs from HIV-infected and healthy individuals after 
stimulation with various ligands for 24h stratified for the CT genotype (n=17 HIV, n=4 HC). C) IL-6 
production by PBMCs from HIV-infected and healthy individuals after stimulation with various ligands 
for 24h stratified for the CC genotype (n=7 HIV, n=4 HC). D) IFNγ production by PBMCs from HIV-
infected and healthy individuals after stimulation with various ligands for 7days stratified for the TT-
genotype (n=13 TT HIV, n=9 TT HC). E) ) IL-17 production by PBMCs from HIV-infected and healthy 
individuals after stimulation with various ligands for 7days stratified for the TT-genotype (n=13 TT HIV, 
n=9 TT HC). F) ) IL-22 production by PBMCs from HIV-infected and healthy individuals after stimulation 
with various ligands for 7days stratified for the TT-genotype (n=13 TT HIV, n=9 TT HC). G) ) IFNγ 
production by PBMCs from HIV-infected and healthy individuals after stimulation with various ligands 
for 7days stratified for the CT-genotype (n=15 CT HIV, n=4 CT HC). H) IL-17 production by PBMCs 
from HIV-infected and healthy individuals after stimulation with various ligands for 7days stratified 
for the CT-genotype (n=15 CT HIV, n=4 CT HC). I) IL-22 production by PBMCs from HIV- infected and 
healthy individuals after stimulation with various ligands for 7days stratified for the CT-genotype (n=15 
CT HIV, n=4 CT HC). J) IFNγ production by PBMCs from HIV-infected and healthy individuals after 
stimulation with various ligands for 7days stratified for the CC-genotype (n=6 CC HIV, n=4 CC HC). K) 
IL-17 production by PBMCs from HIV-infected and healthy individuals after stimulation with various 
ligands for 7days stratified for the CC-genotype (n=6 CC HIV, n=4 CC HC). L) IL-22 production by PBMCs 
from HIV-infected and healthy individuals after stimulation with various ligands for 7days stratified for 
the CC-genotype (n=6 CC HIV, n=4 CC HC).
Figure S2A-L
Supplementary Figure S2. T-cell derived cytokine expression of PBMCS from HIV infected individuals 
versus healthy individuals (in)dependent of IL-32 SNP genotype. A) IFNγ production by PBMCs from 
HIV-infected and healthy individuals after stimulation with various ligands for 7days (n=34 HIV, n=17 
HC). B) IL-17 production by PBMCs from HIV-infected and healthy individuals after stimulation with 
various ligands for 7days (n=34 HIV, n=17 HC). C) IL-22 production by PBMCs from HIV-infected and 
healthy individuals after stimulation with various ligands for 7days (n=34 HIV, n=17 HC). D) IFNγ 
production by PBMCs from HIV-infected and healthy individuals after stimulation with various 
ligands for 7days stratified for the TT-genotype (n=13 TT HIV, n=9 TT HC). E) ) IL-17 production by 
PBMCs from HIV-infected and healthy individuals after stimulation with various ligands for 7days 
stratified for the TT- genotype (n=13 TT HIV, n=9 TT HC). F) ) IL-22 production by PBMCs from HIV-
infected and healthy individuals after stimulation with various ligands for 7days stratified for the TT-
genotype (n=13 TT HIV, n=9 TT HC). G) ) IFNγ production by PBMCs from HIV-infected and healthy 
individuals after stimulation with various ligands for 7days stratified for the CT-genotype (n=15 CT 
HIV, n=4 CT HC). H) IL-17 production by PBMCs from HIV-infected and healthy individuals after 
stimulation with various ligands for 7days stratified for the CT-genotype (n=15 CT HIV, n=4 CT HC). I) 
IL-22 production by PBMCs from HIV-infected and healthy individuals after stimulation with various 
ligands for 7days stratified for the CT-genotype (n=15 CT HIV, n=4 CT HC). J) IFNγ production by 
PBMCs from HIV-infected and healthy individuals after stimulation with various ligands for 7days 
stratified for the CC-genotype (n=6 CC HIV, n=4 CC HC). K) IL-17 production by PBMCs from HIV-
infected and healthy individuals after stimulation with various ligands for 7days stratified for the 
CC-genotype (n=6 CC HIV, n=4 CC HC). L) IL-22 production by PBMCs from HIV- infected and healthy 
individuals after stimulation with various ligands for 7days stratified for the CC-genotype (n=6 CC 
HIV, n=4 CC HC).
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SUMMARY AND GENERAL DISCUSSION
Even though various new discoveries led to effective treatments such as the use of 
statins, other lipid-lowering drugs and anti-inflammatory strategies like anti-IL-1b 
antibodies (e.g. canakinumab), cardiovascular diseases (CVD) are still a major cause 
of death globally (1). The single most important pathological process accountable for 
CVD is atherosclerosis. At the start of exploring the pathogenesis of atherosclerosis, 
it was thought to be a relatively simple vascular lipid storage disease (2, 3). However, 
later it was shown that many inflammatory processes equally contributed to its 
development and was therefore characterized as a chronic inflammatory disorder 
of the arterial vessel wall (4). Ongoing atherosclerosis can eventually lead to either 
stroke, myocardial infarction or peripheral artery disease, with different immune 
mechanisms playing a role in all stages of atherosclerosis (5).
Interestingly, recent epidemiological studies have identified common inflammatory 
mechanisms shared by many chronic inflammatory (autoimmune) diseases such 
as rheumatoid arthritis (RA), systemic lupus erythematousus (SLE) and human 
immunodeficiency virus (HIV-1) infection on the one hand and atherosclerosis on 
the other hand (6-8). Individuals suffering from these diseases are known to have an 
increased risk to develop CVD compared to the general population that may not fully 
be captioned by traditional CVD risk factors (9, 10). Because there is still a strong 
need to improve the understanding of the underlying inflammatory mechanisms 
in atherosclerosis, exploring the inflammatory mechanisms contributing to 
diseases like RA and HIV could help to understand and improve the treatment of 
atherosclerosis and its serious complications.
Therefore, in this thesis, we aimed to explore the hypothesis that interleukin (IL)-32 
is one of the important inflammatory mediators contributing to the increased risk 
for CVD in chronic inflammatory diseases. The last few years IL-32 has gained a lot 
of interest, reports indicating that the cytokine may be involved in the pathogenesis 
of various inflammatory diseases of which most are associated with an increased 
cardiovascular risk. The results of this thesis propose that IL-32 could play a role in 
the development of CVD in patients suffering from chronic low-grade inflammatory 
diseases.
Rheumatoid arthritis is a chronic inflammatory autoimmune disease associated with 
an increased risk for CVD (11, 12). Recent studies have shown a role for IL-32 in disease 
severity of RA and a strong correlation with TNFα expression, a major cytokine in RA 
(13, 14). However, never before has IL-32 been explored as a potential contributor 
to the high CVD burden in these patients. Therefore, in chapter 2, we examined for 
the first time whether IL-32 and more specifically a promoter SNP in the IL32 gene 
could affect important components such as high-density lipoprotein cholesterol 
(HDLc) associated with (prevention of) CVD in RA patients compared to non-RA 
patients. First of all, we observed no significant differences in the allelic distribution 
for the IL-32 promoter SNP between RA patients and non-RA patients. Interestingly, 
we did find a significant increase of HDLc in RA patients when stratified for the 
genotypes of the IL-32 promoter SNP. This effect did not seem to be influenced 
by disease activity in RA patients. In contrast to HDLc, other lipid concentrations 
including LDLc and total cholesterol (TC) were not affected by the promoter SNP. 
Interestingly, atherosclerotic plaques were less frequently encountered in individuals 
bearing the CC genotype, although not statistically significant, independent of their 
HDLc level. Finally, RA patients who previously experienced a CV event had lower 
HDLc levels as expected, with the patients bearing TT- genotype having the lowest 
concentrations of them all. LDLc and TC concentrations were reduced in all patients 
with a prevalence of CVD, independent of genotype.
Following this study, we questioned the exact mechanisms behind the observed 
association of IL-32 and HDLc levels in RA patients. Two major hypotheses evolved, 
one implying the modulatory effect of general inflammation and disease activity 
on lipoprotein levels (15), in which IL-32 would indirectly affect lipids through other 
inflammatory markers already indicated to do that e.g. TNF, IL-1. The other hypothesis 
would postulate a direct effect of IL-32 on lipoprotein metabolism, by modulating 
their production or clearance in circulation. To explore the first hypothesis we turned 
our attention to two chronic inflammatory diseases: rheumatoid arthritis and HIV-
infection. In chapter 3 the IL-32 promoter SNP and the different IL-32 isoforms 
(IL-32α, IL-32β and IL-32γ) and their relation to TNFα/TNFα-inhibitor treatment in 
RA patients have been studied. TNFα is one of the major cytokines involved in RA, 
linked to disease activity and is strongly correlated to IL-32 in a positive feedback 
loop being able to enhance each other’s expression. Moreover, previous studies 
have looked at SNPs in cytokines such as IL-6, IL-1β or TNFα and their association 
to the response to treatment in RA and found positive correlations (16-20). We 
therefore explored the role of IL-32 and the IL-32 promoter SNP in RA patients 
with respect to their clinical response to treatment with TNF- blocking agents. By 
performing ex vivo stimulation with Candida albicans or Pam3Cys we found that IL-
32β and IL-32γ mRNA expression tended to be higher in PBMCs from RA patients 
compared to healthy individuals. Further analysis also showed that intracellular 
IL-32 protein production was increased in RA patients, especially in those bearing 
the CC genotype for the promoter SNP. Even though a tendency towards higher 
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concentrations of pro-inflammatory cytokines was observed, this did not translate 
to higher disease activity scores (DAS28-CRP). Most importantly, ex vivo stimulation 
of PBMCs in the presence of anti-TNF agents etanercept or adalimumab was able to 
potentially identify responders to treatment according to clinical criteria, dependent 
on the genotype for the IL-32 promoter SNP. As IL-32 genotypes are not related with 
disease activity and response to TNF blockade, the results of this study indirectly 
suggest that other mechanisms might be involved for the initial association between 
IL-32 and HDLc concentration.
We further turned our attention to our second hypothesis, which propose a 
direct effect of IL-32 on metabolic pathways. In order to investigate that, several 
approaches have been explored. We firstly studied in a mice model the role of IL-32 
on lipid metabolism and obesity. In general, mice lack the IL32 gene and thereby 
it is an interesting animal species to study the black and white differences of the 
absence/presence of IL-32 in the system. Recently, IL-32 has been suggested to 
be directly implicated in insulin-resistance and diabetes, underlining that this 
cytokine may somehow be connected with intermediary metabolism pathways 
(21). In chapter 4 we therefore studied the effects of IL-32 on lipid metabolism and 
obesity in an in vivo model of human IL-32 transgenic mice on regular chow diet. 
Moreover, the effect of IL-32 presence in mice on their adipose tissue phenotype 
and possible inflammatory state was studied. Interestingly, adipose tissue cell size 
was significantly increased in IL-32 transgenic mice and circulating concentrations 
of leptin were also increased. Furthermore, a trend towards higher circulating 
insulin and cholesterol concentrations in IL-32tg mice was observed. These findings 
suggest that IL-32 plays an important role in lipid metabolism and that studying 
these animals under a high fat diet regimen would result in even more interesting 
data. Moreover, this data prompted us to continue to explore this hypothesis using 
different approaches.
In chapter 5 we performed a more basic science study, trying to explore the role 
of IL-32 and its main isoforms IL-32α,β,γ on mediators involved in lipoprotein 
metabolism. Important mediators such as, ABCA1 and ABCG1, apolipoprotein 
A1 (main component of HDLc) and LXRα which controls transcriptional programs 
involved in lipid homeostasis/inflammation were studied in human primary 
hepatocytes, HepG2 cells, THP-1 derived macrophages and carotid plaque tissue. 
We were able to show that in human primary hepatocytes and HepG2 cells IL-32γ 
mRNA expression is positively correlated with the expression of ABCA1, ABCG1, 
LXRα and ApoA1 in these cells. In contrast, IL-32β and IL-32α did not show any 
correlation or showed a slightly negative correlation. Furthermore, we showed that 
overexpressing the various isoforms of IL-32 in HepG2 cells and THP-1 cells resulted 
in lower intracellular lipid content suggesting increased lipid efflux from the cells. 
Indeed, THP-1 cells overexpressing IL-32γ showed higher ABCA1 expression and 
when IL-32γ was silenced expression of ABCA1 was strongly decreased. Besides in 
carotid plaque tissue from humans both IL-32γ and ABCA1 mRNA expression was 
induced. Eventually, this study added more data to support the hypothesis of the 
direct interactions between IL-32 and intermediary metabolism pathways.
Finally, we were interested to explore whether the results suggested by the animal 
and in vitro models would be confirmed by in vivo human studies. In order to do 
that, we turned our attention to another chronic inflammatory condition, known to 
be associated with higher cardiovascular risk: HIV infection. The risk for developing 
CVD in HIV-infected individuals is at least two times higher than that of non-HIV-
infected (22, 23). From previous studies, it has been described that IL-32 is involved 
in disease progression since high levels of endogenous IL-32 prevented further viral 
replication (24, 25). Subsequently, knocking down IL-32 expression resulted in a 
highly increased viral load (24). Our next approach was to study the role of IL-32 
and its promoter SNP on cardiovascular risk mediators in chronically HIV-infected 
under stable treatment with cART compared to healthy individuals. In chapter 6 
we selected a group of HIV-infected individuals together with a group of healthy 
individuals. We found that IL-32β and IL-32γ mRNA expression in PBMCs from HIV-
infected was different than the expression in PBMCs of healthy individuals dependent 
on the IL-32 promoter SNP genotype. Moreover, we observed IL-32 SNP dependent 
variation in cholesterol transporter mRNA expression of ABCA1 and ABCG1. In HIV-
infected, ABCA1 and ABCG1 were induced in the TT-genotype whereas healthy 
individuals showed this induction when bearing the CC-genotype. Furthermore, 
we studied whether a chaperone protein calnexin could be the explanation for the 
differences in ABCA1/ABCG1 expression dependent on genotype. However, this was 
not the case since ABCA1/ABCG1 were correlated with IL-32γ expression whereas 
calnexin expression was correlated with the IL-32β isoform. This final study adds 
to the previously described body of evidence suggesting a direct modulatory effect 
of IL-32 on intermediary metabolic pathways, specifically HDL production and 
lipoprotein metabolism.
DISCUSSION
Taken together, the results presented in this thesis support a role for IL-32 in 
affecting lipoprotein metabolism pathways and HDL cholesterol. Nevertheless, a 
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question which arose from the observed data and still remains to be investigated is; 
how can a pro-inflammatory cytokine be associated with increased levels of HDLc 
and possible protection against CVD?
From many previous studies it is known that lipid profiles can become pro-
atherogenic during inflammation thereby augmenting the risk of developing CVD 
(26-30). Both in patients suffering from RA or HIV, lipid profiles are changed due to 
the inflammatory status resulting in decreased HDLc and/or ApoA1 and overall higher 
ratios between LDLc and HDLc (31, 32). As it has been described earlier, IL-32 can 
induce pro-inflammatory cytokines and chemokines involved in these diseases and 
is therefore thought of as a novel player in promoting CVD. Interestingly, dependent 
on the IL-32 promoter SNP genotype, HDL cholesterol levels were modulated in RA 
patients treated with biological disease-modifying anti-rheumatic drugs (bDMARDs) 
and non-RA patients but not in HIV-infected patients on stable cART. Literature has 
shown that long-term treatment with TNF inhibitors only results in a minor increase 
in HDLc concentrations and no effect on LDLc concentrations or atherogenic index 
(AI) (33). Moreover, treatment of RA patients with bDMARDs could improve the lipid 
profile due to improved HDLc functions/ cholesterol efflux and overall decrease of 
inflammation but data is still conflicting (34-37). In contrast, antiretroviral therapy in 
HIV has clearly been linked to a worsened CVD outcome (38-40). This could explain 
why the promoter SNP does not show any effects on HDLc in the HIV-infected 
individuals. Besides, LDLc and TC concentrations were not affected by the IL-32 
promoter SNP in RA patients, which could suggest that the SNP effect is specific 
for HDLc metabolism/regulation. Moreover, overexpressing IL-32 in HepG2 cells 
showed to be correlated with increased cholesterol transporter expression, which 
could induce cholesterol efflux and lower intracellular lipid content. This might 
explain the selected effect on HDLc regulation. What we, however, did not show 
in chapter 5 was whether the reduced cellular lipid content is actually caused by 
increased cholesterol efflux due to increased function of cholesterol transporters.
Besides, ABCA1 transporters not only play a role in reverse cholesterol transport 
(RCT), they also play a role in protection against viral infection (41, 42). Enveloped 
viruses depend on cholesterol for their uptake and replication (43). However, when 
ABCA1 cholesterol transporters are highly expressed and functional, intracellular 
lipid content decreases preventing viral infection. Il-32 expression and especially 
the specific isoforms could therefore serve multiple roles within the regulation of 
lipoprotein metabolism. This should be the focus of future research.
To conclude
In this thesis, we have shown that IL-32 and a promoter SNP in the IL32 gene are 
important in regulation of lipoprotein metabolism. We have showed that HDLc 
concentrations differ between genotypes and that by stratifying clinical responding 
RA patients to the promoter SNP genotype, the CC-genotype could serve as a 
possible new biomarker to predict the response to anti-TNF treatment in RA. 
Furthermore, we were able to show that IL-32 transgenic mice on regular chow diet 
already had enlarged adipocytes and increased circulating leptin concentrations 
compared to WT mice, suggesting a disturbed metabolic state as compared with the 
wild-type mice. Next, we showed that the IL-32 promoter SNP affects cholesterol 
mediators differentially in HIV-infected individuals compared to healthy individuals 
and showed variation in IL-32 isoform expression dependent on the genotype. Lastly, 
we were able to unravel part of the underlying mechanism by showing that IL-32γ 
is the main isoform responsible for regulation of cholesterol transporter expression 
and expression of important mediators such as LXRα and ApoA1. We have therefore 
provided evidence supporting the concept that IL-32 is a candidate to be studied in 
the development of CVD in chronic inflammatory diseases.
Future perspectives
We now know that a promoter SNP in the IL32 gene is associated with increased 
concentrations of HDLc and that this SNP might be able to distinguish RA patients 
clinically responding to etanercept or adalimumab after ex vivo stimulation of their 
PBMCs. Furthermore, human IL-32 transgenic mice, which normally lack IL-32 
expression, already show to have increased adipocytes and circulating leptin levels 
on a regular chow diet. Besides, the IL-32 promoter SNP seemed to affect ABCA1 
and ABCG1 mRNA expression differentially in HIV-infected individuals compared to 
healthy individuals. Lastly, mechanistically this effect seemed to be associated with 
specific isoform IL-32γ, which was strongly correlated to mRNA expression of ABCA1, 
LXRα and ApoA1 in various cell types. However, the exact and causal role of the 
promoter SNP and IL-32 isoforms in the risk to develop CVD still needs to be proven. 
Therefore, the precise function of the promoter SNP on IL-32 isoform expression and 
the effect of treatment on IL-32 isoform expression in different inflammatory diseases 
compared to healthy individuals should be studied in more detail.
When trying to explore the role of IL-32 isoforms IL-32α, IL-32β and IL-32γ in 
inflammation and lipoprotein metabolism, the first question that needs to be 
approached is what is the exact function of each isoform intracellularly. To study 
this, it would be important to establish an inducible knock- out cell line (for example 
a macrophage cell-line) in which each individual isoform can be induced/silenced 
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separately. A complete knock-out cell line of the whole IL32 gene by CRISPR/
CAS9 in HepG2 cells was not viable probably due to the importance of IL-32 in cell 
homeostasis (44, 45).
By generating an inducible knock-out we could study the specific effects of each 
isoform in cells important for inflammatory responses and lipoprotein metabolism. 
Macrophages expressing the various isoforms could be loaded with ox-LDL to study 
foam cell formation and expression/function of cholesterol transporter activity 
dependent on IL-32 isoform. Furthermore, expressing only one isoform could help us 
to explore the exact mechanism behind the regulation of ABCA1, ABCG1, LXRα and 
ApoA1 in these cells. Does IL-32γ directly affect LXRα therefore increasing ABCA1/
ABCG1 or is this an indirect affect and what happens in the presence of IL-32β/IL-
32α? Besides studying the isoforms in an in vitro model, it would be interesting to 
study the precise expression pattern of IL-32 isoforms depending on the promoter 
SNP genotype in PBMCs from healthy individuals (ex vivo), The SNP seems to 
activate the promoter region resulting in more IL-32 protein expression (46).
However, how the change of one nucleotide could lead to a change in the type of IL-
32 isoform being expressed still remains an interesting topic of research.
Another question which remains to be addressed is: how does pharmacological 
treatment in the various chronic inflammatory diseases affect IL-32 isoform 
expression, and does that have an impact on HDLc levels or CV risk? In addition, 
it would be interesting to study the effect of statins or the new anti-IL-1β drug 
canakinumab on IL-32 isoform expression. These drugs are known to lower the risk 
for CVD and might influence IL-32 isoform expression in a way that could explain a 
new working mechanism of these drugs. Furthermore, it would be highly interesting 
to study PBMCs from RA patients and HIV patients from the beginning of the disease 
when they are still naïve for treatment and then follow them over the course of 
time. This way we could study the role of the disease on IL- 32 expression and study 
the effect of treatment on expression of IL-32 by PBMCs. Regarding the last two 
questions, we should try to include a large number of patients to be able to stratify 
results for each genotype of the IL-32 promoter SNP. Finally, creating a new ELISA 
able to measure protein expression of the various isoforms would provide a better 
understanding of which isoforms represent the total IL-32 protein concentrations 
(in)dependent of the SNP genotype.
Modulation of IL-32 isoforms to improve cardiovascular disease 
outcome in chronic inflammatory disorders
A relevant clinical question that remains is the following: could strategies regulating 
IL-32 isoform expression contribute to novel therapies to lower atherosclerosis risk 
and additional complications? It is know that SNPs influence the expression/function 
of proteins. One way this can occur is by interfering with alternative splicing (47). 
Various cytokines and other proteins are known to have multiple isoforms including 
IL-1, IL-6, IL-12, Toll-Like receptors (TLRs) and many transcription factors (48-50). 
These isoforms are mostly generated through alternative splicing and about 94% of 
human genes is subjected to alternative splicing (50). Alternative splicing increases 
the diversity of mRNAs, which leads to profound functional effects important for 
innate immune responses (50, 51). It can regulate localization of proteins, the 
binding to other proteins or membranes, the enzymatic activity and interaction with 
ligands such as receptors. Regarding IL-32, alternative splicing results in variation of 
isoform expression. The SNP could affect binding of the spliceosome to the promoter 
region, creating differences in splicing of IL-32 mRNA and post-transcriptional 
changes in isoform expression. Moreover, an online prediction model showed that 
the change from a T-allele to a C- allele could interfere with histone deacetylase 
2 (HDAC2) binding (52). This could suggest that epigenetic changes occur in IL-32 
once individuals bear the CC genotype but how this affects the expression of splice 
variants remains unknown. Subsequently, this could provide a new way to be able 
to try and regulate specific isoform expression of IL-32. To elucidate this, in vitro and 
possible in vivo studies should be performed with the addition of HDAC2 inhibitor 
Romidepsin to study the effect of HDAC2 on IL-32 isoform expression and possible 
effects on lipoprotein metabolism.
Another topic of interest is why would HIV-infected individuals show a different 
expression of IL-32 isoforms dependent on the IL-32 SNP compared to healthy 
individuals? From recent unpublished data we know that poly I:C (dsRNA TLR3 
agonist) somehow affects splicing resulting in mostly IL- 32γ expression but only 
little expression of IL-32β/IL-32α. HIV-infected individuals are infected with a virus 
which can trigger a TLR3 response possibly changing the splicing of IL-32 isoforms 
and changing the isoform expression dependent on genotype. However, these 
effects should be studied in untreated/acute HIV-infected patients compared to 
healthy individuals since treatment with cART could have strong effects on IL-32 
expression.
Besides observed changes in IL-32 splicing due to poly I:C stimulation or cART 
treatment, there is no knowledge on the effect of commonly used RA therapies 
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including methotrexate (MTX) or bDMARDs. MTX was initially used to treat cancer 
until in 1962 the first study of MTX treatment in RA was performed with positive effects 
(53). Low doses of MTX inhibit 5-aminoimidazole-4- carboxamide ribonucleotide 
(AICAR) formylotransferase, which affects intracellular adenosine concentrations 
and result in increased anti-inflammatory responses such as decreased TNFα and 
IL- 6 secretion (54, 55). In that way, MTX can decrease disease activity and lower 
cardiovascular disease risk. Unpublished data from our group showed that MTX also 
influences splicing of IL-32 just like poly I:C. Even more interesting, when we treated 
PBMCs with poly I:C + MTX (10oo-10ng/mL), splicing of IL-32 seemed to be blocked 
completely and only IL-32γ mRNA was produced. It would therefore be highly 
interesting to study the effect of MTX on IL-32 in RA patients negative for MTX 
(or any other treatment) and follow these patients over time to observe possible 
changes in expression profiles. MTX has been shown to lower CVD risk, which could 
be due to its anti- inflammatory effects but additionally could affect cholesterol 
transporter expression due to strong regulation of IL-32γ expression.
IL-32 promoter SNP as biomarker for personalized medicine
Bearing the CC-genotype for the IL-32 promoter SNP could predict the eventual 
ex vivo response of PBMCs to Candida albicans or Pam3Cys in addition to either 
etanercept or adalimumab. This is a completely new finding within the field. We 
therefore hypothesize that the IL-32 promoter SNP could serve as a novel biomarker 
in predicting response to treatment in RA patients on either etanercept or 
adalimumab. Since etanercept is the first choice of bDMARDS RA patients are given, 
this suggests that the IL-32 SNP could make a distinction between patients that will 
respond or will switch to another type of bDMARD and prevents the trouble suffering 
from ongoing disease activity due to lack of response. To obtain an unbiased group 
of RA patients to study response to treatment, preferably untreated RA patients 
should be included and followed over a time course of at least 6 months according 
to EULAR guidelines (56). After 3-months the first follow-up should be performed 
measuring DAS28-CRP to check effect of therapy, however response to treatment 
can still change after three months making a 6 months follow-up necessary.
In line with this patients should be separated on MTX positive or negative since we 
know from unpublished data that MTX could interfere with IL-32 isoform expression. 
Furthermore, during follow-up lipid profiles should be determined to study possible 
changes over the course of time.
Finally, despite many years of attempts to prevent atherosclerosis and cardiovascular 
disease it still remains a global burden. Using novel strategies, like affecting 
cholesterol transporters via new cytokines such as IL-32 and screening patients for 
SNPs that could predict response to treatment, we as researchers can continue to 
work towards the goal of full prevention of CVD in the future.
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Atherosclerose als oorzaak van hart- en vaatziekten (toen en nu)
Iedereen kent wel iemand in zijn of haar omgeving die lijdt aan hart- en vaatziekten 
(HVZ). De meest voorkomende onderliggende oorzaak is atherosclerose, ook wel 
bekend als aderverkalking (Figuur 1). 
Vroeger dacht men dat atherosclerose niets meer was dan de opstapeling 
van cholesterol in de vaatwand. Atherosclerose ontstaat echter doordat witte 
bloedcellen van het immuunsysteem cholesterol opeten. Wanneer de hoeveelheid 
cholesterol in de bloedbaan te hoog is kunnen witte bloedcellen dit niet goed 
verwerken waardoor ze gaan plakken aan de binnenkant van de bloedvaten. Dit 
resulteert in een ontstekingsreactie. Tijdens een ontstekingsreactie produceren 
witte bloedcellen bepaalde stoffen (o.a. cytokines en chemokines) die meer witte 
bloedcellen aantrekken en ervoor zorgen dat de veroorzaker van de ontsteking 
(normaal gesproken een bacterie of virus)  wordt verwijderd. In het geval van 
atherosclerose zorgen de geproduceerde immuunstoffen er echter voor dat meer 
witte bloedcellen stapelen en een plaque ontstaat. Afhankelijk van de hoeveelheid 
van cholesterol in het bloed en de duur van de aanwezigheid kan een plaque zich 
verder uitbreiden en leiden tot verstopping van een bloedvat of  een scheuring van 
de vaatwand. 
Figuur 1. Overzicht van de verschillende fases van atherosclerose.
Tegenwoordig weten we dat de ontstekingsreactie in atherosclerose vergelijkbare 
mechanismen vertoond met ontstekingsreacties bestudeerd in chronische 
ontsteking (auto-immuun-) ziektes zoals reumatoïde artritis (RA), systemische lupus 
erytematodus (SLE) en humaan immunodeficiëntie virus (HIV). Patiënten die lijden 
aan een van deze ziektes hebben een verhoogd risico op het ontwikkelen van hart- 
en vaatziekten/atherosclerose.  Verschillende factoren kunnen een rol spelen in de 
ontwikkeling van deze ziektes en atherosclerose zoals, leefstijl (roken, overgewicht/
lichamelijke inactiviteit)  of onderliggende genetische veranderingen/aandoeningen.
Plaque
In mijn thesis heb ik onderzocht hoe een relatief nieuwe immuunstof genaamd 
interleukine-32 (IL-32) en een genetische verandering in IL-32, betrokken is bij het 
ontstaan van een verhoogd risico op hart- en vaatziekten in patiënten met een 
chronische ontstekingsreactie.  Daarnaast heb ik gekeken of we kunnen voorspellen 
of iemand meer of minder risico loopt in de aan/afwezigheid van deze stof en de 
genetische verandering in gezonde individuen en in patiënten met chronische 
ontstekingsreacties.
Mijn hypothese en projecten in het lab
De grote vraag die ik tijdens mijn PhD heb proberen te beantwoorden was: ‘Op 
welke manier is interleukine-32 en zijn verschillende isovormen (IL-32a, IL-32b en 
IL-32y) betrokken bij het ontstaan van het verhoogde risico op hart-en vaatziekten/
atherosclerose in patiënten die lijden aan chronische ontstekings ziekten?’ 
Gedurende de jaren van mijn PhD onderzocht ik dit in verschillende ziektebeelden 
en op verschillende niveaus. 
Reumatoïde artritis en IL-32
Een deel van mijn onderzoek focuste zich op het effect van IL-32 in HVZ in reuma 
patiënten. Door middel van eerdere studies is bekend dat IL-32 een rol speelt in de 
ziekte activiteit van RA patiënten. Ook is IL-32 sterk gecorreleerd met een andere 
zeer belangrijke immuunstof in RA, namelijk TNF-alfa. Wanneer de ene immuunstof 
toeneemt, stimuleert dit de toename van de ander. Dit wordt ook wel een positive 
feedback loop genoemd. In dit geval resulteert dit in een hogere ziekte activiteit en 
een slechtere prognose voor de patiënt. De rol van IL-32 in HVZ in deze patiënten is 
echter nog nooit eerder bestudeerd. 
Genetische verandering in het IL32 gen
Een van de meest gebruikten methoden om te zien of iemand een verhoogd risico 
loopt op het ontwikkelen van hart- en vaatziekten is het bepalen van het cholesterol. 
In patiënten met een chronische ontsteking is de samenstelling van het cholesterol 
vaak verstoord. Deze verstoring kan bijdragen aan het verhogen van het risico op 
hart- en vaatziekten. Een groot deel van mijn onderzoek richtte zich op een genetisch 
verandering in het IL-32 gen. Deze verandering beïnvloedt cholesterol concentraties 
en daardoor factoren die het risico op hart- en vaatziekten verhogen. In het eerste 
deel van mijn thesis heb ik gekeken naar het effect van deze genetische verandering 
op HDL cholesterol (het “goede” cholesterol) concentraties en risico op HVZ in 
het bloed van reuma patiënten vergeleken met niet-reuma patiënten.  Interessant 
genoeg hadden reuma patiënten, met de genetische verandering, een hogere 
concentratie HDL in het bloed dan niet-reuma  patiënten. Dit was onafhankelijk 
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van de ziekte activiteit. Verder hadden individuen met de genetische verandering 
minder plaques. 
IL-32 en hart- en vaatziekten
Om een beter beeld te krijgen van de manier waarop IL-32 cholesterol concentraties 
kan moduleren, hebben we twee aparte vragen proberen te beantwoorden. De 
eerste hypothese keek naar de mogelijke indirecte manier waarin IL-32, door het 
reguleren van andere inflammatoire stoffen, een verandering in cholesterol tot 
stand kon brengen. De tweede vraag keek juist naar een potentieel direct effect van 
de aanwezigheid van IL-32 op cholesterol concentraties en cholesterol metabolisme.
Om de eerste vraag te beantwoorden is er gekeken naar twee groepen patiënten 
met chronische ontsteking, namelijk reuma patiënten en HIV patiënten. Het is 
bekend van genetische veranderingen in andere immuunstoffen dat ze een de 
expressie van de stof kunnen beïnvloeden en zo een rol spelen in het verhoogde 
risico voor HVZ. Daarnaast dragen enkele van deze veranderingen ook bij aan een 
verslechterde response op medicatie. In reuma patiënten werd daarom gekeken naar 
de response op medicatie (TNF remmers) afhankelijk van de genetische verandering 
in IL-32 (genotype). Om te beginnen werden mononucleaire cellen uit het perifere 
bloed (PBMCs) geïsoleerd om de immuun response van deze cellen te bestuderen. 
PBMCs van reuma patiënten met de genetische mutatie produceerde meer IL-32 
en lichtelijk meer pro-inflammatoire immuunstoffen dan patiënten  met de andere 
genotypen of gezonde individuen. De meeste belangrijke bevinding was dat PBMCs 
gestimuleerd met Candida albicans  en behandeld met TNF remmers ( etanercept of 
adalimumab) een variatie in immuun response lieten zien afhankelijk van het IL-32 
genotype. Het genotype kan daarom mogelijk voorspellen hoe iemand zal reageren 
op de medicatie. Daarnaast gaf dit antwoord op de eerste hypothese doordat IL-32 
inderdaad een indirect effect kan uitoefenen op cholesterol concentraties. 
Om de tweede vraag te beantwoorden hebben we meerdere experimenten 
uitgevoerd. Ten eerste hebben we in een muis model bestudeert of de aanwezigheid 
van IL-32 veranderingen kon veroorzaken in het lipiden metabolisme en het 
ontstaan van obesitas. Andere studies laten zien dat IL-32 geassocieerd is met 
insuline-resistentie en diabetes, wat kan betekenen dat IL-32 een rol speelt in ons 
metabolisme. Muizen met IL-32 hadden grotere vetcellen en circulerende hormonen 
(leptine) geassocieerd met obesitas waren verhoogd. Dit gaf ons reden om deze 
directe link van IL-32 met hart-en vaatziekten verder te onderzoeken.
Om meer te weten te komen over hoe IL-32 het lipoproteïne metabolisme kan 
beïnvloeden hebben we in cellen gekeken naar het effect van meer of minder 
aanwezigheid van IL-32 en de verschillende isovormen op belangrijke componenten 
in het lipoproteïne metabolisme.  Naast bepaalde immuun cellen (macrofagen) is de 
lever een belangrijk orgaan in dit proces. Verschillende lever cellijnen zijn daarom 
bestudeerd. Essentiele mediatoren in het lipoproteïne metabolisme  zoals ABCA1, 
ABCG1 (cholesterol transport kanalen), LXRa en ApoA1, waren positief geassocieerd 
met IL-32y expressie, maar negatief met IL-32a. Na het tot over expressie brengen 
van deze isovormen in zowel lever cellijnen als een macrofaag cellijn constateerden 
we dezelfde resultaten. Deze resultaten bevestigden daarmee de tweede hypothese. 
Als laatste studie hebben we daarom gekeken of de resultaten die we verkregen 
hadden door in vitro studies met cellen en een muizen studie, ook tot stand kwamen 
in een humane studie. Hiervoor hebben we ons gericht op een andere patiënten 
populatie met een chronische inflammatoire aandoening en verhoogd risico op 
hart- en vaatziekten, namelijk HIV patiënten. Voorgaande studies hebben laten 
zien dat IL-32 een rol speelt in de immuun reactie tegen HIV infectie. In mijn thesis 
hebben we gekeken naar de rol van IL-32 en de verschillende isovormen in langdurig 
behandelde HIV patiënten. Afhankelijk van het genotype voor de genetische mutatie 
in IL-32, was de expressie van de isovormen IL-32b en IL-32y anders in PBMCs van 
HIV patiënten ten opzichte van gezonde individuen. Verder, vonden we dezelfde 
link met IL-32y en ABCA1/ABCG1. Echter, welk genotype voor de mutatie in IL-32 
hiermee geassocieerd was bleek tegenovergesteld te zijn in HIV patiënten versus 
gezonde individuen. Ondanks dit verschil afhankelijk van genotype, bevestigde 
deze data dat IL-32 daadwerkelijk een belangrijke modulerende rol speelt in het 
lipoproteïne metabolisme en de immuun respons die bijdragen aan het risico op 
hart- en vaatziekten.
Het idee voor de toekomst
Uiteindelijk is het natuurlijk het idee om specifieke kenmerken te ontdekken in 
verschillende patiënt groepen met een verhoogd risico op hart- en vaatziekten. 
Op die manier kan de patiënt hopelijk persoonlijke medicatie krijgen die het risico 
verkleinen of helemaal wegnemen en daarnaast de chronische ontsteking aanpakken. 
Momenteel is het helaas nog steeds een “trial and error” methode. De truc om de 
juiste combinatie van medicijnen te vinden waar de patiënt de minste bijwerkingen 
van ondervind en die ervoor zorgen dat de ziekte en risico’s niet verergeren kan 
soms heel lang duren. In veel gevallen is het zelfs nog steeds zo dat de medicatie 
niet goed/volledig werkt en de patiënt nergens goed op reageert. Het ontdekken 
van persoonlijke kenmerken en patronen zal een wereld van verschil maken en voor 
heel veel mensen bijdragen aan een betere kwaliteit en duur van het leven.
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